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ABSTRACT 
Staphylococcus aureus (S. aureus) is an opportunistic pathogen capable of causing 
infection at multiple sites and is one of the predominant organisms found in chronic 
wounds, such as venous ulcers.  Furthermore, there is an ever-increasing prevalence of 
multi-drug resistant strains, such as methicillin-resistant S. aureus (MRSA) that can 
contribute to the non-healing and infection of wounds as well as other life-threatening 
complications. The increase in bacterial resistance necessitates the development of 
alternative modes of bacterial targeting and elimination whilst avoiding collateral 
damage to host cells and commensal bacteria. One such modality is photodynamic 
therapy (PDT), whereby the activation of a photosensitiser by light in the presence of 
oxygen produces reactive oxygen species to elicit bacterial cell death. PDT has 
previously been shown to be effective against a wide range of Gram-positive and Gram-
negative bacteria and furthermore selective targeting of the photosensitiser directly to 
the pathogenic bacteria is likely to improve the efficacy of this treatment.  
 
The FliTrx™ bacterially-displayed random peptide library (Invitrogen), displaying 12-
mer peptides in a conformationally constrained manner on the surface of E. coli was 
screened by panning against UV-inactivated MRSA. Panning was also performed 
against S. aureus and S. epidermidis in a similar manner. Clones (n = 20) were then 
randomly selected, DNA sequenced and peptide sequences analysed.  No obvious 
consensus sequence or repeat sequences were observed. Two peptides selected from 
panning against MRSA were commercially synthesised (peptide19 and peptide12) as 
both cyclic and linear constructs with N-terminal biotin for characterisation of binding 
by flow cytometry. Furthermore, one peptide (peptide12) was synthesised as both a 
cyclic and linear construct replacing the biotin with C-terminal FITC for direct 
characterisation of peptide binding by flow cytometry. Binding of the cyclic construct 
was observed against 3 different strains of MRSA, with the greatest binding observed 
against the strain of MRSA originally panned against. No binding of the linear construct 
was observed. Low/no reactivity was observed with other Staphylococcal sp, Gram-
negative bacteria and a mammalian cell line demonstrating apparent specificity for 
MRSA.  
 
Peptide sequences of interest were also cloned in-frame, situated within the full length 
thioredoxin sequence, so as to reflect the original display format, into an E. coli based 
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expression vector. Recombinant protein expression was optimised and the protein 
extracted, purified and characterised by Western blotting. The porphyrin photosensitiser 
(5-(4-isothiocyanatophenyl)-10,15,20-tris-(4-N-methylpyridiniumyl) porphyrin 
trichloride) was conjugated to recombinant protein P12 at a molar ratio of 5:1 and the in 
vitro cytotoxic effect of the resulting bioconjugate was determined against MRSA, E. 
coli and keratinocytes. Pilot data demonstrated a 66% reduction in MRSA growth 
following incubation and irradiation with the bioconjugate in comparison to non-
irradiated control cells. The conjugated porphyrin gave higher levels of cytotoxicity 
than equivalent concentrations of unconjugated capped porphyrin. No toxicity of the 
conjugate or the capped porphyrin against MRSA was observed when light of the 
correct wavelength was not given. Additionally no/little cytotoxic effect against E. coli 
or mammalian keratinocytes was observed. 
 
Additionally, binding of two other purified recombinant proteins (P5 and P19) to 
MRSA, E. coli and keratinocytes was assessed by flow cytometry. Both recombinant 
proteins were observed to bind MRSA in comparison to E. coli and keratinocytes. 
Furthermore, one sequence (P5) was expressed as an additional GFP fusion protein 
construct to allow direct characterisation of recombinant protein binding. A very small 
increase in binding was observed with an increasing concentration of recombinant 
protein against MRSA, E. coli and keratinocytes. 
 
In summary, this thesis has described a system to isolate and characterise novel peptides 
with binding specificity against MRSA. Furthermore, it has demonstrated the feasibility 
of expressing recombinant proteins and conjugation to a porphyrin photosensitiser for 
targeted PDT against pathogenic bacteria whilst limiting damage to the host, providing 
an alternative to antibody-based targeting in microbiology. 
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CHAPTER ONE 
Introduction 
 
1.2 General introduction 
 
The increasing prevalence of bacterial resistance has led to new alternative methods of 
bacterial elimination to be required. The majority of wounds are contaminated and/or 
colonised with bacteria (Filius and Gyssens, 2002), although these do not always illicit a 
host response (e.g. inflammation) or impede wound healing. However, microbial 
‘critical colonisation’ describes a condition whereby bacteria multiply and adversely 
affect the healing of the wound in the absence of an immune response (White and 
Cutting, 2006). This condition can be an important factor for the invasion and 
proliferation of potentially pathogenic organisms that can have a major impact on the 
infection and non-healing of the wound. 
 
Within chronic wounds the normal response to wound healing is altered and can result 
in prolonged inflammation, abnormal wound matrix and deficient regeneration of 
epithelial cells and remodelling (Herrick et al., 1992). In addition these chronic wounds 
such as venous, arterial and diabetic foot ulcers that are infected with resistant 
organisms can be frequently more difficult to treat, resulting in increased cost, 
prolonged treatment and increased trauma to the patient. 
 
Peptide display technology may represent an alternative modality for identification of 
ligands with potential pathogen specific targeting and diagnostic properties that could 
be utilised in the treatment of chronic wounds whilst minimising damage to surrounding 
host tissue. In this thesis, venous ulcers will be used as a wound model to discuss the 
potential utility of novel peptide targeting strategies for the treatment of chronic 
wounds. This wound model was utilised because approximately 70% of ulcers are of 
venous origin and also due to the prevalence, which is an estimated 1% at some point in 
the lifetime of the adult population in developed countries that increases with age 
(O'Meara et al., 2008).  MRSA was used as a target organism due to its increased 
prevalence within chronic wounds (Valencia et al., 2004) and also the threat of 
increasing resistance to ‘last line of defence’ antibiotics, such as vancomycin, has led to 
an urgent need for new strategies of MRSA targeting and elimination. 
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1.2.1 Venous ulcers 
 
Venous ulcers are common chronic wounds that arise due to venous insufficiency, often 
occurring due to obstruction or valve incompetence. The resulting congestion causes 
venous hypertension and leakage of fluid from blood vessels into the extravascular 
space, resulting in oedema (Bjarnsholt et al., 2008). The decreased tissue perfusion 
results in impeded transportation of oxygen and nutrients resulting in ischaemic damage 
and build up of waste products. Not only is the prevalence of venous ulcers high, but 
venous ulcers are often recurrent and are therefore costly to the patient in terms of 
immobility, pain and distress but are also a financial burden on the NHS. The estimated 
cost of treatment is approximately £400 million per year, or 1-2% of total health care 
costs (Ruckley, 1997).  
 
1.1.2 Microorganisms associated with venous ulcers 
 
Venous ulcers are good examples of a chronic wound that is frequently of a 
polymicrobial nature. Of the diverse bacteria isolated, S. aureus is the predominant 
organism isolated in numerous studies investigating the bacteriology of venous ulcers 
(Gjodsbol et al., 2006, Lim et al., 2006, Valencia et al., 2004, Bowler and Davies, 1999, 
Brook and Frazier, 1998, Halbert et al., 1992). Additional aerobic bacteria frequently 
associated include Pseudomonas sp, Streptococci, coagulase-negative Staphylococci, 
Enterobacteriaceae, Proteus sp and Enterococci (Gjodsbol et al., 2006, Brook and 
Frazier, 1998) indicating the diverse aerobic ecology within the wound. However, it is 
not surprising that these organisms frequently feature, as S. aureus is carried 
innocuously by approximately 30% of the population and many other organisms 
frequently isolated contribute to the normal cutaneous/oral flora, nasal passages or 
mucous membranes without clinical consequence, although have pathogenic potential to 
cause infection within a wound environment. 
 
The wound environment usually presents a combination of aerobic and anaerobic 
species. Anaerobes commonly found within the wound environment include 
Peptostreptococcus sp, Propionibacterium sp, Bacteriodes sp, and pigmented and non-
pigmented Provotella sp, presumably of cutaneous origin, or as part of the normal 
faecal or oral flora that may also impact on wound healing  (Stephens et al., 2003, 
Bowler and Davies, 1999, Brook and Frazier, 1998). For example, Bowler and Davies 
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(1999) isolated a significantly greater mean number and higher proportion of anaerobic 
bacteria from infected leg ulcers when compared with uninfected wounds, suggesting 
that anaerobes are potentially key factors involved in pathogenesis of infection.  
However, although anaerobes commonly feature, and may be detrimental to wound 
healing, they are frequently overlooked in a wound management setting probably due to 
lengthy culture and isolation time, and increased expense. 
 
Due to the diverse microbiology of venous ulcers, investigations into the bacteriology 
are conflicting not only in species identification but also in the varying number of 
species isolated within the wound. For example, Brook and Frazier (1998) demonstrated 
the presence of between 1 and 5 bacterial isolates with approximately 25% presenting 
only a single organism isolated from 43 samples derived from 41 patients. This is in 
contrast to Gjodsbol et al (2006) who analysed 342 samples derived from 46 patients, 
detecting more than one bacterial species in all chronic ulcers with a mean number of 
6.3 species per wound, which is likely to be an underestimate as all anaerobes were 
represented as a single species. In addition, resident colonising species (i.e. bacterial 
species present in all or all but one sample taken over the 8 week duration) were found 
in all 46 ulcers, most commonly S. aureus (n = 32) and P. aeruginosa (n = 17). The 
differences in number of bacterial species isolated in these studies may be due to 
different patient cohorts with different exclusion criteria, but moreover is likely to be 
due to the different methodologies of sampling and processing; with particular reference 
to anaerobic species, and also the infection status of the ulcer and duration of the 
studies. Methods of sampling of wounds with swabs or biopsies to determine the 
bacteriology of chronic wounds also remains debatable as such methods may not cause 
a representative spread of organisms capable of causing infection to be isolated. For 
example, Stephens et al (2003) isolated bacterial species from surface swabs compared 
with deep tissue biopsies from 18 patients with non-infected refractory chronic venous 
ulcers of at least 24 months duration that were resistant to conventional treatment. The 
study found that although many bacterial species detected on the swab were also present 
in the biopsy, a greater number of bacterial strains were isolated from the deep tissue 
biopsies and suggested that the presence of Gram-positive anaerobes such as 
Peptostreptococci may impair cell-mediated wound healing in in vitro assays (Stephens 
et al., 2003). Therefore tissue biopsies may provide a greater insight into the presence of 
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bacteria especially the presence of anaerobes, that routine diagnostic techniques would 
have overlooked (Stephens et al., 2003).  
 
Lim et al (2006) demonstrated that although bacteria isolated from swab and punch 
biopsies of chronic lower limb ulcers from 39 patients (20 were of venous origin) were 
often in agreement (46%), 28% showed no similarity between the bacterial species 
isolated. Additionally, when analysing the microbiology of chronic ulcers this group 
advocated taking biopsies instead of swabs due to increased sensitivity and specificity 
and also to rule out ulcer malignancy by histopathology. However, Bjarnsholt et al 
(2008) indicated that bacteria within the wound can exist as a biofilm in infected 
wounds, unevenly distributed in microcolonies, and therefore a swab or biopsy may not 
accurately depict the total bacterial load within the wound. Nonetheless, although 
difficulties with bacterial sampling exist, it is worth noting that the majority of sources 
of bacterial wound contaminants are endogenous to the host and therefore those found 
on devitalised sloughy superficial tissue will also comprise those that have disseminated 
deeper into tissue and more likely associated with infection (Bowler and Davies, 1999).  
 
Furthermore, owing to the increased prevalence of bacterial resistance, there is an 
increased risk of chronic wounds becoming infected with resistant organisms, in 
particular with methicillin-resistant S. aureus (MRSA).  A study evaluating the 
microbiology of leg ulcers over a decade, of which the majority (29/72; 40%) were of 
venous origin, found that S. aureus was isolated in 67% of isolates from leg ulcers of 
which three quarters were MRSA in 2001, an increase from 50% in 1996 and 26% in 
1992 (Valencia et al., 2004). Additionally, this study also highlighted the increasing 
trend in quinolone-resistant P. aeruginosa isolates from leg ulcers: this increased from 
19% in 1992, to 36% in 1996 and 56% in 2001, a further reason for concern over 
bacterial resistance. 
 
It seems apparent that difficulties arise in comparative assessment of bacteria involved 
in venous ulcers. Although single or multiple species may colonise the wound, it is not 
necessarily indicative of infection and furthermore the presence of specific strains of 
bacteria within infected ulcers may not necessary be contributing to the infected 
phenotype. Nonetheless, colonised bacteria remain in the wound and colonisation of 
potentially pathogenic bacteria is an essential factor in invasion and the progression to 
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infection, and therefore knowledge of the microbiology of the wound may assist future 
treatment options. Additionally, determination of the presence of drug resistant 
pathogens is also crucial to deliver optimal treatment regimens.  
 
1.1.3 Impact of organisms on wound healing 
 
The significance of specific organisms within the wound and their adverse effect on 
wound healing has been subject to much debate. Although little attention has been paid 
to anaerobic organisms, various groups have suggested that S. aureus, P. aeruginosa, 
and beta-haemolytic Streptococci within the wound are associated with delayed healing 
and infection (Gjodsbol et al., 2006, Danielsen et al., 1998, Madsen et al., 1996, Halbert 
et al., 1992, Schraibman, 1990). However although S. aureus is a common isolate 
associated with persistent colonisation and/or infection within the wound, Bowler and 
Davies (1999) failed to show a clear correlation between the presence of facultative 
pathogens such as S. aureus and P. aeruginosa and wound infection. This group instead 
suggested that the significant diversity of bacteria and presence of anaerobes, 
particularly in infected ulcers, and aerobic/anaerobic synergy as of potentially greater 
clinical significance impacting on wound healing. For example, wounds are often 
hypoxic environments as a result of tissue necrosis and the oxygen 
consumption/metabolism by host cells, and as such aerobic bacteria provide an ideal 
environment for the proliferation and virulence of anaerobic microorganisms (Bowler et 
al., 2001). 
 
In addition, Trengove et al (1996) demonstrated that no single or group of causative 
species, including aerobes and anaerobes, were detrimental to wound healing. These 
researchers suggested that it was the presence of 4 or more bacterial species in 
combination which was associated with delayed healing, therefore indicating that 
microbial synergy may induce a greater pathogenic potential. For example, the 
production of essential growth factors by specific bacteria, which are often unidentified, 
can enable growth of more fastidious organisms that may enable enhanced virulence 
and increased pathogenicity of bacteria within the wound (Bowler et al., 2001, Bowler 
and Davies, 1999).  Additionally, a critical microbial load, greater than 105 bacteria per 
gram of tissue, has also been cited as a potential cause of infection and non-healing 
(Howell-Jones et al., 2005, Halbert et al., 1992).  
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As has been mentioned previously, bacteria can survive within wounds as biofilms. 
These are complex structures consisting of aggregations of bacteria growing on a solid 
surface. In addition to bacterial synergy, the polymicrobial nature of the wound milieu 
can also enhance genetic exchange between bacteria, further contributing to the 
increasing problem of bacterial resistance (Howell-Jones et al., 2005). The formation of 
biofilms and bacterial synergy can offer some bacterial protection from the host 
immune response and can also offer bacterial protection from antimicrobial therapy, 
contributing to non-healing of the wound (Stephens et al., 2003, Wall et al., 2002). The 
reduced susceptibility of bacteria in biofilms to antimicrobials requires higher 
concentrations of these drugs in order to treat bacteria present in biofilms (Dissemond, 
2009, Reichenberg and Davis, 2005, Anwar et al., 1990).  
 
In summary, chronic wounds are complex in nature and the impact on wound healing 
and infection is likely to be multifaceted involving the bacteria, their virulence 
determinants and the host response. The potential microbial factors that, either 
independently or collectively, can contribute to non healing/wound infection are 
summarised in Figure 1.1. The effect of wound infection and non-healing may result in 
prolonged incapacity and increased trauma to the patient which can impact on quality of 
life. Additionally, the presence of resistant pathogens may result in infections that are 
difficult to treat resulting in longer hospital stays, increased patient distress and greater 
risk of colonisation and transmission. Therefore prompt identification and effective 
appropriate treatment is imperative.  
 
1.1.4 Treatment of venous ulcers 
 
Venous ulcers pose an increasing problem in the Industrialised World owing to an 
ageing population, an increase in obesity and related diseases such as diabetes, venous 
hypertension, cardiovascular disease and an increase in the immunocompromised 
population (e.g. AIDS or cancer therapy) all lead to a larger patient group susceptible to 
the development of chronic wounds (Bjarnsholt et al., 2008, Bowler et al., 2001). 
Compression bandages or stockings are the mainstay of treatment in the treatment of 
venous ulcers to increase blood flow by reducing venous stasis and oedema. 
Additionally, debridement which involves the removal of devitalised or contaminated 
tissue to expose healthier tissue achieved either through surgical, mechanical, autolytic  
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or enzymatic methods can enhance wound closure. Debridement can be of particular 
benefit in the treatment of venous ulcers to remove damaged tissue, as bacteria favour 
growth on necrotic tissue, and furthermore may aid physical removal of biofilms that 
affect the utility of topical or systemic antibiotic therapy (Reichenberg and Davis, 
2005). Additionally, the application of ‘maggot therapy’, an alternative but not new 
form of debridement overlooked due to the development of antibiotics, has also proved 
successful in the management of chronic wounds and has been demonstrated to show 
antimicrobial activity in the treatment of MRSA-infected wounds (Nigam et al., 2006).  
 
Broad-spectrum systemic and topical antimicrobial agents and antiseptics to reduce 
microbial load are frequently used in the management of chronic wounds and are 
essential in the management of infected wounds (Howell-Jones et al., 2005, Bowler et 
al., 2001). Empirical broad-spectrum treatment, prior to organism identification and 
sensitivity testing, includes the use of penicillin, macrolide and quinolone antibiotics 
(Grey et al., 2006). However, various groups have highlighted the possible clinical and 
cost ineffectiveness in the treatment of non-healing venous ulcers without infection with 
antimicrobials; supporting antimicrobial therapy only when there are clinical signs or 
symptoms of infection (Howell-Jones et al., 2005, Bowler et al., 2001, Kac et al., 2000). 
Administration of antimicrobials should take into account the presence of aerobes, 
anaerobes and drug resistant bacterial species to ensure the correct targeting of 
pathogens. In addition to appropriate antimicrobial prescribing practices, good infection 
control procedures (handwashing, gloves, gowns, cleaning, use of disposable devices), 
screening for colonised patients/staff, patient isolation/decontamination, education and 
rapid detection should all be employed to reduce the risk of bacterial transmission as 
many pathogenic bacteria are easily spread through either infection or colonisation 
reservoirs (Valencia et al., 2004, Kac et al., 2000, Carbon, 1999).  
 
The impact of infection, particularly with resistant organisms, may result in an increase 
in morbidity, mortality and cost to both the healthcare system and trauma to the patient. 
It is therefore essential that new methods of appropriate detection and elimination of 
bacteria for treatment of venous ulcers and other chronic wounds  that avoid the 
advancement of bacterial resistance are developed to enable more effective wound 
healing. Current alternative treatment strategies in development have explored the use 
of new antimicrobial therapies such as bactericidal antimicrobial peptides, hyperbaric 
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oxygen therapy or photodynamic therapy (PDT) to target and kill bacterial pathogens 
(reviewed later in the chapter section 1.5).  
 
1.2 Staphylococcus aureus 
 
S. aureus is a Gram-positive spherical bacterium, often considered an opportunistic 
pathogen. This bacterium is a frequent cause of superficial and serious skin and soft 
tissue infections such as infected ulcers, cellulitis, furuncles and impetigo, but can 
invade surgical and other wounds and cause bone and joint infections through 
contamination in orthopaedic surgery (Livermore, 2000). These bacteria are facultative 
anaerobes that grow rapidly by aerobic respiration or by fermentation. They are non-
motile, non-spore forming and although considered potential human pathogens can also 
comprise part of the normal bacterial flora without detriment in healthy humans.  
 
1.2.1 Cell wall structure and virulence factors 
 
The cell wall of S. aureus is composed mainly of peptidoglycan (up to 90% dry weight 
of Gram-positive bacteria) that is approximately 15 to 30 nm thick. Peptidoglycan is a 
continuous polymer that confers shape and rigidity to the cell providing protection from 
the environment and preventing osmotic lysis. It is composed of interlocking glycan 
chains of alternate monomers N-acetylglucosamine (NAG) and N-acetyl muramic acid 
(NAM) cross-linked by pentapeptide bridges from the NAM composed of L-Ala-D-
Gln-L-Lys-D-ala-D-ala (Fig 1.2). Additionally to peptidoglycan, the bacterial cell wall 
is composed of covalently bound teichoic, teichuronic and lipoteichoic acid associated 
with the cell membrane to provide rigidity, and wall-associated surface proteins to 
promote attachment to the host (Fig 1.3).  
 
Aside from resistance determinants, S. aureus possesses a number of virulence factors, 
many of which are not possessed, or only produced in small amounts by coagulase-
negative Staphylococci such as S. epidermidis, a common skin commensal, and may 
help to explain the enhanced virulence and capacity for infection. Virulence 
determinants of S. aureus are summarised in Fig 1.4. Adhesion of pathogenic bacteria to 
host tissues is an essential step in bacterial colonisation and the initiation of infectious 
disease and an important part of pathogenesis. Bacteria need to adhere to epithelial  
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surfaces in order to colonise tissue and avoid the clearing defence mechanisms of the 
host (Westerlund-Wikstrom et al., 1997). S. aureus, amongst other bacterial species, 
possess adhesins known as microbial surface components recognising adhesive matrix 
molecules (MSCRAMMs) that mediate cell anchorage in the infection process by 
binding to collagen, fibrinogen and fibronectin and other host extracellular matrix 
components (Foster and Hook, 1998). Protein A on the bacterial cell surface binds IgG 
molecules by their Fc region hence enabling an immunological disguise from the host, 
inhibiting phagocytic engulfment. Coagulase also protects against phagocytosis and 
immune recognition by catalysing the formation of fibrin around the cell (Dissemond, 
2009). Invasins such as kinases and hyaluronidase aid bacterial invasion and spread. S. 
aureus strains also secrete toxins that cause membrane damage to host cells such as 
toxic shock syndrome toxin (TSST-1), enterotoxins, !-Toxin and leukocidins 
(Dissemond, 2009). Additionally, growth of S. aureus and other colonists within 
biofilms pose further problems in that these bacteria have increased protection from 
host defences and also exhibit enhanced resistance to antibiotics.  
 
1.2.2 Mechanisms of bacterial resistance 
 
Bacterial resistance to antibiotics has continued to increase with time and the extensive 
use of these agents. Resistance can emerge not only due to overuse and misuse of 
antibiotics but also due to treatment regimens of too short a duration or ineffective 
concentrations of the antibiotics at the site of infection. Prior to the discovery and 
development of antibiotics, infections caused by S. aureus and S. pneumoniae were 
often fatal (Trias and Gordon, 1997). Although Staphylococci are inherently susceptible 
to most antibiotics they remain a frequent cause of morbidity and mortality, owing to an 
adept capacity for the development of resistance to antimicrobial agents (Livermore, 
2000). Development of drug resistance in S. aureus and other bacterial species is 
achieved either via mutation in chromosomal genes and selection of resistant strains, or 
more commonly due to the acquisition of resistance genes via DNA transfer between 
bacteria. Bacterial resistance can arise either from a single genetic mutation whilst 
resulting in no detrimental effect to the pathogenicity or viability of a strain, or 
mutations may change an existing resistance mechanism to confer a broader spectrum of 
activity (Gold and Moellering, 1996).  
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Antimicrobial agents have been developed against a range of bacterial targets including 
cell wall synthesis, protein synthesis at 50S and 30S ribosomal subunits, blocking 
nucleotide and mRNA synthesis, blocking DNA topoisomerases and disruption of 
membranes displaying bactericidal or bacteriostatic effects (Walsh, 2003). However, an 
equally diverse range of resistance mechanisms have been utilised by bacteria including, 
efflux mechanisms, modified target, inactivation of the antibiotic, bypass of metabolic 
pathways and modified permeability (Dzidic et al., 2008). For example, Enterococcal 
resistance to aminoglycosides is conferred by production of aminoglycoside modifying 
enzymes to inactivate the drugs but can also be due to decreased permeability of the 
bacterial cell or alterations in the ribosome binding site (Chow, 2000). Resistance to 
tetracyclines and quinolones is often conferred by efflux mechanisms that have been 
identified in both Gram-positive and Gram-negative bacteria (Jayaraman, 2009). 
Additionally numerous target mutations in bacteria exist, for example, alterations of 
RNA polymerase in order to confer rifampicin resistance in Mycobacterium 
tuberculosis (Telenti et al., 1993) and alterations in penicillin-binding proteins in 
pneumococci resulting in penicillin resistance (Nagai et al., 2002). 
 
1.2.3 Methicillin resistant Staphylococcus aureus 
 
MRSA is a significant nosocomial pathogen. Following the introduction of penicillin in 
1944, a "-lactam antibiotic that inhibits cell wall synthesis by inhibition of 
peptidoglycan cross-linking, nearly all isolates were susceptible; however, resistant 
strains of S. aureus began to develop quickly and synthetic drugs including methicillin 
were introduced to combat their emergence. Unsurprisingly, methicillin resistance in a 
clinical S. aureus isolate was first reported in 1961, the year of the drug’s launch 
(Jevons, 1961), from which five major genetic lineages of MRSA have evolved with 
strains resistant to all "-lactams.  
 
Epidemic MRSA strains (EMRSA) are defined as those that have spread to two or more 
patients at two or more hospitals and since the emergence of MRSA, EMRSA strains -1, 
-3, -15 and -16 have been prominent in the UK; the latter strains account for the 
majority of isolates sent annually for epidemiological typing to the Laboratory of 
Hospital Infection (Livermore, 2000). Additionally, S. aureus is not only an important 
nosocomial pathogen but is becoming increasingly worrying as an important frequent 
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cause of infection in the community. Community-acquired (CA) MRSA is genetically 
distinct from hospital-acquired (HA) MRSA and can also differ in the antibiotic 
susceptibility profile (Ma et al., 2002).  However, CA-MRSA can be highly virulent and 
is increasing in prevalence being often associated with skin and soft tissue infections, 
although the distinction between CA- and HA- MRSA infections is becoming more 
difficult due to CA-MRSA crossover into hospitals and healthcare setting causing HA-
infections (Elston, 2007, O'Brien et al., 1999).  
 
1.2.3.1 Mechanism of MRSA resistance 
 
Methicillin resistance is commonly mediated by the presence of the mecA gene within 
the staphylococcal chromosome in a discrete region called the staphylococcal cassette 
chromosome (SCCmec) that is related to the production of a modified penicillin-binding 
protein (PBP), PBP2’ or 2a, a fifth PBP in addition to the four others found in all strains 
of S. aureus (Hiramatsu et al., 2001). Variants of the SCCmec have been identified that 
vary not only in size and organisation but also differ in different genes that they carry 
other than mecA (Hiramatsu et al., 1999). PBPs are essential enzymes involved in cell 
wall synthesis and are the targets for "-lactam antibiotics. Production of PBP2a 
specifies a reduced affinity for binding methicillin and other "-lactam antibiotics such 
as cephalosporins, monobactams and carbapenems to strains of MRSA conferring 
resistance against these antibiotics allowing maintenance of cellular homeostasis.  
 
The expanding use of antimicrobials including methicillin has led to strains of MRSA 
that are multi-resistant to nearly all classes of antibiotics (e.g. macrolides, lincosamides, 
tetracyclines, aminoglycosides, quinolones, trimethoprim and sulphonamides), 
excluding the glycopeptides (e.g. vancomycin and teicoplanin) to which strains of 
MRSA remain susceptible (Trias and Gordon, 1997). However, conjugative transfer of 
vancomycin resistance from Enterococcus faecalis to S. aureus via a vanA- containing 
plasmid has been demonstrated in vitro and in vivo (Noble et al., 1992). In addition, 
horizontal transfer of the vanA gene from Enterococcus faecalis has been shown to 
confer high levels of vancomycin resistance in clinical isolates of S. aureus (Chang et 
al., 2003). Since the first clinical isolate of S. aureus with intermediate vancomycin 
resistance (VISA) was reported from Japan in 1997 (Hiramatsu et al., 1997), other 
VISA and vancomycin resistant S. aureus (VRSA) cases have subsequently been 
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reported in numerous countries. This potential threat of increasing bacterial resistance is 
cause for serious concern in that the antibiotic therapies currently utilised may no longer 
prove effective in the treatment of certain infections. If increased resistance continues, 
there is a possibility that infections caused by S. aureus could potentially revert back to 
a preantibiotic era (Trias and Gordon, 1997). Therefore there is a need for new alternate 
treatment options to those provided by antibiotics that are not hindered by resistance. 
 
1.3 Display technology 
 
Various display and screening methodologies using phage, yeast, ribosomal, synthetic 
and bacterial display systems have been developed that enable libraries consisting of a 
large number of individual peptides and proteins to be expressed on their surface that 
can be screened to select ligands against specific targets. Libraries are synthesised so 
that each individual display vehicle from the library contains a single, different, DNA or 
RNA coding sequence, each representing a specific clone of the library; although each 
sequence will be present in numerous copies (Mersich and Jungbauer, 2008). Screening 
of libraries for clones of interest allows identification of a link between a specific gene 
and not only the protein it codes for, but also allows analysis of the function of that 
protein. Furthermore, the expanding prevalence of genomics and proteomics has led to 
the complete or partial sequencing of many bacterial and human genomes (currently 
over 5500 species identified in Genbank; http://www.ncbi.nlm.nih.gov/sites/ 
entrez?db=genome) (Information, 2009) that allow comparison of genes and gene 
products previously uncharacterised, to gain insight into homology and unknown 
function. These technologies have emerged as powerful tools for the exploration of 
protein-protein interactions, protein identification and mapping, receptor-ligand 
interactions and drug discovery offering many important applications in targeted 
diagnostic and therapeutic technology. One of the first display technologies was phage 
display, from which antibodies have been selected that currently have FDA approval or 
are in clinical trials for the treatment of a variety of diseases (Brekke and Loset, 2003). 
 
1.3.1 Phage display 
 
Phage display, originally described by Smith (1985) is a technique whereby proteins are 
displayed on the surface of bacteriophage. Various strains of phage including M13, f1 
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and fd and also T7 and # have been used that consist of single stranded DNA 
surrounded by several coat proteins (Azzazy and Highsmith, 2002). Foreign DNA 
sequences are inserted into filamentous phage genome and expressed as a fusion 
product with one of the phage coat proteins on the surface of phage, usually pIII or 
pVIII (Azzazy and Highsmith, 2002). Numerous foreign proteins including peptides (El 
Zoeiby et al., 2003), antibody fragments (Fab (de Haard et al., 1999) and scFv (Nissim 
et al., 1994)), enzymes  (McCafferty et al., 1991), enzyme inhibitors (Huang et al., 
1998), hormones (Sidhu et al., 2000), cytokines (Buchli et al., 1997) and also cDNA 
(Somers et al., 2002) have all been displayed on the surface of phage thus showing the 
enormous diversity and potential of this selection technique.  
 
Isolation of phage that bind to a target of interest usually utilises a technique known as 
affinity selection (or panning); this method allows selection of molecules against a 
target by screening and amplification to select specific binders from an excess of non-
binders. Briefly, the phage library is allowed to bind to the target of interest, non-
binding phage are removed by washing, and the remaining phage are eluted and 
amplified in E. coli that are infected by phage using the F-pili as receptors. Successive 
rounds of panning allow amplification and enrichment of specific clones that bind to the 
target. Following panning, DNA sequencing of the clones and translation allows 
deduction of the protein sequence.  
 
Phage display technology is advantageous in that it offers high-throughput screening 
and has had enormous successes in selecting phage particles displaying biologically 
active ligands with the unique, desired, binding specificities, having been routinely used 
against a wide range of targets. One of the most investigated applications of phage 
display has been in the selection of antibodies or antibody fragments (especially Fab or 
scFv) that recognise specific antigens. In addition to the isolation of recombinant 
antibodies, phage display has also been utilised for receptor-ligand isolation, selection 
of enzyme substrates, drug discovery/screening, identification of novel therapeutic 
targets, epitope mapping and recovered proteins may also have potential as novel 
vaccine candidates, diagnostic or prognostic markers (Mullen et al., 2006, Azzazy and 
Highsmith, 2002, Benhar, 2001).  
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Peptide phage display has emerged as a powerful complement to antibody display that 
can generate reagents with similar binding affinities to those of antibodies, with the 
advantage that peptides are easier to produce in large quantities. One particular 
application of phage display is the emergence of this technology as a promising tool for 
the detection and generation of novel therapeutics against pathogens. For example, 
Carnazza et al (2008) identified a 9-mer cationic peptide that binds highly selectively to 
the cell surface of P. aeruginosa. These peptides, selected from rounds of whole cell 
panning against P. aeruginosa, have enormous potential to act as biosensors/diagnostic 
tools against this frequent human pathogen, and most importantly this technology is 
applicable to a range of clinically relevant microorganisms (Carnazza et al., 2008). 
Furthermore, a peptide that specifically binds to Mycoplasma arginini infected 
pancreatic " cells and not other Mycoplasma strains or non-infected cell lines was 
isolated from phage peptide display; clearly demonstrating the widespread use of this 
technology as detection and purification reagents and even drug delivery vehicles (De et 
al., 2005), in a similar manner to those employed in the field of cancer.  Interestingly, 
unlike the peptide sequences derived against P. aeruginosa (Carnazza et al., 2008), the 
peptides derived against M. arginini were synthesised and shown to retain binding 
potential in the absence of the phage vehicle (De et al., 2005). Furthermore, 
tetramerisation of the peptide was shown to increase its binding affinity for the target, 
presumably because multivalent display is more similar to the original phage 
configuration whereby 3-5 copies are presented on the phage surface (De et al., 2005). 
The specific targeting potential of ligands isolated from phage display indicates the 
possible utility of phage to act as carrier systems as drug delivery vehicles, which may 
have important applications in infection and disease states to deliver drugs directly to 
the target of interest. Phage display has been employed not only to identify S. aureus 
specific peptides, but also phage were conjugated to chloramphenicol through a labile 
linker to deliver controlled release of chloramphenicol whilst retaining binding 
specificity (Yacoby et al., 2006). This work showed that growth obstruction of S. aureus 
using the targeting conjugate was as efficient as administration of a 20-fold higher 
concentration of free chloramphenicol and importantly, the equivalent concentration of 
free chloramphenicol to that conjugated to the phage did not obstruct bacterial growth 
(Yacoby et al,. 2006).  Cell specific delivery of therapeutic agents is therefore expected 
to improve the efficacy of the drugs, decrease unwanted side effect and reduce the 
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concentration required for treatment thus reducing the possibility of drug resistance 
development (Yacoby et al., 2006, De et al., 2005). 
 
1.3.2 Bacterial display libraries 
 
Bacterially-displayed libraries have emerged as a viable alternative platform to phage 
display technology. Bacterial libraries have been generated in both Gram-negative 
species, including E. coli and Salmonella sp, and Gram-positive bacteria such as 
Staphylococci and Streptococci that display peptides and proteins on the bacterial 
surface expressed on a range of outer membrane proteins (OMP). Peptides or proteins 
are expressed on the microbial cell surface by fusion with an anchoring motif via N- or 
C-terminal, or more commonly sandwich fusion depending on the characteristics of the 
display/carrier proteins (Lee et al., 2003). Early work established that peptides could be 
expressed on the bacterial cell surface of recombinant E. coli as fusions such as OmpA 
(Freudl et al., 1986), LamB (Charbit et al., 1988), and PhoE (Agterberg et al., 1990). 
However, in most applications these carrier systems were not permissive for the display 
of large proteins on the cell surface (Mersich and Jungbauer, 2008, Tommassen et al., 
1993). This is presumably because regions at the N- and C- termini are required 
unaltered for efficient outer membrane targeting of most OMP (Georgiou et al., 1997) 
and therefore lateral fusion of a polypeptide end to end is not possible without 
interference with membrane insertion thus allowing only display of peptides and not 
full-length proteins within integral OMP (Chen and Georgiou, 2002). This indicates that 
the positioning and length of the peptide as well as choice of carrier protein are 
important factors that influence efficient peptide display (Nakajima et al., 2000). To 
circumvent these limitations the Lpp-OmpA system was constructed utilising E. coli 
lipoprotein and OmpA to display full length heterologous protein (Francisco et al., 
1992).  Furthermore, ice nucleation protein is an OMP found in Pseudomonas, amongst 
other species, that has an internal repeated domain that is adjustable in-frame in length 
allowing successful expression of foreign proteins as large as 60kDa (Lee et al., 2003).  
 
Bacterial display libraries have also been successfully generated for display on 
lipoproteins, S-layer proteins and extracellular appendages, such as flagella, fimbriae 
and pili. In addition to the display of peptides, bacterial display technology has also 
been utilised for the display of antibodies (Gunneriusson et al., 1996, Fuchs et al., 
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1996), enzymes (Strauss and Gotz, 1996, Francisco et al., 1992) on both Gram-positive 
and Gram-negative bacteria and also human cDNA library in E. coli for high-
throughput screening of recombinant human proteins (Bussow et al., 2000). However, 
the more rigid structure of Gram-positive cells walls makes them generally more 
suitable for the development of whole cell catalysts/adsorbants (Lee et al., 2003). One 
of the most common applications of microbial cell surface display has been the 
development of live vaccine delivery by displaying heterologous immunogenic epitopes 
to induce an antibody response in the host (Lee et al., 2000).  Additionally, bacterial 
display systems for environmental applications such as bioremediation purposes for 
removal of heavy metals have also been utilised. For example, insertion of yeast and 
mammalian metallothioneins, cellular metal sequestering peptides, into Omp LamB and 
expressed in E. coli demonstrated a twenty-fold increase in its natural Cd(2+) 
accumulation ability (Sousa et al., 1998).  
 
One important feature of bacterial display is that it allows libraries to be screened by 
fluorescence activated cell sorting (FACS) enabling a high-throughput process of 
quantitative screening and direct functional analysis of clones avoiding lengthy 
immobilisation, elution and reinfection steps needed with phage technology (Dane et 
al., 2006, Chen and Georgiou, 2002). Furthermore, analysis of clones utilising FACS 
enables distinction of clones with different binding abilities, allowing selection of the 
‘better binders’ or those against epitopes of varying density. Screening by FACS 
analysis is not often utilised using phage technology as phage are too small to be 
directly detected unless labelled with, for example, an antibody with a fluorescent tag. 
FACS using bacterial display libraries is emerging however as an important tool in the 
rapid isolation of clones with specific binding properties. Dane et al (2006) used 
fluorescent bacterial display libraries and FACS analysis, incorporating negative 
selection steps to remove clones that bound to healthy breast tissue, in order to identify 
peptides that bind to a human breast cancer cell line, with one identified clone 
displaying over 80-fold specificity for the tumour cell type relative to healthy breast cell 
lines (Dane et al., 2006). In addition to peptide display, flow cytometry has been used to 
screen cell surface expressed scFvs utilising the Lpp-OmpA system to select from a 105 
excess of control bacteria (Francisco et al., 1993) and also been utilised for screening of 
enzyme libraries (Olsen et al., 2000).  
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Bacterial display libraries offer additional advantages over phage display counterparts. 
For example, a bacterial display library was successfully used for the identification of 
peptides that mediate entry into eukaryotic cells by using antimicrobial agents to 
eliminate extracellular bacteria, whereas this differentiation is not as easily achievable 
using phage technology due to the difficulties involved in the selective separation of 
intracellular and extracellular phage (Taschner et al., 2002). In general, the utilisation of 
bacterial display libraries is slightly simpler than that of phage in that it does not require 
separation and infection steps, and also that direct visualisation by microscopy can be 
used without the need for further labelling (Nakajima et al., 2000). Additionally the 
expression of large polypeptides, such as antibodies or antibody fragments, by phage 
display is not usually permissive as fusions to pVIII, and therefore expression as fusions 
to pIII is usually adopted (Benhar, 2001). However, a phage particle only expresses 3-5 
copies of pIII as compared with 2,700 copies of pVIII. The low expression of phage 
coat protein genes and the usual unconstrained nature of peptides is often 
disadvantageous, particularly in structural studies of isolated peptides, whereas 
constrained peptides offer advantages in the identification of structural epitopes (Lu et 
al., 1995).  Microbial surface display also offers an advantage in that it enables surface 
expression of larger proteins than is typically permitted by phage display (Lee et al., 
2003). However, the diversity of peptides that can be displayed is usually lower in 
bacterially displayed libraries, whereas phage display libraries are frequently created 
displaying diversities as high as 1010 (Willats, 2002, Nakajima et al., 2000).  
 
1.4 Flagella peptide display 
 
The bacterial flagellum is the organelle associated with motility consisting of a filament, 
hook and basal body (Fig 1.5). FliC (flagella filament protein) is the major structural 
component of the E. coli flagellum. The filament is made by polymerisation of 
approximately 20,000 FliC molecules that assemble at the distal end of the filament, and 
extends from the cell surface that is capped with five FliD molecules (Majander et al., 
2005). The N- and C- termini of FliC proteins are highly conserved whereas the central 
region is highly variable (Westerlund-Wikstrom, 2000). Flagella display is based on 
insertion of foreign DNA into this variable region of FliC, displayed as fusion proteins 
in a functional form, and has been shown to permit the insertion of large peptides (up to 
302 amino acids), although this may not represent the largest insert that could be  
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expressed (Westerlund-Wikstrom et al., 1997). Additionally, it has also been 
demonstrated that FliD can be used as a carrier of foreign peptides (Majander et al., 
2005) but this is less common. 
 
1.4.1 The FliTrx™ random peptide display library 
 
The FliTrx™ random peptide library is based on research carried out by Lu et al (1995). 
This group demonstrated that the entire thioredoxin gene can be inserted into the non-
essential region of the flagellin gene (fliC) and the resulting fusion proteins are 
efficiently transported and assembled into partially functional flagella on the cell 
surface. The random dodecapeptides are inserted in-frame into the active site loop of 
thioredoxin, that is itself contained within the non-essential region of the fliC gene. 
Subsequent analysis demonstrated the display of constrained peptides on the flagella of 
E. coli. More than 90% of the flagella were functional, and can accumulate up to 20% 
of total cellular protein (Lu et al., 1995). 
 
The library contains an estimated 1.77 x 108 individual 12-mer peptides that are flanked 
by Cys-Gly-Pro and Gly-Pro-Cys sequences at the N and C terminus, respectively. 
These sequences form a disulfide loop which displays the peptide on the cell surface in 
a conformationally constrained manner, making peptides easily accessible to ligands for 
binding (Fig 1.6). For expression of the library, the plasmid, pFliTrxTM, propagated in 
E. coli G1820, uses the PL promoter from bacteriophage λ to drive expression of the 
peptide fusion construct where the cI repressor gene is under control of the trp promoter 
(Xin et al., 2003). Expression of the fusion proteins is induced by the addition of 
tryptophan that blocks cI repressor synthesis, enabling transcription of the thioredoxin-
flagellin fusion proteins. A schematic representation of expression of the peptide library 
is shown in Figure 1.7. 
 
1.4.2 Applications of the FliTrxTM peptide library 
 
The previous applications of the FliTrxTM library principally include the exploration of 
protein-protein interactions such as receptor-ligand binding and enzyme-substrate 
specificity.  Antibody-antigen recognition studies using the library have been performed  
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by many groups based on epitope mapping, and various groups have highlighted the 
potential for use in vaccine development. Studies focussing on epitope mapping work as 
well as examples of other applications are shown in Table 1.1 to show the libraries 
versatility. 
 
Interestingly, similar to phage display, the FliTrx™ library has also been utilised to 
screen against whole cells in order to identify novel targets for potential new diagnostic 
and therapeutic approaches. For example, Brown et al (2000) used the library to identify 
tumour vasculature binding peptides by panning against tumour-derived murine 
endothelial cells. This group applied a negative selection step to remove clones that 
bound non-specifically to cellular markers and generated tumour endothelial cell 
specific reagents, highlighting the potential of the library to be used for specific 
targeting (Brown et al., 2000). Similarly, Li et al (2008) have recently screened a 
normal liver cell line and a hepatoma cell line, again using negative selection, to 
identify tumour specific peptides. Yang et al (2008) have also screened the library with 
negative selection to identify a peptide that bound to a metastatic prostate cell line, with 
the synthetic peptide showing specificity for metastatic prostate, breast, lung and gastric 
cells both in vitro and in vivo but no reactivity against non-metastatic cells. 
 
Additionally, Zitzmann et al (2005) identified specific peptides derived from panning 
against a human prostate carcinoma cell line that showed a reduced affinity to HUVECs 
and benign prostate cells. Peptides were radiolabelled with 125-I or 131-I and shown to 
bind tumour cell lines preferentially in in vitro studies. Biodistribution studies in a 
mouse model showed moderate tumour accumulation, identifying the possible utility of 
peptide technology for directing radioisotopes to tumours that may have the potential 
for tumour targeting and diagnostic/imaging purposes (Zitzmann et al., 2005). In 
summary, screening of display libraries has led to the identification of a vast array of 
proteins with unique binding applications. These libraries offer a great deal of potential 
for isolation of ligands that bind to specific targets enabling development of new 
systems for drug delivery or as diagnostic reagents. 
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1.5 Photodynamic therapy (PDT) 
 
1.5.1 History of PDT 
 
The antimicrobial effect of PDT was originally published in 1900 when Raab noted the 
toxicity of acridine hydrochloride when combined with certain wavelengths of light to 
Paramecia cauatum (Raab, 1900). Further to this, in 1904 Raab’s tutor designated the 
phrase ‘photodynamic reaction’ (von Tappeiner, 1904). The discovery of many classes 
of antibiotics with the capacity for broad and effective killing of microbes resulted in 
the antimicrobial action of PDT not being fully investigated and utilised. However, the 
rise in bacterial resistance has led to alternative approaches of antimicrobial action to be 
researched and developed. The use of PDT as an alternative approach in this instance is 
particularly attractive as it is not hindered by bacterial resistance (Wainwright and 
Crossley, 2004). 
 
1.5.2 Mechanism of action 
 
PDT involves the administration of a photosensitiser that is activated by illumination 
with light of an appropriate wavelength and the presence of oxygen. The energy 
absorbed by the photosensitiser converts it from ground state into an excited singlet 
state and then to a more stable lower energy triplet state and reacts with oxygen. The 
activity of PDT is based on two photooxidative reactions: type I and type II (Maisch, 
2007). In type I reactions, the photosensitiser reacts directly with substrates other than 
molecular oxygen via electron or hydrogen atom transfer to produce free radicals such 
as superoxide, hydrogen peroxide or hydroxyl radicals. In type II reactions the activated 
photosensitiser reacts with ground state molecular oxygen to produce highly reactive 
singlet oxygen, which is the main bactericidal species produced that reacts rapidly with 
the environment. A summary of antimicrobial PDT is summarised in Figure 1.8. 
 
The lethal damage to bacteria following PDT can result in damage to either DNA and/or 
the cytoplasmic membrane that results in leakage of cellular contents, enzyme 
inactivation and non-functional membrane transport systems (Hamblin and Hasan, 
2004). The different classes of compounds that show effective antimicrobial action are  
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summarised in Table 1.2, whereby methylene blue and toluidine blue have been used 
clinically for antimicrobial applications. 
 
1.5.3 Photodynamic inactivation of bacteria 
 
The application of PDT has been shown to be effective against a wide range of both 
Gram-positive and Gram-negative bacteria utilising a range of different photosensitisers 
and light sources. The differences in cell wall structure renders Gram-negative bacteria 
less susceptible to anionic and neutral photosensitisers than Gram-positive isolates due 
the negative charge conferred by lipopolysaccharides in the outer membrane (O’Riordan 
et al., 2005). However, other groups have demonstrated that addition of the nonapeptide 
polymyxin or EDTA resulted in greater membrane permeability thus allowing 
successful photoinactivation of Gram-negative bacteria utilising anionic 
photosensitisers (Nitzan et al., 1992, Bertoloni et al., 1990). In comparison, cationic 
photosensitisers have been utilised as compounds that are capable of photoinactivation 
of Gram-positive and Gram-negative species (Hamblin et al., 2002b, Segalla et al., 
2002, Merchat et al., 1996, Minnock et al., 1996). 
 
The penetration of light through the skin decreases with depth. Different classes of 
antimicrobial photosensitisers have varying absorption maxima depending on the 
molecular structure, generally within the 300-700 nm range (Wainwright, 1998) and 
diffusion of light through tissue increases with increasing wavelength within 400-700 
nm (Maisch, 2007). Effective PDT requires delivery of light not only of the correct 
wavelength but also of sufficient intensity. Therefore penetration of light can be a 
problem at lower wavelengths and as such the PDT to kill pathogenic bacteria within 
wounds should consider the absorption spectrum of the photosensitiser and the 
penetration depth required (Maisch, 2007). Following accumulation of the 
photosensitiser, numerous light sources such as lasers or lamps of appropriate 
wavelengths can be utilised for PDT via either direct illumination of treatment site, fibre 
optics or bundles or implanted light emitting diodes (Hamblin and Hasan, 2004). The 
application of PDT for treatment of chronic wounds has some advantages; not only can 
the photosensitiser be directly placed on the affected area, but the light source used to 
activate the compound can also be accurately applied (Hamblin and Hasan, 2004). 
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PDT may also be effective as a treatment of bacteria present within biofilms. 
Wainwright et al (2002) demonstrated that treatment of a P. aeruginosa biofilm with 
new methylene blue caused both a bactericidal effect and breakdown of the extracellular 
polymeric substance that was superior to biofilm treatment with ampicillin. This 
technology has also been demonstrated to be effective in the treatment of oral biofilms 
(Zanin et al., 2006, Wilson et al., 1996). In addition, antimicrobial PDT has also been 
shown to reduce microbial virulence factors (lipopolysaccharide and proteases) that may 
contribute to the pathogenesis of infection (Komerik et al., 2000). Furthermore, Di Poto 
et al (2009) demonstrated that PDT was effective against S. aureus biofilms and that 
nearly complete eradication was observed when PDT was used in conjunction with 
either exposure to vancomycin or the phagocytic action of whole blood. Therefore, the 
bactericidal effect achieved with photodynamic therapy my be enhanced by being used 
in conjunction with antimicrobial therapy (Di Poto et al., 2009, Zolfaghari et al., 2009). 
 
1.5.4 Photodynamic therapy of S. aureus and MRSA 
 
Previous research has shown that numerous different photosensitisers have been shown 
to have a bactericidal effect on MRSA and drug sensitive S. aureus both in vitro and in 
vivo. A selection of these photosensitisers utilised over the last 15 years are 
characterised in Table 1.3, based on a search of Web of Knowledge and Pubmed, that 
are categorised according to the compound type and then reverse chronological order. 
Although many of these compounds have shown efficacy against various strains of 
Staphylococci, few/if any of these antimicrobial agents are in everyday use and 
therefore further work is needed to make this a real treatment option to eradicate 
bacteria present in wounds.  
 
1.5.5 Conjugation of photosensitisers to biomolecules 
 
The optimum photosensitiser used for effective antimicrobial PDT would be a 
compound that is localised to the bacteria causing the infection, whilst avoiding host 
cells or commensal bacteria (O’Riordan et al., 2005). Conjugation of the photosensitiser 
with a targeting moiety specifically for pathogens would be advantageous in that it 
would improve specificity of treatment without damaging normal tissue, and targeting 
may require lower drug doses. The different biomolecules that have been conjugated to  
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photosensitisers for targeting of MRSA and S. aureus are summarised in Table 1.4. 
Similarly, biomolecules have been used to target photosensitisers to other bacterial 
strains and are given in Table 1.5.  
 
In addition to delivery of photosensitisers conjugated to biomolecules for specific 
bacterial targeting, other forms of improved photosensitiser delivery have been 
investigated. For example, Ferro et al (2006) demonstrated greater inactivation of 
MRSA when the photosensitiser (haematoporphyrin) was delivered by positively 
charged liposomes than was achieved with the free dye. A similar effect was also 
observed by Tsai et al (2009) whereby the concentration of liposome and micelle 
encapsulated haematoporphyrin required for S. aureus and MRSA eradication was 
lower than that of the free form, presumably by reducing photosensitiser aggregation 
thus limiting the quenching potential of the photosensitiser and an increase in reactive 
oxygen species (ROS) production. 
 
1.5.6 Other applications of PDT 
 
PDT has been used clinically for many years for the treatment of age-related macular 
degeneration (Bressler and Bressler, 2000) and recently for cancer (Brown et al., 2004). 
However, PDT has successfully been applied to the treatment of skin diseases including 
psoriasis (Boehncke et al., 2000) and acne (Hongcharu et al., 2000) and also against oral 
pathogenic bacteria (Chan and Lai, 2003). 
 
In addition to utilisation against bacteria, PDT has also been applied to the inactivation 
of viruses, mainly for sterilisation of blood components (Santus et al., 1998), and 
against parasites (Grellier et al., 1997). Furthermore, PDT has shown promise in the 
treatment of fungi (Calzavara-Pinton et al., 2005), such as Candida sp (Bliss et al., 
2004), and the protection/decontamination of food (Kreitner et al., 2003) and 
disinfection of water (Kuznetsova et al., 2007, Alouini and Jemli, 2001). In summary, 
PDT has shown potential in many disease states, the most useful clinically being age-
related macular degeneration, however for widespread use in microbiology there 
remains the problems of specificity and effectiveness.  
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1.6 Aims 
 
The overall aim of this thesis was to identify novel peptides with MRSA binding 
specificity that may prove useful in targeted PDT of chronic wounds. These could 
provide new modes of targeting bacteria that are not hindered by the development of 
bacterial resistance. The main objectives of this study were: 
 
1. Identification of MRSA-specific peptides derived through panning of the 
FliTrx™ bacterially display random peptide library. Following DNA sequencing 
of positive clones, peptides were synthesised and binding characterised by flow 
cytometry against a range of Gram-positive and Gram-negative species. 
2. Expression, purification and characterisation of recombinant proteins containing 
the specific peptides sequences of interest. Recombinant proteins were also 
expressed as green fluorescent protein (GFP) fusion proteins to allow direct 
assessment of recombinant protein binding. 
3. Analysis of recombinant protein binding and functional effects, followed by 
conjugation to a porphyrin for cytotoxicity assays against MRSA, E. coli and 
keratinocytes.  
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CHAPTER TWO 
Materials and methods 
 
2.1 Materials 
 
2.1.1 Bacterial strains and keratinocyte cell line 
 
Three strains of MRSA (MRSA1, MRSA2 and MRSA3), S. aureus, S. epidermidis, E. 
coli and P. aeruginosa used in this study were community-acquired samples obtained 
from Hull Royal Infirmary. The NCTC2544 human keratinocyte cell line was kindly 
provided and maintained by Huguette Savoie. 
 
2.1.2 Bacterial cell lines 
 
♦ E. coli GI826: F-, lacIq, ampC:: Ptrp cI, $fliC, $motB, eda::Tn10 (Flitrx™ 
library strain, Invitrogen, Paisley, UK) 
♦ E. coli DH10B: F– mcrA $(mrr-hsdRMS-mcrBC) %80lacZ$M15 $lacX74 
recA1 endA1 araD139 $(ara leu) 7697 galU galK rpsL nupG #– (Cloning strain, 
kindly provided by Dr Frank Voncken, University of Hull) 
♦ E. coli JM109: endA1, recA1, gyrA96, thi, hsdR17 (rk–, mk+), relA1, supE44, $( 
lac- proAB), [F´ traD36, proAB, laqIqZ$M15] (Cloning strain, Promega, 
Southampton, UK) 
♦ E. coli BL21: F- ompT hsdSB(rB- mB-) gal dcm tonA (Cloning strain, Sigma 
Chemical Company Ltd., Poole, UK 
♦ E. coli GC10: F- mcrA $(mrr-hsdRMS-mcrBC) %80dlacZ$M15 $lacX74 
endA1 recA1 $(ara, leu)7697 araD139 galU galK nupG rpsL #- T1R (Cloning 
strain, Sigma) 
2.1.3 Vectors 
 
♦ pPROTet (Clontech, Saint-Germain-en-Laye, France) 
♦ pFlitrx™ (Invitrogen) 
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2.2 Methods 
 
2.2.1 Bacterial cell culture 
 
MRSA, S. aureus and S. epidermidis  were cultured in nutrient broth (‘Lab-Lemco’ 
powder 1 g/L, yeast extract 2 g/L, peptone 5 g/L and sodium chloride 5 g/L; Oxoid, 
Basingstoke, UK) in 250 ml Erlenmeyer flasks. E. coli and P. aeruginosa were cultured 
in Luria-Bertani (LB) medium (yeast extract 5 g/L, tryptone 10 g/L and NaCl 10 g/L). 
All media was made with dH20 and autoclaved at 121°C for 15 min. Bacterial cultures 
were grown at 30ºC with shaking and subcultured aseptically using a 1% (v/v) inoculum 
every 24 h. Cultures were plated out onto nutrient broth or LB plus agar (15 g/L; Oxoid) 
in 90 mm Petri dishes and incubated at 30ºC. For glycerol stocking, cultures were 
centrifuged at 2,000 x g for 20 min at 4°C and the bacterial pellets resuspended in 1 ml 
phosphate buffered saline (PBS; 0.01M phosphate buffer, 0.0027 M KCl, 0.137 M 
NaCl, pH 7.4 and autoclaved; Sigma) supplemented with 15% (v/v) glycerol and stored 
at –80ºC until required. New aliquots of bacteria taken from glycerol stocks were used 
every 1-2 weeks in order to maintain genotype and phenotype. 
  
2.2.2 Determining the presence of MRSA 
 
Selective mannitol broth (Oxoid), originally described by Gurran et al (2002), was used 
in order to determine the presence of MRSA. A 50 µl sample of bacterial culture was 
used to inoculate 5 ml selective mannitol broth and incubated overnight at 30ºC. 
Presence of MRSA is confirmed by fermentation of mannitol that acidifies the medium 
as denoted by a colour change from red to yellow. Similarly, the presence of MRSA 
was confirmed by plating out a bacterial culture suspension onto chromogenic MRSA 
agar (Oxoid) used to detect phosphatase activity. Plates were incubated for 24-48 h at 
30ºC and presence of MRSA determined by the presence of denim blue colonies, 
described by Macrae (2006). 
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2.3 Determination of optimal killing time of MRSA using UV radiation 
 
The effect of UV radiation to kill MRSA cultures was first determined to ensure that the 
MRSA target cells were not able to compete with the E. coli expressed peptide library 
during the panning process. In preliminary investigations a 15 W 254 nm UV lamp was 
used to kill the bacteria. Bacterial cultures were grown to late log phase and a 10 ml 
sample was applied to 90 mm Petri dishes. The plates were subject to irradiation by 
UV-C exposure at 15 cm distance for 0-60 min and 100 µl samples extracted every 5 
min and plated onto nutrient agar. The agar plates were incubated at 30ºC for 24-48 h 
and then inspected for bacterial growth. 
 
Furthermore, a 40 ml overnight culture was centrifuged at 2,000 x g for 20 min at 4ºC. 
The pellet was resuspended in 20 ml PBS to concentrate the bacteria and 10 ml samples 
were applied to 90 mm Petri dishes. The plates were subject to irradiation and culture 
samples were taken every 5 min and plated out as described above. This method was 
also repeated utilising a new 15 W 254 nm lamp using the method described above 
except that the lamp was placed 10 cm distance from the plate prior to irradiation. 
 
2.3.1 Confocal microscopy analysis 
 
Bacterial viability was assessed utilising the LIVE/DEAD BacLight Bacterial Viability 
kit (Invitrogen), a fluorescence-based assay that employs the use of two fluorescent 
dyes – SYTO 9 and propidium iodide (PI) that differ in their spectral characteristics and 
ability to penetrate healthy bacterial cells. The excitation/emission maxima are 480/500 
nm for SYTO 9 and 490/635 nm for PI respectively. For STYO 9 and PI dye staining, 
two bacterial cultures (30 ml) were grown in nutrient broth to late log phase. One 
sample was UV irradiated using a 15 W 254 nm lamp at a 10 cm distance in order to 
effectively kill the bacteria (section 2.3). The MRSA cultures, both viable and 
irradiated, were concentrated by centrifugation at 10,000 x g for 15 min. The 
supernatants were removed and the pellets resuspended in 2 ml of 0.85% (w/v) 
sterilised NaCl. An aliquot (1 ml) of each suspension was added to centrifuge tubes 
containing 20 ml of 0.85% (w/v) NaCl and these were incubated for 1 h at room 
temperature (RT) mixing every 15 min to ensure thorough homogeneity. Samples were 
centrifuged at 10,000 x g for 15 min and the pellets washed using 20 ml 0.85% (w/v) 
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NaCl and re-centrifuged. Both pellets were resuspended in 10 ml 0.85% (w/v) NaCl. A 
1 ml aliquot of bacterial suspensions was mixed with 3 µl of equal parts of SYTO 9 and 
PI, and incubated in the dark for 15 min. A 5 µl sample of stained bacterial suspension 
was used for confocal microscope analysis. 
 
Samples were analysed on Biorad Radiance 2100 attached to a Nikon TE200 inverted 
microscope. Briefly, samples were placed on a slide, sealed with a coverslip and 
inverted for visualisation with the confocal microscope, the argon 488 nm laser line was 
used and fluorescent emission was collected in photomultiplier tubes 1 and 2 collecting 
light using a 515+/-30 (SYTO 9) and 570 long pass (PI) filters, respectively. 
 
2.4 Bacterial immobilisation 
 
Bacterial immobilisation assays were performed using 6-well pre-coated poly-D-lysine 
or collagen I plates (Nunclon® Delta, Nunc, Raskilde,  Denmark) or 6-well plates 
coated in poly-L-lysine (Sigma). MRSA bacterial cultures (40 ml) were centrifuged at 
2,000 x g for 20 min at 4ºC and resuspended in 20 ml PBS. One sample (10 ml) was UV 
irradiated using a 15 W 254 nm lamp at a 10 cm distance in order to kill the bacteria 
(section 2.3). A 2 ml aliquot of either live or dead/non-viable bacterial suspensions were 
added to each well, except for the control wells containing no bacteria, and the bacteria 
were left to adhere for 2 h at RT, 2 h at 4°C or overnight at 4ºC. The bacterial culture 
was carefully aspirated from the wells and the plates rinsed with PBS and bacterial 
immobilisation determined by light microscopy and visible examination of the plates to 
ensure plate coverage. All plates were washed 5 times with 2 ml wash solution used in 
the panning protocol (section 2.5.1) and vortexed for 30 s. Methylene blue (0.3% (w/v); 
0.5 ml) was added to each well and incubated for 15 min. The plates were rinsed 5 times 
with 2 ml PBS and destained with ethanol and the absorbance of the stained bacteria 
was measured on a spectrophotometer (Pharmacia) at 668 nm. 
 
2.5 Peptide display library 
 
The FliTrx™ peptide library (Invitrogen) is a bacterially-displayed peptide library. The 
library displays random dodecapeptides on the surface of E. coli and has a diversity of 
1.77 x 108 different specificities based on manufacturer’s information. The peptides are 
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displayed within the active site loop of thioredoxin that is itself inserted into the 
dispensable region of the flagellin gene and are displayed on the surface within a 
conformationally constrained manner (section 1.4.1, Fig 1.6). 
 
2.5.1 Growth media and solutions 
 
5X M9 salts (1 L) 
5 x M9 salts containing 200 mM Na2HPO4, 100 mM KH2PO4, 42.5 mM NaCl and 100 
mM NH4Cl (Sigma) were dissolved in 900 ml double distilled water (ddH2O) and the 
pH adjusted to 7.4 with 10 M NaOH. Double distilled water was added up to 1 L and 
the solution autoclaved at 121ºC for 15 min. 
 
Ampicillin stock 
Ampicillin (Melford) was made at a 100 mg/ml stock solution in 0.2 µM filter sterilised 
(Millipore, Watford, UK) ddH2O. Aliquots were stored at -20ºC. 
 
L-tryptophan 
L-tryptophan (Sigma) was made at a 10 mg/ml stock solution in 0.2 µM filter sterilised 
ddH2O Aliquots were stored protected from light at 4ºC. 
 
IMC medium (1L) 
1 x M9 salts (40 mM Na2HPO4, 20 mM KH2PO4, 8.5 mM NaCl, 20 mM NH4Cl, pH 
7.4), 0.2% casamino acids, 0.5% glucose, 1 mM MgCl2 containing 100 µg/ml 
ampicillin. Casamino acids were dissolved in 775 ml ddH2O before autoclaving. After 
sterilisation, the solution was left to cool to ~55ºC before aseptic addition of 5X M9 
salts, MgCl2, glucose and ampicillin. The solution was stored at 4ºC. 
   
RM medium (1L) 
1 x M9 salts, 2% casamino acids, 1% glycerol 1 mM MgCl2 containing 100 µg/ml 
ampicillin. Casamino acids and glycerol were dissolved in 790 ml ddH2O before 
autoclaving. After sterilisation, the solution was left to cool before aseptic addition of 
5X M9 salts, MgCl2 and ampicillin. The solution was stored at 4ºC. 
 
 
 46 
RMG plates 
1 x M9 salts, 2% casamino acids, 0.5% glucose, 1 mM MgCl2, 100 µg/ml ampicillin 
supplemented with 1.5% agar. Casamino acids and agar were dissolved in 775 ml 
ddH2O before autoclaving. When the solution had cooled to ~55ºC, 5X M9 salts, 
MgCl2, glucose and ampicillin were added aseptically. The agar (approximately 25 ml 
aliquots) was poured into 90 mm Petri dishes and stored protected from light at 4ºC. 
 
Blocking solution 
IMC medium containing 100 µg/ml ampicillin supplemented with 1% non-fat dry milk, 
150 mM NaCl and 1% α-methyl mannoside (Sigma) 
 
Wash solution 
IMC medium containing 100 µg/ml ampicillin supplemented with 1% α-methyl 
mannoside 
 
2.5.2 Growth and induction of the peptide library 
 
One vial of FliTrx™ peptide library was used to inoculate 50 ml IMC medium 
containing 100 µg/ml ampicillin. The culture was grown to saturation at 250 rpm for 15 
h at 25ºC. Expression of the FliTrx™ library was induced by adding 1 x 1010 colonies of 
the overnight culture to 50 ml IMC medium containing 100 µg/ml ampicillin and 100 
µg/ml tryptophan. The culture was grown for 6 h at 25ºC. 
 
2.5.3 Immobilisation of bacteria onto culture plates as panning target 
 
Tissue culture plates (60 mm; Nunclon®) were coated with 1 ml poly-L-lysine. The 
plate was gently rocked for 5 min, rinsed with 5 ml PBS and allowed to dry for 4 h. 
MRSA cultures (40 ml) at log phase were centrifuged at 2,000 x g for 20 min at 4ºC and 
the pellet resuspended in 20 ml PBS. Cultures (10 ml) were added to the plate and 
allowed to adhere overnight at 4ºC.  The plate was then rinsed with 5 ml PBS and 10 ml 
blocking solution added and the plate gently agitated at 50 rpm for 1 h (Gyrorocker, 
Stuart). The blocking solution was decanted and the bacteria subject to UV irradiation at 
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254 nm for 5 min. This method of bacterial immobilisation prior to panning was also 
repeated using cultures of S. aureus and S. epidermidis. 
 
2.5.4 Panning of the random peptide display library 
 
Following 6 h growth of the FliTrx culture, a mixture of 0.1g non-fat dry milk, 300 µl 
5M NaCl and 500 µl 20% (w/v) α-methyl mannoside were added to sterile, conical 
centrifuge tubes. A 10 ml aliquot of the induced culture was added to each tube and 
gently mixed. The library cultures were added to the plates onto which the target 
bacteria had been immobilised (section 2.5.3). The plates were gently agitated at 50 rpm 
on a shaker for 1 min and then incubated at RT for 1 h to allow library clones to bind. 
 
The bacterial cultures were decanted and the plates then washed by gentle rotation with 
5 ml wash solution (section 2.5.1) at 50 rpm for 5 min. The wash procedure was 
repeated four more times to remove non-specific or weakly bound clones. The fifth 
wash was decanted and the plates vortexed for 30 s to elute the bound bacteria. IMC 
medium (10 ml) containing 100 µg/ml ampicillin was added to each plate and 
transferred to culture flasks. The cultures were grown at 250 rpm for 15 h at 25ºC. The 
same selection procedure was performed in four subsequent rounds of panning. After 
the fifth round of panning against the target bacteria, overnight cultures were streaked 
onto RMG plates and incubated overnight at 30ºC. After each round of panning, the E. 
coli library and MRSA cultures were plated out onto agar to ensure that there was no 
contamination of cultures and cultures were inoculated into oxoid selective mannitol 
broth to verify the presence of MRSA and ensure no contamination of the library 
(section 2.2.2). Glycerol was added to a final concentration of 20% (v/v) to the panned 
library and stored at –80ºC until required.  
 
2.5.5 Negative panning step 
 
Following 5 rounds of positive panning, bacterial stock cultures that were isolated from 
the final panning round were grown in 50 ml IMC medium containing 100 µg/ml 
ampicillin. The cultures were grown for 15 h at 250 rpm and 25ºC. The bacterial culture 
was induced by the addition of tryptophan (final concentration 100 µg/ml). The panning 
protocol was conducted in the same way as the previous method (section 2.5.4) except 
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that the induced culture was added to lysine only coated plates to remove clones which 
bound to lysine for 1 h before those clones that did not bind were transferred to the 
bacteria coated plates. The wash procedure was performed and isolation of positive 
clones performed according to the panning protocol. 
 
2.6 Plasmid DNA isolation 
 
Plasmid DNA was isolated from the panned library using the S.N.A.P. ™ (Simple 
Nucleic Acid Prep) Miniprep Kit (Invitrogen) and buffers supplied according to the 
manufacturer’s instructions. Colonies were randomly selected from RMG plates and 
inoculated into 2 ml RM medium containing 100 µg/ml ampicillin to obtain high yields 
of plasmid DNA. Bacterial cultures were grown at 250 rpm for 16-24 h at 30ºC. 
Overnight cultures were pelleted by centrifugation at 2,000 x g for 10 min at 4ºC. The 
cell pellet was resuspended in 150 µl of resuspension buffer by vortexing. The cells 
were lysed to release the plasmid by the addition of 150 µl lysis solution. The lysate was 
gently mixed and incubated at RT for 3 min. A 150 µl aliquot of precipitation salt was 
added and the solution gently inverted 6-8 times to ensure thorough mixing. The 
solutions were centrifuged at 13,000 x g for 5 min at RT in order to precipitate the 
unwanted proteinaceous solution. 
 
The supernatant was transferred into a 1.5 ml sterile microcentrifuge tube and 600 µl 
binding buffer added to the tubes and inverted 6 times. The plasmid containing solution 
was pipetted onto the S.N.A.P. ™ Miniprep Column that was then centrifuged at 3,000 
x g for 30 s at RT. The column flow through was discarded and first washed with 500 µl 
of wash buffer. Columns were centrifuged at 3,000 x g for 30 s at RT and column flow 
through was discarded. A 900 µl aliquot of 1X final wash buffer was added and tubes 
centrifuged for 3,000 x g for 30 s at RT. The column was centrifuged at 13,000 x g for 1 
min in order to dry the resin. To elute the plasmid DNA the columns were transferred to 
sterile 1.5 ml polypropylene microfuge tubes and 60 µl of sterile water was added 
directly to the resin. The tubes were incubated at RT for 3 min and centrifuged at 
13,000 x g for 30 s at RT in order to elute the plasmid DNA from the column. Plasmid 
DNA was stored at -20ºC until required. 
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2.6.1 DNA quantification 
 
The concentration and purity of the isolated DNA was determined 
spectrophotometrically by measuring the absorption of each sample at 260 and 280 nm. 
Distilled water was used as a reference to calibrate the spectrophotometer. The 
absorption was measured using a 6 µl aliquot of DNA diluted in 54 µl of distilled water 
or undiluted in a quartz cuvette. The concentration of DNA in each sample was 
calculated using the following formula: 
 
DNA concentration (µg/ml) = A260 x dilution factor x Extinction Coefficient for DNA (50) 
 
Assessment of the purity of the DNA in the samples was determined by measuring the 
A260 /A280 ratios. A ratio greater than 1.8 was considered acceptable and indicative of a 
relatively high purity of DNA (Maniatis et al., 1982). 
 
2.7 Polymerase chain reaction (PCR) of plasmid preparations 
 
PCR is an in vitro technique used to exponentially amplify sections of DNA and was 
performed to amplify the DNA sequence encoding the unknown peptide. DNA 
amplification was performed using Master Mix (Promega) that contains all the 
necessary components (Taq DNA polymerase, dNTPs and MgCl2). The amplification 
reactions were performed in 50 µl reaction mixtures containing: 
 
Plasmid DNA       1 µl 
Master Mix     25 µl 
FliTrx™ Forward Primer (200 ng/µl)   1 µl 
FliTrx™  Reverse Primer (200 ng/µl)   1 µl 
Nuclease free water    22 µl 
Final volume     50 µl 
 
Additionally, a negative control reaction containing no template DNA was included to 
ensure no PCR reagent contamination and amplification of the correct DNA. The 
reaction mixtures were cycled in a Thermal Cycler (Techne) using the programme 
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shown below in Table 2.1 under conditions described in the FliTrx™ manual 
(Invitrogen), except that the number of cycles was optimised to 35 cycles to increase the 
amount of amplified DNA. 
 
Table 2.1: PCR programme 
 
Phase Temp No. of cycles Time Event 
DNA 
denaturation 
94°C 1 2 min 
Denaturation 
of DNA 
PCR 
94°C 
 
55°C 
 
72°C 
35 
1 min 
 
1 min 
 
1 min 
Denature DNA 
strands 
Annealing of 
primers 
Extend DNA 
Final extension 
72°C 
 
 
4°C 
1 7 min 
Final extension 
of unfinished 
strands 
Final hold 
 
2.7.1 Agarose gel electrophoresis 
 
Agarose gel electrophoresis was used to separate DNA fragments on the basis of their 
rate of movement through a gel under the influence of an electrical field. The PCR 
product (section 2.7) was visualised by gel electrophoresis. A 4.5% (w/v) Agarose-1000 
(Invitrogen) gel was prepared in TBE buffer (90 mM Tris, 90 mM Boric acid, 2 mM 
EDTA) by heating in a microwave until the agarose had dissolved. After addition of 2 
µl ethidium bromide (10 mg/ml; Sigma) to a final concentration of 0.2 µg/ml, the gel 
was poured into an electrophoresis tray with the appropriate comb and left to set for at 
least 30 min at 4°C. After setting, the combs were removed and the tray placed in an 
electrophoresis tank and covered with TBE buffer. A DNA ladder was prepared with 5 
µl of a commercial 10 bp ladder (Invitrogen) and 10 µl 1X loading dye (0.25% (w/v) 
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bromophenol blue, 0.25% (v/v xylene cyanol FF and 30% (v/v) glycerol in dH20. The 
PCR samples were loaded at a 1:1 ratio with loading dye (10 µl final volume). Samples 
were mixed by repeated pipetting and loaded into the wells. Electrophoresis was carried 
out at 100 V for 1 h or until the bands were 1 cm from the end of the gel. The DNA 
bands were visualised using a UV transilluminator (UVItec, Cambridge, UK) and 
photographed. 
 
2.7.2 DNA sequencing of PCR products 
 
DNA sequencing was performed using the dideoxy chain termination method developed 
by Sanger et al (1977). This technique uses a mixture of four specific terminator 
dideoxynucleotides (ddNTP) that are each labelled with a specific fluorescent dye, that 
stop chain elongation. Primers bind to the complementary section of DNA and the DNA 
chain extends linearly incorporating normal dNTPs into the chain until DNA 
polymerase, by chance, incorporates a ddNTP into the chain and elongation is 
terminated. Following elongation, the DNA fragments are sorted by size using capillary 
electrophoresis and a laser beam excites each different ddNTP to produce a different 
fluorescent colour that is translated into a DNA sequence. 
 
DNA sequencing of PCR products was performed by MWG (Eurofins MWG Operon, 
Germany (MWG)). PCR products were purified and prepared for sequencing using 
exonuclease I, shrimp-alkaline phosphatase (SAP) (both GE Healthcare, 
Buckinghamshire, UK) and ethanol precipitation in order to concentrate the amount of 
DNA. A 1 µl aliquot of exonuclease I was mixed with 10 µl SAP. A 1.3 µl aliquot of 
this solution was added to 50 µl aliquots of PCR fragments. The samples were mixed, 
incubated at 37ºC for 15 min and heat inactivated for 15 min at 80ºC. Ethanol 
precipitation of purified PCR products was performed by mixing aliquots (50 µl) with 5 
µl sodium acetate (3 M) and 165 µl ice cold ethanol and stored on ice for 30 min to 
precipitate the DNA. The samples were centrifuged at 12,000 x g for 30 min at 4ºC. The 
supernatant was discarded and the samples washed in 200 µl ice cold ethanol (70%) and 
centrifuged at 12,000 x g at 4ºC for 5 min. The wash step was repeated, the supernatant 
discarded and the samples air dried. All PCR fragments were sequenced in both 
directions. 
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2.8 Peptide synthesis 
 
Following panning of the bacterial library against MRSA, DNA sequences of 20 peptide 
inserts were determined. Two peptides that shared similar homology with the other 
sequences (peptide12 and peptide19), but not overly similar to each other, were 
synthesised commercially (PeptideSynthetics, Fareham, UK). Peptides were synthesised 
with the N and C-terminal cysteine residues linked by a disulphide bridge in order to 
conformationally constrain the peptide and so retain its proposed binding motif as per 
panning. Additionally, peptides were synthesised as a linear construct in order to act as 
a comparison to assess binding ability. All peptides were synthesised with N-terminal 
biotin to allow subsequent characterisation of binding. Additionally, peptide12 was 
synthesised as a cyclic and linear construct with a C-terminal FITC instead of N-
terminal biotin for direct assessment of binding. 
 
2.8.1 Assessment of biotinylated peptide binding by flow cytometry 
 
The binding of the peptides to both live and UV-inactivated MRSA stains (MRSA1, 2 
&3), S. aureus and S. epidermidis were evaluated by flow cytometry. Bacterial cultures 
(40 ml) were centrifuged at 2,000 x g for 20 min at 4°C. The supernatant was discarded 
and the bacterial pellets were washed twice in 20 ml of filter sterilised (0.2 µM) PBS, 
that was used subsequently throughout the experiment, and the pellet resuspended 
finally in 10 ml PBS. 
 
Bacterial suspensions (4 ml) were blocked with an equal volume of 2% (w/v) milk 
powder in PBS supplemented with 1% (w/v) bovine serum albumin (BSA; Sigma) by 
incubation for 30 min at 4°C. The bacteria were then centrifuged for 5 min at 2,000 x g, 
4°C and the pellets resuspended in 4 ml PBS. An aliquot (2 ml) of each bacterial culture 
was subject to UV-C exposure, (15 W 254 nm) for 5 min in order to inactivate the 
bacteria. Live and UV irradiated bacterial cultures were adjusted with PBS to give a cell 
density of 1.67 x 107/ml. Preliminary data acquired by FACS and confocal analysis 
demonstrated that streptavidin FITC and streptavidin PE:Cy5 (both Serotec) alone are 
capable of binding to MRSA. In order to reduce the level of binding of streptavidin 
alone, peptide solutions were preincubated at a ratio of 5:1 with streptavidin-PE:Cy5 in  
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equal volumes (10 µl each) at 4°C for 30 min. An aliquot (20 µl) of each preincubated 
peptide: streptavidin PE:Cy5 solution was applied to 30 µl (5 x 105) bacteria and 
incubated at 4°C for 1 h ensuring gentle mixing every 15 min. Bacteria were washed by 
centrifugation at 6, 000 x g for 5 min at 4°C to remove excess, unbound peptide and the 
bacterial pellet resuspended in 300 µl with PBS and transferred to 75 x 12 mm 
polypropylene tubes (Sarstedt, Leicester, UK) prior to analysis by flow cytometry. A 
non-treated bacterial suspension, bacteria stained with SYTO 9 and bacteria labelled 
with streptavidin-PE:Cy5 for 1 h (all containing 5 x 105 cells) were used to determine 
parameters for FACS analysis. 
 
Furthermore, biotin and unconjugated streptavidin (20 µl) were preincubated at a ratio 
of 5:1 and 50:1 for 30 min prior to initial incubation with blocked bacterial cells at 4°C 
for 30 min in order to saturate non-specific binding of biotin and/or streptavidin.  
Bacteria were washed as described above and then the preincubated 
peptide:streptavidin-PE:Cy5 complex (20 µl) was then added to the bacterial aliquots 
and incubated for 1 h at 4°C mixing gently every 15 min. Bacteria were washed again 
prior to flow cytometry analysis. Additionally, peptide solutions (10 µl) were 
preincubated at a molar ratio of 1:1 with an anti-biotin-Cy5 antibody (10 µl; Abcam) at 
4°C for 30 min. Preincubated solutions were incubated with 30 µl (5 x 105) bacteria at 
4°C for 1 h, mixing gently every 15 min. Bacteria were washed prior to analysis by flow 
cytometry.  
 
2.8.1.2 Assessment of FITC-labelled peptide binding to bacteria and keratinocytes 
by flow cytometry 
 
Binding of FITC-labelled peptides was assessed against 3 strains of MRSA (MRSA 1, 2 
& 3) and also S. aureus, S. epidermidis, E. coli, P. aeruginosa and keratinocytes. 
Bacteria were prepared and blocked as described previously (section 2.8.1). 
Keratinocytes (grown to approximately 80% confluence) were detached from tissue 
culture flasks by cell scraping. Keratinocytes were washed in 5 ml PBS, centrifuged at 
180 x g for 3 min, and resuspended in PBS. Bacteria (5 x 105 cells) and keratinocytes (1 
x 105 cells) were incubated with 25 µl of peptide12 (previously diluted in PBS giving 
approximately 100,000 peptide molecules per cell). Following incubation for 30 min at 
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RT, bacteria and keratinocytes were washed and resuspended in 300 µl PBS prior to 
analysis by flow cytometry. 
 
2.9 Cloning 
 
2.9.1 Primer sequences and vector constructs 
 
All of the primers (all synthesised by MWG) used subsequently for cloning experiments 
are shown below in Table 2.2. Primers are shown in the 5’ to 3’ direction. The 
appropriate primers were constructed to contain restriction sites, shown as underlined 
bases, to allow subsequent cloning into a vector for bacterial expression. Italicised bases 
are additional bases as flanking sequences to allow the relevant restriction enzyme to 
cut efficiently. A flow diagram demonstrating the overall cloning process is summarised 
in Figure 2.1 depicting cloning of thioredoxin containing peptides only (A) and also as a 
GFP fusion construct (B). The final overall thioredoxin/pPROTet (A) and 
thioredoxin/GFP/pPROTet (B) cloning vector constructs are shown in Figure 2.2. 
 
2.9.2 Amplification of thioredoxin inserts containing individual peptide sequences 
by PCR 
 
PCR was performed to amplify DNA from plasmid preparations (section 2.7) of 
samples that contained no stop codons following sequencing (section 2.7.2). PCR was 
performed using forward (ThioFor) and reverse (ThioRev) primers shown in Table 2.2 
designed in order to amplify the entire thioredoxin gene containing the individual 
peptide sequences of interest. The entire thioredoxin sequence was amplified to allow 
greater stability of the 12-mer peptides and also to keep the same structural context 
from which the peptides were originally selected. The amplification reactions were 
performed in 50 µl reaction mixtures under similar conditions described previously 
(section 2.7). Amplification was performed similar to conditions described in Table 2.1 
(section 2.7) except that the annealing temperature was changed to 69°C and the 
number of cycles to 30. 
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2.9.2.1 Optimisation of primers 
 
Conjugation of photosensitisers to thioredoxin inserts requires the presence of lysine 
moieties. Although the thioredoxin sequence does contain lysine residues this was 
optimised by incorporation of a 15 lysine residue linker on the forward thioredoxin 
primer to allow multiple sites for the photosensitiser to be conjugated. Individual 
thioredoxin inserts containing the peptide inserts of interest were amplified again from 
plasmid DNA using a forward primer (ThioLysineFor; Table 2.2) to amplify 
thioredoxin containing a 15 lysine linker by PCR using the same conditions described in 
Table 2.1 in conjunction with the reverse ThioRev primer. 
 
2.9.3 PCR product purification and quantification 
 
PCR products were purified directly from the reaction samples using the NucleoSpin® 
Extract II kit (Macherey-Nagel GmbH & Co. KG, Germany) using buffers supplied to 
remove contaminants such as salts, dNTPs and unused primers, according to the 
manufacturer’s instructions. Each PCR reaction (50 µl) was adjusted to 100 µl with 
nuclease free water and mixed with 200 µl diluted Buffer NT. Buffer NT was diluted 
with 4 volumes of distilled water, whereby the dilution of Buffer NT lowers the binding 
efficiency of smaller unwanted DNA fragments to the silica membrane that may 
interfere with subsequent cloning applications. The samples were loaded onto spin 
columns and centrifuged at 11,000 x g for 1 min to bind the DNA to the silica 
membrane. The column flow-through was discarded and the membrane washed with 
600 µl ethanolic buffer, NT3, and centrifuged at 11,000 x g for 1 min to remove 
contaminants. The column flow through was discarded and the columns centrifuged at 
11,000 x g for 2 min to dry the silca membrane.  The columns were transferred to clean 
1.5 ml polypropylene tubes and 28 µl Elution Buffer NE (5 mM Tris-HCl, pH 8.5) was 
added to the membrane, incubated at RT for 1 min, and centrifuged at 11,000 x g for 1 
min to elute purified DNA. The concentrations of the purified PCR products were 
determined spectrophotometrically (section 2.6.1) using 5 mM Tris-HCl, pH 8.5 as a 
reference for calibration of the spectrophotometer. All samples were stored at -20°C. 
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2.9.3.1 Test gel of PCR products following clean-up 
 
Agarose gel electrophoresis was used to analyse the size of PCR products following 
purification (section 2.7.1) on a 2% (w/v) Seakem gel (FMC Bioproducts) in 100 ml 
TBE buffer supplemented with 2 µl ethidium bromide to a final concentration of 0.2 
µg/ml.  Aliquots (3 µl) were mixed at a 1:1 ratio with loading dye and loaded into wells 
alongside 2-3 µl 100 bp ladder (Promega). Electrophoresis was carried out at 100 V for 
approximately 1 h. The DNA was visualised using a UV transilluminator and 
photographed. 
 
2.9.4 DNA digestion of PCR products and pPROTet vector 
 
The PCR products and the pPROTet bacterial expression vector (Clontech) were 
digested using SalI and BamHI restriction endonucleases (both NEB) in the appropriate 
buffer to cut the DNA at specific sites. Double digestion reactions were performed to 
digest an aliquot (25 µl) of each PCR product with 25 U (1.25 µl) SalI and 25 U (1.25 
µl) BamHI in a reaction mixture containing 4 µl 10X buffer (NE Buffer 3), 0.4 µl 100X 
BSA and 8.1 µl nuclease free water. The samples were incubated at 37°C for 90 min 
and the reactions stopped by storage at -20°C. To optimise SalI digestion a futher 
aliquot of 25U of SalI was added halfway through the reaction. The pPROTet vector 
(2.5 µg) was digested with 25 U (1.25 µl) SalI and 25 U (1.25 µl) BamHI in a reaction 
mixture containing 4 µl 10X buffer, 0.4 µl 100X BSA and 28.1 µl nuclease free water at 
37°C for 90 min and the reactions stopped by storage at -20°C. 
 
2.9.4.1 Purification of digested DNA from agarose gel 
 
The digested pPROTet vector (40 µl) and PCR products (40 µl) were purified by gel 
extraction using the NucleoSpin® Extract II kit according to the manufacturer’s 
instructions. Samples were mixed with 10 µl of loading dye and applied to a 1.5% (w/v) 
low melting point gel (Seaplaque, Cambrex Bio Science) in 100 ml TBE buffer 
supplemented with a low concentration of ethidium bromide to minimise DNA damage 
(1 µl; final concentration 0.1 µg/ml) in order to facilitate the extraction and purification 
of the products without inducing mutation. An aliquot (2-3 µl) of 100 bp ladder 
(Promega) was used to analyse the size of the products. Electrophoresis was carried out 
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at 100 V for approximately 1 h. The DNA was visualised using a UV transilluminator, 
photographed and excised from the gel using a clean scalpel. The weight of each 
excised gel fragment was determined and 200 µl of Buffer NT was added per 100 mg of 
gel fragment. The gel fragments were incubated at 50°C until completely dissolved. 
Each sample was then loaded onto a spin column purified as previously described 
(section 2.9.3). The pPROTet vector was eluted in 48 µl elution buffer and the PCR 
products eluted in 25 µl elution buffer. Agarose gel electrophoresis was performed 
(section 2.9.3.1) to confirm the presence and size of purified DNA following extraction. 
 
2.9.5 Ligation of PCR products into the pPROTet vector 
 
Each ligation reaction was set up to join 150 ng of vector with a 25:1 molar ratio of 
PCR product insert to vector supplemented with 10X buffer (10% final volume) and 
DNA ligase (5% final volume; both NEB). Ligation reactions were incubated at room 
temperature for 3 h and the reactions stopped by storing at -20°C. Control ligation 
reactions were set up with cut plasmid and no insert DNA, replacing insert DNA with 
nuclease free water. Gel electrophoresis of ligation reactions was performed under 
similar conditions described previously (section 2.7.1) using a 0.7% (w/v) Seakem gel 
to analyse ligated vectors prior to transformation. Aliquots of ligation reactions (1 µl) 
mixed with 4 µl loading dye were loaded alongside 2-3 µl of 100 bp ladder (Promega) 
or 1 kb ladder (Fermentas, York, UK). Following electrophoresis, DNA was visualised 
and photographed. 
 
2.9.6 Transformation of thioredoxin/pPROTet ligated vectors into E. Coli JM109 
 
E. coli JM109 bacterial cells were thawed on ice, gently mixed and 50 µl per reaction 
transferred to chilled, sterile 75 x 12 mm polystyrene culture tubes (BD Biosciences). 
An aliquot (1 µl) of each ligated vector was added and the tube flicked quickly several 
times and incubated on ice for 10 min. The bacteria were subsequently heat-shocked at 
exactly 42°C for 45-50 sec and then returned to ice for 2 min. Following incubation, the 
bacteria were mixed with 900 µl of 4°C SOC medium (2% (w/v) tryptone, 0.5% (w/v) 
yeast extract, 10 mM NaCl, 2.5 mM KCL, 10 mM MgSO4, 10 mM MgCl2, 20 mM 
glucose) and incubated for 60 min with shaking (~225 rpm) at 37°C. Additionally, E. 
coli JM109 cells without an expression vector and also JM109 cells transformed with an 
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empty pPROTet vector were used as controls. Transformed cells (100 µl): neat, diluted 
1:10 and 1:100 were plated on LB plates containing 34 µg/ml chloramphenicol to select 
for the pPROTet vector and incubated overnight at 37°C. Transformations were also 
attempted using E. coli GC10 and BL21 (both Sigma) to increase protein yield. 
 
2.9.7 Colony PCR of transformants 
 
Colony PCR was performed in order to confirm that individual transformants contained 
the thioredoxin insert in the correct orientation using a forward primer that anneals to 
the pPROTet vector (pPROTetFor; Table 2.2) and a reverse primer that anneals to the 
C-terminal of thioredoxin (ThioRev; Table 2.2). Additionally, competent cells alone and 
competent cells transformed with the empty expression vector were amplified by colony 
PCR using various paired primer combinations that anneal to the N- and C- termini of 
thioredoxin and the pPROTet vector (ThioFor, ThioLysineFor, pPROTetFor, ThioRev, 
pPROTetRev; Table 2.2). Amplification reactions were performed under similar 
conditions described previously (section 2.7) except that template DNA was obtained 
from individual colonies selected from each transformant plate with a sterile tip. 
Amplification was performed under similar conditions (section 2.7) except that the 
annealing temperature was 66°C for 26 cycles. 
 
2.9.8 Bacterial culture and glycerol stocks of transformants 
 
Glycerol stocks were made of transformants confirmed positive by colony PCR in order 
to have an continuous supply of bacteria for expression and purification of proteins. 
Individual colonies were inoculated into 7 ml LB medium supplemented with 34 µg/ml 
chloramphenicol to select for the pPROTet vector and grown overnight at 250 rpm at 
37°C. Cultures were centrifuged at 2,000 x g for 10 min at 4°C and the bacterial pellets 
resuspended in 1 ml PBS supplemented with 15% (v/v) glycerol and stored at –80ºC 
until required. 
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2.9.9 Plasmid DNA extraction and DNA sequencing 
 
Plasmid DNA was isolated from the transformants using the Nucleospin Plasmid 
(Macherey-Nagel) purification kit with buffers supplied, according to the 
manufacturer’s instructions under to similar conditions described in section 2.6. 
Following plasmid purification, plasmid DNA was ethanol precipitated under similar 
conditions previously described (section 2.7.2) prior to DNA sequencing. Sequencing 
was conducted by MWG using primers pPROTetFor and pPROTetRev (Table 2.2). 
 
2.10 Transformation of GFP and amplification by PCR 
 
The GFP vector (Clontech) was transformed into JM109 E. coli competent cells 
(Promega; section 2.9.6). Individual colonies were screened for successful 
transformation of GFP using confocal microscopy (section 2.3.1). Single colonies that 
were confirmed to contain GFP were amplified in 7 ml LB supplemented with 50 µg/ml 
ampicillin and grown overnight at 37°C. Following culture, purified plasmid DNA was 
extracted from bacterial cultures and stored at -20°C. GFP was amplified by PCR from 
purified plasmid DNA using primers designed to amplify GFP retaining the natural stop 
codon of GFP, and alternatively a substitution to allow read through. The amplification 
reactions were performed in 50 µl reaction mixtures similar to that previously described 
(section 2.7) using GFPFor primer (Table 2.2) and GFPRev(WS) or GFPRev(NS) 
primer (Table 2.2). The reaction mixtures were amplified as described previously 
(section 2.7) except that the annealing temperature was 67°C and 25 amplification 
cycles were performed. Amplified PCR products were stored at -20°C. 
 
2.10.1 Gel extraction of GFP PCR products 
 
An aliquot (40 µl) was mixed with 10 µl of loading dye and separated on an 1.5% (w/v) 
low melting point agarose gel using a 100 bp ladder (Invitrogen) to analyse the size of 
the products then extracted and purified from the gel (section 2.9.4.1). Samples were 
eluted in 48 µl nuclease free water and stored at -20°C. Following purification, a test 
agarose gel was performed (section 2.9.3.1) to confirm the presence of DNA at the 
expected size following transformation. The concentration of the purified PCR products 
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were determined spectrophotometrically (section 2.6.1) using nuclease free water for 
calibration. 
 
2.10.2 Digestion of PCR products and pPROTet vector 
 
Amplified GFP PCR products and the pPROTet vector were digested using PstI and 
PvuI restriction enzymes (NEB). An aliquot (2.5 µg in 16.7 µl) of each PCR product 
was digested with 25 U (1.25 µl) PstI and 25 U (2.5 µl) PvuI in a reaction mixture 
containing 4 µl 10X buffer (NE Buffer 3), 0.4 µl 100X BSA and 15.15 µl nuclease free 
water. Similarly, 2.5 µg (5 µl) of the pPROTet vector was digested with 25 U (1.25 µl) 
PstI and 25 U (2.5 µl) PvuI supplemented with 4 µl 10X buffer, 0.4 µl 100X BSA and 
26.85 µl nuclease free water. All samples were incubated at 37°C for 90 min and the 
reactions stopped by storage at -20°C. Digested DNA (20 µl pPROTet vector and 40 µl 
PCR products) were gel extracted and purified from a 1.5% (w/v) Seaplaque agarose gel 
supplemented with a low ethidium bromide concentration (1 µl; final concentration 0.1 
µg/ml in  TBE buffer (section 2.9.4.1). All samples were eluted in 48 µl nuclease free 
water. Agarose gel electrophoresis was performed (section 2.9.3.1) to confirm the 
presence and size of purified DNA following extraction. 
 
2.10.3 Ligation of GFP PCR products into the pPROTet vector 
 
Ligations reactions were set up to ligate each GFP PCR product both with and without a 
stop codon into 100 ng of the pPROTet vector at a molar ratio of 5:1 under similar 
conditions described in section 2.9.5. pPROTet plasmid DNA was incubated with the 
relevant PCR product in a reaction tube containing 10X Buffer, DNA ligase and 
nuclease free water alongside a negative control using nuclease free water in place of 
the insert. Each reaction was incubated at RT for 3 h and the reaction stopped by storing 
at -20°C. A test gel of ligation reactions was performed (section 2.9.5) to analyse ligated 
vectors prior to transformation on a 0.7% (w/v) Seakem gel by loading 1 µl of each 
ligation reaction in 4 µl loading dye. 
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2.10.4 Transformation of GFP/pPROTet ligated vectors 
 
An aliquot (1.5 µl) of each ligated vector was transformed into DH10B E. coli 
competent cells under similar conditions described in section 2.9.6 except that bacteria 
were heat shocked at 42°C for 90 sec. Each aliquot was mixed with 300 µl of 4°C LB 
and incubated with shaking at 225 rpm for 1 h at 37°C.  Transformed cells were plated 
out and incubated as previously described (section 2.9.6). Following transformation, 
single colonies were selected and confocal microscopy used to check transformants for 
the presence of GFP (section 2.3.1). Individual colonies that were confirmed positive to 
contain GFP by confocal microscopy were amplified, plasmid DNA isolated (section 
2.6), and glycerol stocks were made (section 2.9.8) and stored at –80ºC until required. 
 
2.10.5 GFP/pPROTet and thioredoxin insert digestion and purification 
 
Purified GFP/pPROTet plasmid DNA (section 2.10.4) and thioredoxin PCR products 
amplified using thioredoxin forward and reverse primers (without the 15 lysine linker) 
(section 2.9.2) were digested using SalI and BamHI restriction enzymes. Double 
digestion reactions were performed to digest an aliquot (35 µl) of each PCR product 
with 20 U (1 µl) SalI and 20 U (1 µl) BamHI in a reaction mixture containing 4 µl 10X 
buffer and 0.4 µl 100X BSA. Aliquots of the  purified GFP/pPROTet vectors (45 µl) 
were digested with 20 U (1 µl) SalI and 20 U (1 µl) BamHI in a reaction mixture 
containing 5 µl 10X buffer supplemented with 0.5 µl 100X BSA. All double digestion 
reactions were incubated at 37°C for 90 min and the reactions stopped by storage at -
20°C. The digested GFP/pPROTet DNA and thioredodin PCR products were resolved 
by agarose gel electrophoresis and purified (section 2.9.4.1). Following purification, a 
test gel was performed (section 2.9.3.1)  to ensure successful extraction and to confirm 
the size of the extracted PCR products and vectors. 
 
2.10.6 Ligation of thioredoxin inserts into GFP/pPROTet vectors and 
transformation into E. Coli GC10 
 
Ligation reactions  were set up to ligate 100 ng of GFP/pPROTet vector at a 10:1 insert 
to vector molar ratio of thioredoxin inserts supplemented with the appropriate volumes 
of 10X buffer and DNA ligase (section 2.9.5). Control ligation reactions were set up 
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with cut plasmid and no insert DNA, replacing insert DNA with nuclease free water. A 
test gel of ligation reactions was performed (section 2.9.5) to analyse ligated vectors 
prior to transformation loading 1 µl of each ligation reaction in 4 µl loading dye. GC10 
competent cells (Sigma) were thawed on ice and transformed with 1.5 µl of each 
ligation reaction or negative control under similar conditions described in section 2.9.6 
except that bacteria were incubated on wet ice for 30 min prior to heat shock. Following 
incubation, cells were heat-shocked at 42°C for exactly 45 sec and returned to ice for 10 
min. SOC media (450 µl) was added to each tube and the reactions transferred to sterile 
75 x 12 mm polystyrene culture tubes and incubated at 37°C for 60 min with continuous 
shaking (~225 rpm). Transformed cells were plated out and incubated as previously 
described (section 2.9.6). Glycerol stocks were made of individual transformants 
(section 2.9.8). Following selection of single transformants, all other transformants were 
selected from whole plates and inoculated into 20 ml LB/chloramphenicol media and 
centrifuged at 2,000 x g for 20 min at 4°C. The bacterial pellets were suspended in 5 ml 
15% glycerol in PBS and stored at -80°C as 1 ml aliquots. 
 
2.10.7 PCR and DNA sequencing of transformants 
 
Plasmid DNA was extracted from individual transformants (section 2.6) and analysed 
for the presence of thioredoxin and GFP inserts using the primers pPROTetFor and 
either GFPRev(WS or NS) primer or pPROTetRev primers (Table 2.2). Amplification 
reactions were performed and amplified under similar condition to those previously 
described (section 2.7), except that the annealing temperature was 57°C for 25 cycles. 
DNA was visualised by agarose gel electrophoresis (section 2.9.3.1) by mixing 5 µl of 
each PCR product with an equal volume of loading dye and loading onto a 2 % Seakem 
gel. All PCR products were stored at -20°C. Extracted plasmid DNA (section 2.6) was 
ethanol precipitated (section 2.7.2) and samples were sequenced commercially by 
MWG. 
 
2.11 Determination of optimal protein induction and expression 
 
Optimal protein induction and expression analysis was determined according to the 
manufacturer’s instructions. Glycerol stocks of E. coli transformed with pPROTet 
vectors containing each thioredoxin insert were streaked onto LB/agar plates 
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supplemented with 34 µg/ml chloramphenicol and incubated at 37°C overnight. Single 
colonies were picked and inoculated into 5 ml LB media containing 34 µg/ml 
chloramphenicol and grown at 37°C overnight with shaking. An aliquot (2 ml) of the 
overnight culture was used to inoculate 100 ml LB/chloramphenicol media and grown 
at 37°C with shaking until the culture reached an OD600 of 0.5. This culture was used to 
start 5 x 20 ml cultures that were induced with varying concentrations (0-100 ng/ml) 
anhydrotetracycline (Clontech). The cultures were incubated at 37°C with shaking and 
at 0,2,4,6,7 and 24 h time points following induction, 1 ml samples were removed and 
diluted to give to a pre-induction OD600 of 0.5 to give the same concentration of 
bacteria. Bacteria were centrifuged at 13,000 x g to pellet the cells and these were stored 
at -20°C until analysis. 
 
2.12 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
SDS-PAGE and Western blotting were used to ensure that the recombinant protein was 
expressed. SDS-PAGE was performed using 10% or 4-20% gradient precast gels 
(Pierce, Rockford, USA). The gels were placed into the electrophoresis tank covered in 
running buffer (100 mM Tris base, 100 mM HEPES, 0.3 mM SDS, pH 8.0 (all Melford) 
in dH2O) ensuring that all air bubbles were removed from the wells. The bacterial 
pellets were resuspended in 100 µl sample buffer (13 ml 1M Tris-HCl (pH 6.8), 6.5 ml 
20% (w/v) SDS, 5.2 ml 100% glycerol and 0.26 ml 0.5% (w/v) bromophenol blue). For 
reducing gels, beta-mercaptoethanol ("-ME 1.43M; Sigma) was added to 10% (v/v) 
final volume of loading buffer. The bacterial pellets were then boiled for 5 min to 
denature the proteins and centrifuged at 13,000 x g for 10 min. An aliquot (12 µl) of 
supernatant was loaded into each well alongside 15 µl Benchmark™ pre-stained protein 
ladder (Invitrogen) in order to determine protein size. The gel was subject to 
electrophoresis at 120 V for approximately 1 h or until the dye front had reached the 
bottom of the gel. 
 
2.12.1 Coomassie staining 
 
Coomassie staining was used to observe the induction of protein expression. Following 
electrophoresis, the stacking gel was removed and the gel rinsed with dH2O to remove 
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residual SDS. The gel was stained with Coomassie (Severn Biotech) and incubated on a 
rocker at RT for 3 h or overnight at 4°C. The gel was destained by washing with dH2O 
and visualised on a lightbox. 
 
2.12.2 Western blotting 
 
Following electrophoresis, the stacking gel was removed and the gel plus a sheet of 
nitrocellulose membrane were placed in transfer buffer at 4°C (25 mM Tris base, 25 
mM bicine (Melford), 10% (v/v) methanol in dH2O) and allowed to equilibrate for 
approximately 5 min. Proteins were transferred from the gel to the membrane by 
assembling a transfer unit consisting of a fibre pad, 2 sheets of wetted filter paper, the 
gel, the nitrocellulose membrane and 4 pieces of wetted filter paper. The transfer unit 
was placed in a Biorad cassette in the correct orientation in a tank of transfer buffer to 
transfer negatively charged proteins to the membrane. The proteins were transferred 
whilst stirring continuously at 100 V for 1 h or overnight at 30 V at 4°C. 
 
Following transfer the membrane was blocked in 20 ml PBS supplemented with 2% 
(w/v) non-fat dry milk and 1% (w/v) BSA for 1 h at room temperature or overnight at 
4°C. After blocking, the membrane was incubated with the primary antibody (Table 2.3) 
in the blocking buffer for 2 h at RT. The membrane was washed 3 times for 5 min each 
wash with PBS/0.05% (v/v) Tween 20 (Sigma) and then incubated with the relevant 
secondary antibody conjugated to horse radish peroxidase (HRP) (Table 2.3) in 
blocking buffer for 1 h at RT.  Following a second wash to remove the unbound 
antibody the membrane was placed in equal volumes of ECL detection reagents (GE 
Healthcare) for 1 min ensuring complete coverage of the membrane before 
development. 
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Table 2.3: Antibodies used for Western blotting 
 
Primary antibody 
Dilution 
 
Secondary 
antibody 
Dilution 
 
Rabbit anti-
thioredoxin 
polyclonal antibody 
(Abcam) 
1:1000 
Sheep anti-rabbit 
IgG:HRP (Serotec) 
1:4000 
Rabbit anti-6xHN 
tag polyclonal 
antibody (Clontech) 
1:1000 
Sheep anti-rabbit 
IgG:HRP (Serotec) 
1:4000 
 
2.12.2.1 Development of the film 
 
Following immersion in ECL detection reagents, the membrane was placed between an 
acetate sheet in the X-Omatic Fine Cassette (Kodak, Rochester, US) and exposed onto a 
film (Amersham) for between 1-30 min depending on the primary antibody used. 
Following exposure, the film was placed in developer (Sigma), rinsed in 1% (v/v) acetic 
acid and then fixed (Sigma). The film was rinsed with water and left to air dry. 
 
2.12.2.2 Stripping and reprobing the membrane 
 
Following development of the film the membrane was stripped with Restore™ PLUS 
stripping buffer (ThermoScientific) according to the manufacturer’s instructions. The 
membrane was washed for 5 min in 20 ml PBS to remove all traces of the ECL 
detection reagent and 12 ml stripping buffer added to the membrane and incubated for 
15 min at RT at 30 rpm. Following incubation, the membrane was washed 3 times with 
20 ml PBS for 5 min. The membrane was blocked and probed with the secondary 
antibody and developed to ensure stripping of both the primary and secondary 
antibodies (section 2.12.2, 2.12.2.1). Following successful stripping, the membrane was 
washed and blocked again and incubated with the next primary antibody followed by 
the appropriate secondary and development (section 2.12.2.1). 
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2.13 Shake-flask expression and purification 
 
2.13.1 Protein expression 
 
LB/chloramphenicol media (100 ml) was subcultured with a 2% inoculum of an 
overnight culture of E. coli transformed with pPROTet expression plasmids and 
amplified with shaking at 37°C until an OD600 of 0.5 was reached. A 1 ml aliquot was 
removed from the culture and centrifuged at 13,000 x g and stored at –20°C as a 
representation of bacterial expression prior to induction. The bacterial cultures were 
induced by addition of anhydrotetracycline (final concentration: 0.1 ng/ml) and 
incubated for a further 2 h. A further 1 ml aliquot was stored following induction to 
confirm protein expression prior to purification. 
 
2.13.2 Protein sample preparation 
 
Protein samples of interest were purified using the TALON® metal affinity resin 
(Clontech) according to the manufacturer’s instructions in order to isolate native 
proteins. The protocol was optimised to lyse bacteria using a One Shot Cell Disruptor 
(Constant Systems, Northants, UK) instead of sonication. The 150 ml cell culture was 
centrifuged at 2,000 x g for 15 min at 4°C. The cell pellet was resuspended in 4 ml 
chilled Equilibration/Wash buffer (50 mM Na2HPO4, 300 mM NaCl, pH 7.0) 
supplemented with 20 µl protease inhibitor cocktail set 3 (Calbiochem). Bacterial 
cultures were lysed by passage once through a One Shot Cell disruptor. The cell extract 
was centrifuged at 12,000 x g for 20 min at 4°C to pellet any insoluble material and the 
supernatant containing native proteins extracted. This method was repeated 6 times for 
each different recombinant protein of interest to produce sufficient amounts of 
recombinant protein for downstream applications. 
 
2.13.3 Column purification 
 
The following protocol was performed at 4ºC in order to decrease protein breakdown 
and loss. An aliquot (2 ml) of TALON® metal affinity resin (equal to 1 ml bed volume) 
was thoroughly resuspended per protein sample to be purified and centrifuged at 700 x 
g for 2 min to pellet the resin. The supernatant was discarded and 10 bed volumes of 1 x 
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Equilibration/Wash buffer was added and briefly vortexed to pre-equilibrate the resin. 
The resin was centrifuged for a further 2 min at 700 x g and washed with a further 10 
bed volumes of 1 x Equilibration/Wash buffer. The supernatant was discarded and the 
clarified protein samples applied to the resin. Polyhistidine tagged proteins were bound 
to the pre-equilibrated resin by gently agitating the resin and extracted proteins on a 
platform shaker for 20 min at RT. Following incubation, the samples were centrifuged 
at 700 x g for 5 min and the supernatant removed. The resin was washed by adding 12 
bed volumes of 1 x Equilibration/Wash buffer and agitated for 10 min. The suspension 
was centrifuged at 700 x g for 5 min and the supernatant discarded and the wash step 
repeated. The resin was resuspended by vortexing in one bed volume of 1 x 
Equilibration/Wash buffer and transferred to a 2 ml gravity flow column and allowed to 
settle out of suspension. The buffer was allowed to drain off until the top of the resin 
bed and then the column washed with 5 bed volume of 1 x Equilibration/Wash buffer. 
The polyhistidine tagged proteins were eluted by applying 5 bed volumes of 1 x Elution 
buffer (50 mM Na2HPO4, 300 mM NaCl and 150 mM imidazole, pH 7.0) to the column 
collecting the eluate in fractions. 
 
2.13.4 Protein concentration 
 
Following elution, protein samples were concentrated and the buffer exchanged to 
remove imidazole and elute proteins in the appropriate buffer for conjugation in spin 
columns with a 10,000 MWCO (Sartorius Stedim Biotech, France). Eluted proteins 
were applied to the concentrator and centrifuged at 3,000 x g in a swing bucket 
centrifuge for 10-30 min at 4ºC until the samples were concentrated from approximately 
5 ml start volume to 0.5 ml final volume. The lower filtrate container was emptied and 
the concentrator refilled with 7 ml 0.05 M Na2CO3 buffer, pH 9.6 (Sigma) and the 
samples centrifuged again. Buffer exchange was completed following 2 further washes 
in Na2CO3 buffer for a total of 3 wash cycles. 
 
2.13.5 Bradford assay 
 
Extracted protein was quantified using a modified Bradford (1976) method. The method 
is based on the interaction of dye and protein producing a shift in absorbance that is 
correlated to the concentration of protein in the sample. A standard curve was prepared 
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using known concentrations of BSA (0-2,000 µg). Each BSA standard or sample (10 µl) 
was applied in triplicate to a 96-well flat-bottomed tissue culture plate and 300 µl 
Coomassie reagent (Pierce) added to each well. The samples were mixed for 30 s, 
incubated at RT for 10 min, and absorbance measured at 595 nm on a plate reader 
(Anthos 2010, SLS). Absorbance at 595 nm was used to calculate unknown protein 
concentration based on the standard curve. 
 
2.13.6 SDS-PAGE and Western blotting 
 
Purified proteins were analysed by SDS-PAGE using 4-20% gradient gels (section 2.12) 
and either stained with Coomassie (section 2.12.1) or subject to Western blotting 
(sections 2.12.2, 2.12.2.1) using antibodies shown in Table 2.3. An aliquot (30 µl) of 
each protein fraction was mixed with 20 µl sample loading buffer and boiled for 5 min. 
A 30 µl aliquot was loaded into each well of the gel alongside 15 µl Benchmark™ pre-
stained ladder for comparison. 
 
2.14 Bioconjugation of recombinant protein to porphyrin 
 
2.14.1 Porphyrins 
 
The porphyrin used in this study was kindly provided by Dr Ross Boyle and Dr Cristina 
Alonso (Department of Chemistry, University of Hull). The porphyrin structure (5-(4-
isothiocyanatophenyl)-10,15,20-tris-(4-N-methylpyridiniumyl) porphyrin trichloride) is 
shown in Fig 2.3 (left hand side) with the NCS group able to react with lysine residues. 
The porphyrin was dissolved in anhydrous DMSO (Sigma) to a stock concentration of 5 
mM prior to conjugation to the protein of interest. Additionally, a 5 mM stock solution 
of the same porphyrin was prepared in anhydrous DMSO except that the NCS group 
had been capped with an amino group, as shown in Fig 2.3 (right hand side), to use as a 
control in later toxicity assays. 
 
 
 
 
 
 72 
Fig 2.3: Porphyrin structures 
 
 
Fig 2.3: Structure of 5-(4-isothiocyanatophenyl)-10,15,20-tris-(4-N-
methylpyridiniumyl) porphyrin trichloride. 
 
2.14.2 Bioconjugation and purification procedure 
 
Recombinant protein was conjugated to the porphyrin at a molar ratio of 5:1 
porphyrin:protein by gentle agitation at RT for 1 h protected from light. Following 
conjugation, immediate purification of the conjugate was achieved through application 
onto a PD10 desalting column (GE Healthcare), according to the manufacturer’s 
instructions, in order to remove unbound porphyrin.  Briefly, the column storage 
solution was removed from the column and the column washed 4 times in 0.05M 
bicarbonate buffer (pH 9.6) discarding the column flow-through. Following 
equilibration, the conjugate was applied to the top of the column and the volume 
adjusted to 2.5 ml with bicarbonate buffer. The conjugate was eluted by addition of 3.5 
ml bicarbonate buffer in seven 500 µl fractions and each eluate collected for analysis. 
 
Fractions were characterised spectrophotometrically at 280 and 420 nm to monitor the 
protein and porphyrin respectively in order to determine which fractions contained the 
highest concentration of conjugate. Fractions containing the highest concentration, 
denoted by the highest absorbance readings (4 aliquots in total) were combined together 
and the absorbance at 260, 280, 320 and 420 nm determined in order to calculate the 
concentration of the protein/porphyrin and the degree of loading to calculate the moles 
of porphyrin per mole of protein. Conjugated protein and capped porphyrin were 
separated on a 4-20% gradient gel in order to visualise the conjugate using similar 
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methods to that described in sections 2.12.  Following electrophoresis, the gel was 
illuminated with UV light to visualise the porphyrin and then stained with Coomassie in 
order to visualise the conjugated protein and porphyrin (section 2.12.1). The conjugate 
was stored protected from light at 4°C. 
 
2.15 In vitro bacterial cytotoxicity assay 
 
Cytotoxicity assays were performed against MRSA and E. coli based upon an optimised 
method established within our group (Hall, 2008). Bacterial cultures were adjusted with 
PBS to give a cell density of 1.11 x 107/ml. Bacterial aliquots (540 µl) were incubated 
with 540 µl P12 conjugated protein (final concentration; 1.25 µM). Additionally, 
bacteria (540 µl) were incubated with either 540 µl capped porphyrin to a final 
concentration of 1.25 mM or 54 µl capped porphyrin (final concentration; 12.5 µM) 
adjusted to a final volume of 1.08 ml with media. Bacteria only (540 µl) in 1.08 ml 
media and media only (1.08 ml) were also used as controls. Bacteria were allowed to 
incubate with the conjugate or capped porphyrin for 30 min at RT before centrifugation 
at 6,000 x g for 10 min to pellet the bacteria. The supernatant was carefully removed 
and discarded and each pellet resuspended in 1.08 ml fresh media. Aliquots (180 µl 
containing 1 x 106 cells) of each suspension were transferred in triplicate onto 2 
separate 96-well flat bottomed plates. One plate (light plate) was irradiated with 40 
J/cm2 red light from a lamp at 633 nm (Omnilux EL1000A Phototherapeutics Ltd, 
Altrincham, UK) in a dark room to ensure light dose control and the other plate kept in 
the dark as a control (dark plate). Following irradiation, both plates were incubated for 
30 min at 30°C at 225 rpm to replenish the oxygen levels. Once incubated, the light 
plate was further subject to irradiation with 40 J/cm2 red light whilst the dark control 
plate remained in the dark. Both plates were incubated at 30°C overnight with shaking 
at 225 rpm. After incubation, the absorbance of each well was measured at 630 nm on 
an automated plate reader (Bio-tek Instruments) and the absorbance from triplicate 
wells averaged for data analysis. Cell growth (%) was determined in comparison to 
untreated control bacteria. Following overnight incubation, MRSA cultures from the 
light plate following incubation with the conjugate, capped porphyrin and bacteria only 
were serially diluted across the range of 10-3 to 10-7 in PBS and 100 µl plated out onto 
nutrient agar. The plates were incubated overnight at 30°C and bacterial colonies 
counted in order to determine the colony forming units (cfu)/ml. 
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2.15.1 In vitro keratinocyte cytotoxicity assay 
 
Keratinocyte cytotoxicity assays were kindly performed by Huguette Savoie.  
Keratinocytes (1.11 x 106cells/ml) in supplemented media without foetal bovine serum 
(FBS) were incubated with conjugate, capped porphyrin (1.25 µM final concentration) 
or 10-fold excess of capped porphyrin (final concentration; 12.5 µM) in sterile 75 x 12 
mm polystyrene tubes for 30 min at RT in the dark. Following incubation, keratinocytes 
were washed with 5 ml of supplemented media without FBS to remove unbound 
conjugate or porphyrin. The cells were centrifuged at 1,200 x g for 10 min and 
resuspended in serum free media.  Aliquots (180 µl containing 1x105 keratinocytes) 
were plated out in triplicate onto two separate 96-well flat bottomed plates. One plate 
(light plate) was irradiated with 40 J/cm2 whilst the other non-irradiated plate was kept 
in the dark. Both plates were incubated for 30 min at 37°C and the light plate irradiated 
for a further 40 J/cm2. FBS (5 µl) was added to each well and each plate incubated 
overnight at 37°C.  
 
An MTT assay was performed to determine the number of viable cells that utilise the 
tetrazolium salt (3-4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) that is 
reduced to formazan in the mitochondria of metabolically active cells. The greater the 
amount of formazan product produced the greater the cell growth which is therefore 
proportional to the amount of living cells. MTT reagent (10 µl; Sigma) was added to 
each well and incubated at 37°C to allow the colour to develop (~90 min). Following 
sufficient colour development, 150 µl MTT lysis solution (0.02 M isopropanol/HCl) 
was added to stop the reaction and dissolve the formazan product by vigorous 
pippetting. The plates were read at 630 nm using an automated plate reader. 
 
2.16 Flow cytometric analysis of unconjugated purified proteins 
 
Flow cytometric analysis was performed to characterise binding of purified 
unconjugated recombinant proteins P5 and P19 with proposed binding affinity for 
MRSA and also against E. coli and a human keratinocyte cell line for comparison. The 
concentration of P5 and P19 was determined by Bradford assay (section 2.13.5). 
Bacterial cultures (4 ml) were centrifuged at 2,000 x g for 10 min at 4°C. The 
supernatant was discarded and each pellet was resuspended in 4 ml filter sterilised (0.2 
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µM) PBS, used in all subsequent applications, supplemented with 2% milk powder and 
1% BSA. The bacteria were incubated in blocking buffer for 30 min at 4°C and re-
centrifuged and each pellet resuspended in 4 ml PBS. Individual bacterial aliquots of 
MRSA and E. coli (both 5 x 105) were incubated separately with 200 µl of P5 or P19 
(final concentration 173 µg/ml) and the proteins were allowed to bind to the bacteria for 
30 min at RT. Following incubation, bacterial suspensions were incubated with 10 µl of 
a rabbit anti-thioredoxin antibody (Abcam) (0.5 µg; 1:10 dilution in PBS) and incubated 
for 30 min at RT. 
 
PBS (200 µl) was added and bacteria were centrifuged at 6,000 x g for 5 min and 
resuspended in 25 µl secondary sheep anti-rabbit:FITC (Serotec).  The secondary 
antibody was incubated for 30 min at RT. PBS (400 µl) was added to each tube and then 
centrifuged for a further 6,000 x g for 5 min to wash the cells. The supernatant was 
discarded and each pellet was resuspended in 150 µl PBS for flow cytometric analysis. 
A non-treated bacterial suspension and also bacteria incubated individually with either 
the primary or secondary antibody or both antibodies without recombinant protein were 
used to define FACS analysis parameters. Furthermore, recombinant protein binding to 
a human keratinocyte cell line was also performed using the method described except 
that 1 x 105 cells were used. Keratinocytes were prepared for flow cytometry as 
described in section 2.8.1.2. 
 
2.16.1 Determination of GFP tagged recombinant protein binding by flow 
cytometry 
 
The binding ability of P5/GFP to MRSA, E. coli and keratinocytes was characterised by 
flow cytometry. Bacterial suspensions of MRSA and E. coli were blocked and 
resuspended in PBS, as described in section 2.16. Keratinocytes were prepared for flow 
cytometry under the same conditions as illustrated in section 2.8.1.2. The concentration 
of P5/GFP was determined by Bradford assay (section 2.13.5). Bacterial suspensions (5 
x 105) or keratinocytes (1 x 105) were incubated with 0, 5, 25 and 50 µl (0 – 398 µg/ml) 
of P5/GFP at RT for 45 min. The cells were washed as described above in section 2.16 
and each pellet resuspended in 150 µl of filtered PBS prior to flow cytometry analysis. 
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CHAPTER THREE 
Identification and characterisation of novel peptide sequences derived from a 
MRSA-panned library 
 
3.1 Introduction 
 
Chronic wounds such as venous ulcers are frequently of a polymicrobial nature that 
usually includes a combination of aerobic and anaerobic bacterial species. However, 
although the bacteriology of venous ulcers is diverse, S. aureus, including drug resistant 
strains such as MRSA, is often one of the predominant organisms isolated from venous 
ulcers (Gjodsbol et al., 2006, Valencia et al., 2004). S. aureus can be carried 
innocuously by healthy people but is an important opportunistic pathogen capable of 
causing a wide range of superficial and serious skin and soft tissue infections at multiple 
sites (Livermore, 2000). Resistant strains of S. aureus quickly emerged following the 
introduction of penicillin, and furthermore to synthetic drugs such as methicillin, 
originally developed to combat the emergence of these resistant strains. MRSA has 
emerged not only as a significant nosocomial pathogen but also an important and 
frequent cause of community acquired infection. Bacterial resistance to antibiotics has 
continued to increase over time resulting from multiple factors including the extensive 
use of antibiotics, antibiotic misuse and ineffective treatment regimens. As a result, 
strains of MRSA have emerged that are multiply resistant to nearly all classes of 
antibiotics (Barrett, 2004). 
 
Since the first display system, pioneered by Smith (1985) to display small peptide 
fragments on the surface of phage, the display of foreign peptides/proteins has been 
achieved utilising various display platforms which have identified ligands with high 
affinity and specificity that interact with target molecules. Display technologies can 
offer a high-throughput and relatively inexpensive methodology to identify a wide range 
of ligands with different binding specificities. Affinity selection, or panning, using 
display technologies involves the selection of ‘binders’ to a target of interest, from an 
excess of non-binders, that are then successively recovered and amplified through 
rounds of panning in order to enrich clones with specific, desired binding affinity.  
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Bacterial display in which proteins are displayed on the surface of bacteria have since 
emerged as a successful complement to phage display, although phage display remains 
the most described within the literature. Bacterial display offers an attractive alternative 
to phage display in that it can offer advantages including the potential of utilising flow 
cytometry for high throughput screening and direct microscopy without the need for 
additional phage labelling. The methodology also allows direct recovery of clones of 
interest from a self-replicating system without additional infection steps required with 
phage technology (Dane et al., 2006, Chen and Georgiou, 2002). Peptides, proteins, 
antibodies and enzymes have all been successfully displayed on the cell surface of both 
Gram-negative and Gram-positive species as either fusion proteins to outer membrane 
proteins, or displayed on surface appendages such as flagella or fimbriae. Bacterial 
display systems have been utilised to identify an array of ligands with specificities to 
numerous different targets including those with potential targeting/drug delivery 
properties, vaccine development and bioremediation applications (Wernerus and Stahl, 
2004, Lee et al., 2003). 
 
In this study the FliTrx TM bacterially-displayed random peptide library (Invitrogen), 
developed by Lu et al (1995), displaying 12-mer peptides in a conformationally 
constrained manner was screened in order to identify peptide sequences that bind to the 
surface of MRSA. Such MRSA-specific peptides could be of value in early detection of 
antibiotic-resistant isolates within a wound as well as having potential in targeted drug 
delivery. Peptides with proposed binding specificity to MRSA were selected by panning 
against MRSA. The DNA sequences of randomly selected clones following panning 
were determined and sequence homology compared. Peptides were synthesised and 
their binding ability characterised by flow cytometry to 3 different strains of MRSA and 
also against S. aureus and S. epidermidis, P. aeruginosa, E. coli and a mammalian 
keratinocyte cell line to evaluate specificity. 
 
3.2 Methods 
 
3.2.1 UV irradiation and fluorescent staining of MRSA 
 
Bacterial cultures were grown to late log phase and subject to UV-C exposure. Bacterial 
aliquots were extracted and plated onto nutrient agar and inspected for bacterial growth 
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following incubation at 30ºC for 24-48 h (section 2.3). Bacterial viability following UV 
irradiation of MRSA was also assessed using a fluorescence-based assay utilising 
SYTO 9 and PI fluorescent dyes and confocal microscopy analysis to discriminate 
between viable and non viable cells (section 2.3.1). 
 
3.2.2 Investigation of bacterial immobilisation 
 
Immobilisation of both live and UV-inactivated MRSA was performed using 6-well 
plates coated with either poly-L-lysine, poly-D-lysine or collagen I (section 2.4) in 
order to simplify recovery of clones expressing the random peptides from the target 
cells. Bacteria were allowed to adhere overnight at 4°C and washed according to the 
panning protocol. The remaining immobilised bacteria were stained with methylene 
blue and measured spectrophotometrically (section 2.4).  
 
3.2.3 Panning and DNA sequencing 
 
The panning procedure was performed against MRSA adsorbed onto poly-L-lysine 
coated tissue culture plates (section 2.5.2, 2.5.3, 2.5.4). Both MRSA and E. coli library 
cultures were plated out onto nutrient agar following each round of panning to ensure 
that there was no contamination of bacterial cultures, and were used to inoculate oxoid 
mannitol broth to confirm the presence or absence of MRSA as appropriate (section 
2.5.4). Following 5 successive rounds of panning, cultures were plated out onto RMG 
plates (section 2.5.4). A negative panning step was performed following the successive 
rounds of positive panning (section 2.5.5). Single colonies were then selected and 
grown in RM medium to obtain high yields of plasmid DNA. Plasmid DNA was 
extracted and quantified (section 2.6, 2.6.1). PCR was performed to amplify the insert 
(section 2.7) for subsequent sequencing reactions and analysed by electrophoresis 
(section 2.7.1). Following PCR clean-up, ethanol precipitation was performed prior to 
double stranded DNA sequencing (section 2.7.2). 
 
3.2.4 Peptide synthesis 
 
Two different peptides sequences were synthesised commercially with disulphide linked 
N- and C- terminal cysteines to retain the proposed binding structure as per panning, 
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and without this disulphide bond to give a linear construct for comparison. All peptides 
were synthesised with an N-terminal biotin (section 2.8). Additionally, one of these 
peptides was synthesised replacing the N-terminal biotin with a C-terminal FITC, in 
both the cyclic and linear constructs for assessment of binding directly, without the need 
for additional probes.  
 
3.2.4.1 Assessment of binding of biotinylated and FITC-labelled peptides by flow 
cytometry 
 
Cyclic and linear biotinylated peptides were assessed for binding potential to both live 
and UV-irradiated MRSA, S. aureus and S. epidermidis (section 2.8.1). Preincubated 
peptide: streptavidin-PE:Cy5 solutions were incubated with bacteria, washed and 
analysed by flow cytometry. Additionally, bacteria were incubated with biotin and 
unconjugated streptavidin to saturate non-specific binding sites prior to incubation with 
peptide: streptavidin-PE:Cy5 solutions for flow cytometric analysis (section 2.8.1). 
Cyclic and linear FITC-peptides were incubated with 3 different strains of MRSA and 
also S. aureus, S. epidermidis, P. aeruginosa, E. coli and keratinocytes and analysed by 
flow cytometry (section 2.8.1.2).  
 
3.3 Results 
 
3.3.1 Investigation of UV irradiation and fluorescent staining to determine optimal 
killing of MRSA cultures 
 
The effect of UV irradiation to inactivate MRSA cultures was first determined so that 
the target cells (MRSA) were not able to compete with the E. coli peptide library, and 
therefore simplify the recovery of positive library clones. Preliminary investigation 
using a 15 W 254 nm UV lamp demonstrated that irradiation of a bacterial culture (10 
ml) positioned 15 cm distance from the lamp, and irradiated for up to 30 min, had an 
effective bactericidal consequence, as determined by no growth on nutrient agar 
following overnight incubation. Furthermore,  doubling the density of bacteria/ml (from 
3.3 x 108 to 6.7 x 108/ml) in order to improve bacterial coverage of the plates for later 
immobilisation studies meant that 120 min of UV exposure at 15 cm distance using the 
15 W lamp was required to kill the bacteria. Due to this lengthy killing time a new 15 W 
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254 nm UV lamp was installed. A maximum of 5 min of UV exposure of a 10 ml 
culture (6.7 x 108 bacteria/ml) that was 10 cm distance from the lamp was sufficient to 
kill the bacteria prior to each round of panning.  
 
To confirm the effect of UV irradiation, visualisation of MRSA cultures by confocal 
microscopy utilising fluorescent dyes that differ in their ability to penetrate healthy cells 
was performed. Live MRSA cultures were dual stained with the fluorescent dyes SYTO 
9 and PI and a different culture was stained following exposure to UV radiation. SYTO 
9 stains both live and dead bacteria and fluoresces green. Whereas, PI penetrates only 
bacteria with damaged membranes and fluoresces red. Results indicated that overall, 
UV radiation is effective at killing MRSA (Fig 3.1). The non-irradiated cultures stained 
predominantly green, indicating healthy viable cells, although some were stained red 
denoting bacterial cell death. In contrast, UV irradiated bacteria were mainly stained red 
indicating cell death with only a small proportion of live bacteria present.  
 
3.3.2 Investigation of bacterial immobilisation 
 
The effect of MRSA immobilisation onto different substrates was investigated prior to 
panning experiments. Preliminary investigations showed that bacterial cultures left to 
adhere to wells overnight at 4°C resulted in greater bacterial adhesion than those left to 
adhere for 2 h at RT or 4°C. Furthermore, preliminary investigation into doubling the 
density of bacteria/ml and subsequent immobilisation of bacteria onto plates resulted in 
near maximal plate coverage as determined by light microscopy and visible examination 
of the plates. Following immobilisation, the wash procedures used in panning were 
performed in order to confirm that bacteria would remain adhered to the plate for the 
duration of the panning protocol. The greatest amount of bacterial immobilisation was 
observed using plates coated with collagen I as determined by staining the bacteria that 
had adhered with methylene blue and measuring the absorbance (A668 = 1.07) as shown 
in Figure 3.2. Plates coated in poly-L-lysine showed a reduction in bacterial adhesion 
compared with collagen I coated plates (A668 = 0.88) and a further decrease in bacterial 
adhesion was observed using plates coated in poly-D-lysine (A668 = 0.81) (Fig 3.2). 
Furthermore, staining of collagen I immobilised live bacteria demonstrated a greater 
than two-fold increase in absorbance than when using UV inactivated cells (A668 = 1.07 
vs. 0.43), suggesting that the irradiation was inhibiting an active adhesion process. A  
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similar effect was observed when immobilising live bacteria compared with UV 
inactivated onto both poly-L-lysine (A668 = 0.88 vs. 0.42) and also poly-D-lysine (A668 
= 0.81 vs. 0.38). This result was further supported by visualisation of the immobilised 
bacteria, demonstrating that near maximal plate coverage was still retained following 
washing according to the panning protocol (Fig 3.3).  
 
3.3.3 Panning and DNA sequencing 
The panning process was undertaken against MRSA, S. aureus and S. epidermidis to 
select for peptides with binding specificity for the desired target cell. No contamination 
of either the library of target bacterial cultures was observed from plating of cultures 
onto nutrient agar or utilising mannitol fermentation to confirm the presence/absence of 
MRSA in any round of panning. Following negative selection, sequencing of plasmid 
DNA from panned library cultures resulted in a low signal to noise ratio, whereby 
accurate determination of each individual DNA sequence was problematic. 
Subsequently PCR was performed to amplify the insert from plasmid DNA for DNA 
sequencing. Preliminary investigations were performed varying the number of cycles, in 
order to optimise the DNA amplification process, together with the type and percentage 
gel to be used to best visualise the inserts. It was determined that 35 cycles, and running 
the PCR products on a 4.5% (w/v) Agarose-1000 gel was most effective at amplifying 
and visualising the peptide inserts. Following PCR amplification and verification by 
agarose gel electrophoresis confirming a DNA fragment of 177 bp, the samples were 
sequenced. Further details of the molecular cloning of the thioredoxin moiety 
containing the selected peptides are given in detail in Chapter 4. 
 
3.3.3.1 MRSA peptide sequence analysis  
 
The amino acid sequences of 20 randomly selected peptides from the completed 
panning process against MRSA were determined and analysed for possible consensus 
sequences including criteria such as charge of the amino acid R-groups and repeats. The 
amino acid sequences of the selected peptides are shown in Figure 3.4. No obvious 
consensus sequence amongst these 20 peptide sequences was observed, and no clones of 
the same sequence were selected more than once. Additionally, no clear repeating 
sequences were observed.  
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The most frequently occurring amino acid was arginine accounting for 14.6% of 
residues from the 20 sequences. Other frequently occurring amino acids include alanine, 
glycine, valine and serine (9.2%, 9.2%, 7.9% and 6.7% of residues respectively). 
Analysis based on charge of the amino acid R-group also revealed no distinct patterns. 
However, nearly all of the peptides sequenced contained at least one charged residue 
with positively charged residues (15.8%) occurring slightly more frequently than 
negatively charged residues (11.3%), however one peptide sequence was composed 
entirely of neutral amino acids (peptide3). Surprisingly, eleven of the 20 randomly 
selected sequences contained in-frame stop codons. 
 
3.3.3.2  S. aureus and S. epidermidis peptide sequence analysis 
The amino acid sequences of randomly chosen peptides derived from panning against S. 
aureus and S. epidermidis are shown in Figures 3.5 and 3.6 respectively. Similarly to 
MRSA derived peptide sequences, no clear consensus sequences were observed for 
either set of sequence data. The predominantly occurring amino acids in the S. aureus 
derived sequences were arginine (14.8%), valine (13.9%), glycine (13%) and leucine 
(12%). Positively charged residues accounted for 18.5% of all amino acids and 
negatively charged residues accounted for 10.2%. Only 1 peptide sequence contained a 
stop codon and all sequences contained at least one charged residue. 
 
Similarly to sequences derived against MRSA and S. aureus, arginine (23.5%) was the 
most predominant amino acid residue that occurred within the selected sequences 
against S. epidermidis. Serine (12.1%), glycine (10.6%), leucine and lysine (both 8.3%) 
also occurred frequently. Positively charged residues accounted for 31.8% of all amino 
acids sequenced whereas only 2.3% were negatively charged and charged residues were 
present in all of the derived sequences. One peptide sequence contained a stop codon.  
 
3.3.4 Assessment of biotinylated peptide binding by flow cytometry 
 
Two peptide sequences derived from panning (Fig 3.4; peptide19 and peptide12) that 
were not particularly similar to each other in sequence, but did share sequence 
homology with the other sequences selected against MRSA, were commercially  
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synthesised. Both peptides were synthesised as both linear and conformationally 
constrained structures with N-terminal biotin for characterisation of binding to bacteria. 
 
This method was subject to extensive optimisation. Preliminary investigation by flow 
cytometry and confocal microscopy compared streptavidin FITC and streptavidin 
PE:Cy5 as detection molecules to assess peptide binding of the biotinylated peptides. 
Although both streptavidin FITC and streptavidin PE:Cy5 and biotin alone were 
demonstrated to be able to bind to the surface of bacteria, subsequent analysis was 
performed using streptavidin PE:Cy5 as this gave a brighter signal with flow cytometry 
and more stable signal with confocal microscopy. 
 
Preliminary investigations to assess binding of freely available peptides in solution 
followed by secondary labelling with streptavidin PE:Cy5 demonstrated no clear 
peptide binding to the bacterial surface. Therefore, the peptides were preincubated with 
streptavidin at a molar ratio of 5:1 prior to binding to bacteria in order to saturate the 
biotin binding sites on the streptavidin with the intention of excluding any contribution 
to binding from streptavidin. Additionally, preliminary binding studies were performed 
using a range of serially diluted peptide concentrations and was optimised so that all 
binding studies were performed assuming that there were 100,000 targets/cell for the 
peptide to potentially bind to. Therefore all experiments were calculated to contain the 
same number of peptide molecules (100,000 peptides per bacteria) and the relative 
number of streptavidin PE:Cy5 molecules based on a ratio of 5:1, all in the same 
volume, in order to optimise peptide binding. The binding of the peptides to both live 
and UV-inactivated strains of MRSA1 is shown in Figure 3.7. The FSC/SCC (Panel A) 
of MRSA1 was used to identify the main bacterial population for analysis.  No binding 
was observed for any peptide construct, demonstrated by no difference between the 
cyclic and linear constructs or compared with the streptavidin PE:Cy5 only as a 
negative control (Panels B-E; Fig 3.7). However, in both cases, binding of peptides and 
streptavidin PE:Cy5 was greater to live bacteria than binding to UV-inactivated bacteria 
(Fig 3.7). Furthermore, no binding of peptides was observed against two other strains of 
MRSA (MRSA2 & MRSA 3), S. aureus or S. epidermidis. 
 
Due to the non-specific binding capability of streptavidin and biotin alone, attempts 
were made to block the bacteria with unconjugated streptavidin preincubated with  
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biotin, or a 10-fold excess of biotin in order to saturate non-specific binding before 
addition of peptides. Flow cytometry profiles characterising binding are shown in 
Figure 3.8. Bacterial populations were similarly identified based on FSC/SSC analysis 
for MRSA1 (Fig 3.8; Panel A). Binding of peptide12 and peptide19 to MRSA1 are 
shown in panels B-E. Mean fluorescence and the percentage of the gated marker are 
shown in Table 3.1. Generally, no binding of either peptide was observed in comparison 
to the streptavidin alone control (Fig 3.8, Table 3.1). A very small difference between 
the cyclic and linear constructs was observed with cyclic peptide19 binding slightly 
better to MRSA than the linear peptide19 construct, whereas the linear peptide12 
appeared to bind better than cyclic peptide12 to MRSA (Table 3.1, Fig 3.8). However, 
in both cases there was a slight increase in mean fluorescence following preincubation 
with the biotin:unconjugated streptavidin complex (5:1) that was further increased 
following preincubation with the biotin:unconjugated streptavidin (50:1) complex  
compared with the negative control presumably due to non specific protein interactions 
(Table 3.1, Fig 3.8). A similar effect was observed following binding to a different 
strain of MRSA (MRSA2). 
 
Due to streptavidin and biotin apparently binding to MRSA alone, an anti-biotin 
antibody conjugated to Cy5 was used to attempt to characterise peptide binding in a 
different way that did not involve streptavidin (Fig 3.9). Bacterial populations of 
MRSA1 and MRSA2 were selected based on FSC/SSC properties as before (Panels A 
and B respectively). Binding of cyclic and linear peptide19 and peptide12 to MRSA1 
are shown in Panels C and D respectively. Panels E and F represent FACS profiles used 
to determine binding of both peptides (in both cyclic and linear constructs) to MRSA2. 
Overall, no peptide binding was observed against either strain of MRSA.  
 
3.3.4.1 Characterisation of binding of FITC-labelled peptides by flow cytometry 
Due to the difficulties associated with secondary labelling in order to assess peptide 
binding to bacteria, one of the peptides of interest was re-synthesised directly 
conjugated to a fluorophore (FITC). It was not considered possible to re-synthesise 
peptide19 to characterise binding due to the presence of a lysine residue within the 
sequence that would affect conjugation of the peptide to the fluorophore. The binding of 
FITC-labelled peptide12 alone in a cyclic and linear conformation against 3 strains of  
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MRSA was characterised by flow cytometry. FACS profiles used to determine peptide 
binding to MRSA are shown in Figure 3.10a. A typical FSC/SCC profile (Panel A) was 
used to identify the main bacterial population for analysis as described previously. 
Binding of the cyclic peptide12 to MRSA1 was demonstrated by an increase in 
fluorescence (Panel B - green; mean = 33.8, gated marker = 37.5%) compared to that of 
MRSA alone (mean = 19.5, gated marker = 8.3%). However, no binding of the linear 
construct was observed (Panel B - pink; mean = 9.2, gated marker = 3.7%). Similarly, 
an increase in fluorescence was observed denoting binding of the cyclic peptide12 
(Panel C - green; mean = 20.6, gated marker = 34.2%) to MRSA2 alone (Panel C; mean 
= 8.7, gated marker = 8.5%). The linear peptide12 demonstrated no binding affinity 
(Panel C - pink; mean = 7.3, gated marker = 7.9%). Binding of the cyclic peptide12 was 
also observed to a different strain of MRSA (MRSA3) (Panel D - green; mean = 7.5, 
gated marker = 32.4%) in comparison to MRSA3 alone (mean = 4.0, gated marker = 
8.7). Again, no binding of the linear construct was observed (Panel D - pink; mean = 
3.8, gated marker = 10.9%). 
Furthermore, peptide binding was also assessed against S. aureus, S. epidermidis, P. 
aeruginosa, E. coli and a mammalian keratinocyte cell line for comparison and to 
determine whether the peptide has any reactivity for a eukaryotic cell type (Fig 3.10b). 
Bacterial populations were determined based on FSC/SSC analysis shown previously. 
Panel A demonstrates binding of peptide12 to S. aureus. A limited amount of binding of 
the cyclic construct was observed (Panel A - green; mean = 3.4, gated marker = 30.1%) 
compared to S. aureus alone (mean = 2.0, gated marker = 8.5%). A very small increase 
in mean fluorescence was observed following incubation with the linear construct 
compared with control values (Panel A - pink; mean = 2.2, gated marker = 13.0%). 
Similarly, peptide12 (cyclic) showed a small level of binding to S. epidermidis (Panel B 
- green; mean = 3.7; gated marker = 45.0%) compared to S. epidermidis alone (mean = 
1.6, gated marker = 8.8%) and peptide12 (linear) (Panel B - pink; mean = 2.9; gated 
marker = 35.4%). Binding of cyclic peptide12 was observed against P. aeruginosa 
(Panel D -green; mean = 6.1; gated marker = 49.6%) in comparison to the control (mean 
= 1.2, gated marker = 8.1%). The linear construct demonstrated a small degree of 
binding (Panel D- pink; mean = 2.1; gated marker = 29.7%). No binding was observed 
for either the cyclic or linear construct of peptide12 against E. coli (Panel C). 
Additionally, no binding was observed against a keratinocyte cell line (Panel E).
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3.4 Discussion 
 
Peptides with MRSA binding properties were selected through panning of a random 
peptide library and characterised by DNA sequencing. Two peptides were synthesised 
commercially and the ability of selected peptides to bind methicillin-sensitive and 
methicillin-resistant strains of S. aureus was assessed by flow cytometry. Additionally, 
one peptide was synthesised that was directly conjugated to a fluorophore for direct 
assessment of binding against Staphylococci, Gram-negative bacteria and a keratinocyte 
cell line by flow cytometry.  
 
The effective UV inactivation of MRSA bacterial cultures prior to panning experiments 
was considered important in order to simplify the recovery of positive clones from the 
E. coli library culture to ensure that MRSA was not able to compete with the peptide 
library. The application of UV radiation in this investigation was successful in 
inactivating the MRSA cultures as no bacterial growth was observed on any occasion (n 
= 20) following 5 min UV exposure. The use of UV-C radiation (200-280 nm) has a 
lethal effect on bacteria whereby absorption by DNA causes genetic damage and 
inactivation of bacteria. The use of UV radiation has previously been shown to kill 
cultures of MRSA in vitro (Conner-Kerr et al., 1998) and reduce MRSA in chronic 
superficial wounds following a 180 second exposure (Thai et al., 2005). The use of 
fluorescence staining techniques further confirmed the bacterial death following UV 
exposure. Overall, live bacterial cultures of MRSA were mainly stained green indicating 
healthy viable cells, although some were stained red denoting bacterial cell death, 
presumably this being due to the sample preparation time of approximately 2 h. In 
contrast, >90% of UV-irradiated bacteria were stained red indicating cell death. 
However, although some bacteria may fluoresce green indicating an intact bacterial 
membrane, UV exposure was presumably sufficient to prevent growth in a nutrient 
medium.  
 
Immobilisation of the MRSA onto tissue culture plates prior to panning was needed to 
enable simple recovery of positive library clones, whereby the unbound library without 
the desired binding abilities are washed away from the specifically bound clones. The 
library clones displaying peptides that bind MRSA can subsequently be eluted by 
mechanical shearing, amplified, and subject to successive rounds of panning in an 
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analogous fashion to epitope mapping using the FliTrx™ library (Ito et al., 2004, Lu et 
al., 1995, Singleton et al., 2001). Concentration of the bacteria and overnight adhesion 
to the plates greatly improved bacterial plate coverage. Furthermore, it was 
demonstrated that immobilisation improved significantly using live bacterial cultures as 
opposed to those previously UV irradiated, indicating that bacterial immobilisation onto 
the precoated surfaces is an active process. It was expected that the bacteria would 
adhere to collagen as the bacteria express collagen-binding adhesins on the cell surface 
(Foster and Hook, 1998). Furthermore, there have been numerous reports in the 
literature regarding the use of poly-lysines (D- or L-) to promote cell attachment to 
surfaces whereby the negatively charged bacterial cell wall is attracted to the positively 
charged poly- L- or D- lysine. Poly-L-lysine was used for subsequent bacterial 
immobilisation onto tissue culture plates prior to panning due to the unavailability of 
collagen I coated plates, even though this had initially given slightly better bacterial 
adhesion.  
 
DNA sequencing of bacterial clones selected at random following panning against 
MRSA revealed that no predominant peptide sequence was isolated and neither were 
any obvious repeating subunits found. The variety of peptide sequences isolated and 
lack of consensus sequence observed may simply reflect the diversity of the bacterial 
target. A lack of overall consensus sequence was also observed by Brown et al (2000) 
following sequencing 100 clones derived from panning of the FliTrx™ library against a 
tumour-derived endothelial cell line. However although no obvious consensus was 
observed, this group did identify some recurring repeat sequences of 3-mer or more (17) 
that were predominately of a positive-positive-hydrophobic sequence.  
 
Determination of the surface target to which the individual peptides bind is difficult to 
determine but possible surface targets could include peptidoglycan, teichoic acid or 
surface proteins that are all abundant bacterial cell wall components. If panning was 
performed against a single target it seems reasonable to assume that a greater degree of 
homology may be observed from the isolated peptide sequences. Consensus sequences 
are often obtained from epitope mapping of antibodies and would be expected to result 
in a higher frequency of consensus sequences obtained because sequences are selected 
for the antibody binding site only. However, Yacoby et al (2006) used a phage display 
peptide library displaying random 12-mer disulphide constrained peptides to pan against 
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live S. aureus in 4 rounds from a display library with a diversity of approximately 109 
clones and identified repeated peptide sequences. Similarly, Dane et al (2006) used 
fluorescent bacterial display libraries of a diversity of 2x109 and identified several 
consensus groups following screening against a breast cancer cell line by affinity 
selection by flow cytometry after screening of 70 clones. Therefore, a natural 
continuation of this work is to screen further clones from the MRSA panning, as the 
data may then yield a more obvious consensus sequence or repeated sequences.  
 
Arginine was the most frequently isolated amino acid from all of the sequence data 
obtained, suggesting that this positively charged arginine residue may have been 
selected for from the diverse library by binding to the negatively charged bacteria. 
Arginine rich peptides were also identified by Brown et al (2000), following panning 
against tumour derived endothelial cells whereby most repeating sequences were basic 
in charge. However, lysine is also a positively charged amino acid that was not 
particularly prevalent in MRSA or S. aureus derived peptide sequences, although it was 
one of the most frequently occurring in S. epidermidis derived peptides. It would be 
anticipated that if it was simply the charge of the amino acids in the peptides that was an 
important determinant of individual peptide binding to bacteria then lysine and arginine 
residues would be seen at an equal frequency. However, six different codons code for 
the amino acid arginine whereas only two code for lysine, which may account for why 
less lysine residues were identified than arginine in the selected peptide sequences. 
Additionally, negatively charged residues were also isolated in individual sequences. 
Collectively all 20 different amino acids (not including selenocysteine and pyrrolysine) 
were represented within the sequences further suggesting that the displayed peptides 
could be against a diverse range of targets present on the bacterial surface rather than 
against a few predominately negatively charged moieties.   
 
Numerous in-frame stop codons were identified in DNA sequences following panning 
against bacteria. Other studies selecting potential binding clones from the FliTrx™ 
library have also identified the presence of stop codons within sequences (Dinglasan et 
al., 2005, Yoshida et al., 2002); although do not identify the actual proportion. 
Therefore it may be expected that other studies performed using this library may have 
also identified stop codons within sequences that were unreported within the literature. 
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Following sequencing, two peptide sequences (peptide 19 and peptide12) that shared 
the greatest sequence homology with the other peptides with proposed binding to 
MRSA (Fig 3.4), but were not overly similar to each other in sequence, were selected 
and synthesised.  The peptide binding ability against a range of bacteria, including the 
strain of MRSA that the library was panned against and also two other MRSA strains 
for comparison was determined by flow cytometry. Assessment of the binding ability of 
the two different peptides was difficult to determine due to the relatively high degree of 
binding of streptavidin or biotin alone to bacteria. This adhesive/‘sticky’ nature of the 
cell surface of MRSA may be due to the numerous surface proteins expressed by the 
bacteria (such as collagen, fibronectin and fibrinogen binding proteins) that help 
contribute to the pathogenic potential of MRSA that promote attachment leading to 
colonisation and invasion (Foster and Hook, 1998). 
 
Peptide display technology can identify peptides with a range of affinities. Display 
systems vary in the amount of each ligand that is expressed, and in the original display 
vehicle (FliTrx™ library), peptides are expressed as a multivalent construct. Increasing 
the valency of the interaction is likely to cause an increase in the strength of binding; 
whereby selection from the FliTrx™ library may be based either on selection of strong 
binders based on high affinity, or, selection of modest/low affinity binders selected due 
to strong binding based on an avidity effect (Lu et al., 1995). Therefore selection using 
this library may possibly adopt a conformation to bind and therefore peptide binding 
may be improved by adopting a multivalent display approach as opposed to single 
peptides where weak/low affinity binding may be observed. Therefore, attempts were 
made to optimise the methodology by preincubating the peptide and streptavidin to 
form a peptide:streptavidin complex. One advantage of this would be to exclude the 
binding potential of streptavidin and another advantage would be the multimerisation of 
the peptides as four individual peptides would saturate the biotin-binding sites on the 
streptavidin molecule and therefore increase the avidity towards the target. De et al 
(2005) identified that tetramerisation of the peptide increased target binding affinity 
suggesting this effect by arguing that multivalent display showed greater similarity to 
the original phage expression (3-5 copies) during selection. However, in this instance, 
even though a multivalent approach to improve binding was attempted, removal from 
the overall display structure used in panning and potentially low binding affinity may 
have contributed to a limited binding effect. Although no peptide binding to any strain 
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of bacteria was observed compared with the control, flow cytometry analysis did 
indicate that binding of peptides was increased following peptide incubation with live 
bacteria cultures than those that had been previously UV-irradiated. This suggests that 
binding is an active process requiring the presence of live bacteria within the sample for 
maximum peptide binding or may indicate non-specific peptide uptake by live bacteria 
as the negative control also increased.  
 
Further attempts to identify binding were undertaken by blocking the bacterial surface 
with unconjugated streptavidin and biotin to saturate any non-specific binding prior to 
testing of peptide binding. This appeared to improve binding presumably by increasing 
protein-protein interactions due to aggregation at the bacterial surface and may not 
necessarily reflect a true increase in peptide binding. This additional step of blocking 
the bacteria may have changed the surface of the bacteria to improve binding or 
possibly altered the target. Additionally, although preincubation steps were performed 
at a molar ratio of 5:1 in order to saturate the biotin binding sites on the streptavidin, if 
there were free binding sites on the streptavidin this may have contributed to an increase 
in mean fluorescence observed. Further attempts to characterise peptide binding 
utilising an anti-biotin antibody for secondary detection to try to utilise a different 
mechanism than streptavidin for detection were also unsuccessful. However, bacteria 
labelled with streptavidin PE:Cy5 only as a negative control to determine peptide 
binding may not be an appropriate control due to the ‘sticky’ bacterial surface. 
Similarly, an IgG anti-biotin antibody will bind non specifically to the surface of 
bacteria to a certain extent due to surface expression of protein A that enables the 
binding of numerous isotypes of IgG antibodies (such as the anti-biotin Cy5 used for 
detection) (Roberts and Gaston, 1987). Nonetheless, although there were difficulties 
associated with selecting an appropriate negative control for binding assessment and 
extensive optimisation to improve peptide binding, there was neither any difference in 
binding potential of the two different peptides or between cyclic and linear constructs 
indicating that no biotinylated peptide showed any particular affinity towards any 
bacterial strain investigated. All future similar studies based on target selection should 
therefore concentrate on using direct labelling or increasing valency to mimic the 
original selection construct to assess peptide binding when using flow cytometry.  
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Direct labelling of the peptides with a FITC fluorophore demonstrated binding of the 
cyclic construct against all three strains of MRSA tested. In all FITC-peptide binding 
studies, the cysteine constrained cyclic construct bound greater than the linear version in 
binding studies against bacteria, and in particular against MRSA. This ‘better binding’ 
would be expected as this conformation reflects its structure when originally panning to 
select for peptides ligands of interest. Previously, conformationally constrained peptides 
have been demonstrated to bind the selected target three times greater than linear 
peptides (Giebel et al., 1995, Oneil et al., 1992). Interestingly, the cyclic peptide bound 
most successfully to the strain of MRSA that it was panned against originally and 
therefore lends weight to the possibility that this technique could be suitable to identify 
a range of peptides against different pathogens. Furthermore, no binding to 
keratinocytes was observed, suggesting no binding potential towards eukaryotic cell 
types that can permit the selective targeting of pathogens without harmful effects to the 
host. The cyclic peptide also showed some binding to S. aureus and S. epidermidis. 
Peptides with specificity for MRSA may be expected to be effective against non-
resistant S. aureus due to a similar bacterial cell surface and may suggest an enhanced 
role of isolated peptides for bacterial targeting. Some binding ability may also be 
expected against S. epidermidis due to homology amongst members of the 
Staphylococci, although may bind less, possibly due to slight differences and targets on 
the bacterial surface. No binding was observed against E. coli, a Gram-negative bacteria 
used as a control, suggesting that the peptide is not directed towards a target that is 
expressed on all prokaryotic cell types. However, interestingly binding of the cyclic 
construct was observed against P. aeruginosa, also Gram-negative, suggesting that this 
peptide sequence may have other useful applications rather than just targeting of MRSA 
or other Staphylococcal sp. This may be particularly useful as P. aeruginosa is also a 
frequent human pathogen that is becoming increasingly difficult to treat due to 
increasing resistance (Valencia et al., 2004). 
 
Visualisation of peptide binding using peptides directly conjugated to a fluorophore 
appears to be the most suitable approach for characterising binding by flow cytometry 
and future work could investigate binding of the other selected clones utilising the same 
methodology. However, although flow cytometry is an efficient system for peptide 
screening, it may not be the optimal technique for characterising peptide binding. For 
example, the peptide may bind highly specifically to a single target that is not expressed 
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sufficiently highly on the bacterial surface and therefore the unique targets to MRSA 
may be undetectable, whereas a peptide that binds to a non-specific target on the cell 
surface that is highly expressed may appear to be the ‘best binder’/peptide of choice. In 
order to be detectable using flow cytometry it is generally considered that 
approximately 8,000 targets/cell must be present. This argument could also be true for 
selecting peptides with perceived good binding properties by other techniques such as 
ELISA. Therefore, panning and a consensus sequence and subsequent binding analysis 
may not necessarily be a reflection of the ‘best binders’ that can be identified from a 
random peptide library.  
 
Screening of display libraries has previously enabled successful identification of 
proteins that have specific binding properties to a range of different targets, including 
bacteria. Ideally, the optimal target would be an abundant and yet specific marker on the 
bacterial cell surface. Additionally, the target antigen should be exclusively expressed 
on bacteria, a marker that cannot be changed by resistance and whereby expression is 
not dependent on factors such as growth phase. Future work should include screening of 
more clones identified from the panned library using the direct binding assay to identify 
other peptides that display good MRSA specificity.  
 
The screening technique described here allows for peptides to be selected against a 
target that is a relatively high-throughput and inexpensive system in order to identify 
new ligands that can be utilised in novel detection and drug delivery applications.  The 
development of novel cell-specific reagents with excellent binding specificity that 
allows identification and targeting of bacteria may offer future potential in the treatment 
of wounds in addition to the usual culture methods and antimicrobial therapy. The 
panning technique described in this chapter is a versatile technique that could 
additionally be utilised to screen many other bacterial pathogens/numerous targets, such 
as Pseudomonas or Streptococcal species. 
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CHAPTER FOUR 
Expression and purification of novel peptide-containing thioredoxin proteins 
 
4.1 Introduction 
 
The production of recombinant proteins is a common procedure that is well described 
within the literature. Such proteins can be expressed in a wide range of hosts, including 
bacteria, yeast, mammalian and insect cells, using a range of expression vectors and 
promoters. Selection of the optimal host and promoter for protein production is usually 
dependent on the target protein (Terpe, 2006). Production of recombinant proteins in E. 
coli is most probably the commonest procedure. This system has numerous advantages 
including rapid bacterial growth, high density expression, ease of handling, relatively 
low expense (media, strains and purification), a fully mapped genome, numerous 
strains/vectors and a long history of published data (Baneyx, 1999). Depending on the 
expression system, recombinant proteins may accumulate in the cytoplasm, in the 
periplasmic space, or be secreted into the culture medium. Typically total protein can 
accumulate between 1 and 20% of total cellular protein (LaVallie et al., 2000). One 
disadvantage of protein production in bacteria is that production can frequently result in 
the formation of inclusion bodies (insoluble misfolded intermediates) that then requires 
additional solubilisation and refolding of the protein (Baneyx and Mujacic, 2004). In 
addition to the expression of prokaryotic proteins, the expression of eukaryotic proteins 
in prokaryotic cell systems is frequently performed. However, one disadvantage of 
using the bacterial expression system is the lack of post-translational modifications, for 
example, glycosylation, and this may prevent the use of E. coli expression systems in 
some cases (Terpe, 2006).  
 
In this chapter, a selection of the previously identified peptide sequences of interest 
(Chapter 3) were cloned in-frame within the entire thioredoxin sequence into the 
pPROTet E. coli expression system vector (Clontech). Thioredoxin is a small disulphide 
containing redox protein that has a conserved active site loop composed of a Cys-Gly-
Pro-Cys (CGPC) motif (Stefankova et al., 2005). Thioredoxin has the potential to 
reduce substrate proteins and is itself maintained in a reduced state by thioredoxin 
reductase and NADPH (Kern et al., 2003). Thioredoxin across species have the same 
structure: a central core consisting of five beta strands flanked by four alpha helices and 
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a disulphide group active site (Kern et al., 2003). The pPROTet bacterial expression 
vector is one of the PRO™ bacterial expression system based on vectors developed by 
Lutz and Bujard (1997), allowing for tightly regulated expression of a protein without 
compromising the yield of protein induced (up to 10% of total protein). The pPROTet 
vector contains the PLtetO‐ promoter that is induced in response to the addition of 
anhydrotetracycline (aTc), Col E1 (a high copy replication origin with a 2,500 fold 
range of inducibility) and a chloramphenicol resistance gene to select for transformants.   
 
Furthermore, one thioredoxin insert containing a peptide sequence of interest was also 
expressed as a GFP fusion protein construct for subsequent direct characterisation of 
peptide binding. Recombinant protein expression frequently employs the use of an 
affinity tag fused to the protein of interest to enable protein purification and detection 
(Terpe, 2003). In the system described here, the pPROTet vector contains a 6xHis-Asn 
affinity tag for subsequent purification using immobilised metal affinity 
chromatography (IMAC). Placement of polyhistidine tag for optimal affinity 
purification is recombinant protein specific but has been frequently placed either at N- 
or C- termini (Terpe, 2003). Following expression in E. coli, protein production was 
optimised and the protein extracted and purified for subsequent analysis (see Chapter 5).  
 
4.2 Methods 
 
4.2.1 PCR amplification of thioredoxin inserts containing different specific random 
peptide sequences and GFP 
 
PCR was performed to amplify the DNA of the entire thioredoxin sequence each 
containing different peptide sequences of interest either with or without an additional 15 
lysine residue linker (section 2.9.2, 2.9.2.1). Additionally following transformation of 
the GFP expression vector into E. coli JM109 (section 2.10) and selection of positive 
transformants (section 2.10), GFP was amplified by PCR with and without its natural 
stop codon (section 2.10). Following amplification all PCR products were purified 
either directly (section 2.9.3) or by gel extraction (section 2.10.1). Following 
purification an aliquot of each PCR product was visualised by agarose gel 
electrophoresis (section 2.9.3.1) and the concentration determined 
spectrophotometrically (section 2.6.1).  
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4.2.1.1 Digestion of PCR products from thioredoxin or GFP and the pPROTet 
expression vector 
 
Following purification, double digestion reactions were performed to digest the 
amplified thioredoxin and GFP coding DNA and pPROTet bacterial expression vector 
using restriction enzymes previously described prior to ligation (section 2.9.4 and 
section 2.10.2 respectively). The digested PCR products and pPROTet vector were 
purified by gel extraction from a low melting point agarose gel. A test gel was 
performed following clean-up to ensure recovery of purified DNA of the correct size 
(section 2.9.3.1).  
 
 4.2.1.2 Ligation of thioredoxin or GFP products into pPROTet vector and E. coli 
transformation 
 
Ligation reactions were performed in order to ligate individual thioredoxin insert 
fragments into the pPROTet vector at a molar ratio of 25:1 alongside control ligation 
reactions that contained cut plasmid DNA but no insert (section 2.9.5). Ligation 
reactions (1 µl) were visualised by agarose gel electrophoresis prior to transformation 
into E. coli JM109 (section 2.9.6). Additionally, PCR products, coding for GFP both 
with and without a stop codon, were ligated into the pPROTet vector at a molar ratio of 
5:1 alongside control reactions containing no insert DNA (section 2.10.3). An aliquot of 
each GFP/pPROTet ligation reaction was transformed into E. coli DH10B competent 
cells (section 2.10.4). Transformed cells were then plated onto LB agar plates 
supplemented with antibiotic to select for positive thioredoxin/pPROTet or 
GFP/pPROTet transformants.  
 
4.2.1.3 Confirmation of positive transformants 
 
Colony PCR was performed to determine that the thioredoxin insert was successfully 
present and in the correct orientation within the vector (section 2.9.7). Following 
amplification, PCR products were visualised by agarose gel electrophoresis (section 
2.9.7). Positive transformants were amplified by bacterial culture and glycerol stocks 
prepared (section 2.9.8). Plasmid DNA was extracted and ethanol precipitated prior to 
DNA sequencing in order to confirm the presence of the insert (section 2.9.9). 
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Furthermore, competent cells only and competent cells transformed with the empty 
expression vector were analysed by colony PCR following transformation to determine 
the presence and size of natural E. coli thioredoxin (section 2.9.6). For GFP 
transformants, single colonies were selected and the presence of GFP was confirmed by 
confocal microscopy analysis of individual transformants (section 2.10.4). Following 
confirmation of successful transformation of GFP, individual colonies were amplified 
and glycerol stocked (section 2.10.4). 
 
4.2.2.3 Generation and verification of thioredoxin/GFP/pPROTet vectors  
 
Plasmid DNA was extracted from positive bacterial cultures transformed with 
GFP/pPROTet plasmids (section 2.10.4). Double digestion reactions with SalI and 
BamHI restriction enzymes were performed in order to digest both purified 
GFP/pPROTet plasmid vector DNA and amplified thioredoxin PCR products (amplified 
without the lysine linker) (section 2.10.5). The digested DNA products were both 
purified by gel extraction (section 2.10.5). Ligation reactions were performed to join 
digested and cleaned GFP/pPROTet plasmid DNA at a 10:1 insert to vector molar ratio 
with each thioredoxin insert, alongside control reactions containing no insert DNA 
(section 2.10.6). Each thioredoxin/GFP/pPROTet ligated vector was transformed into E. 
coli GC10 competent cells (section 2.10.6). Plasmid DNA was isolated from individual 
transformants and PCR performed to confirm the presence of thioredoxin and GFP 
inserts (section 2.10.7). Isolated plasmid DNA was ethanol precipitated and the DNA 
sequenced using pPROTetFor primer and either GFPRev(WS or NS) or pPROTetRev 
primers (Table 2.2).  
 
4.2.3 Determination of optimal protein induction and expression 
 
Each bacterial culture was grown to an OD500 of 0.5. Cultures were then divided and 
induced with varying concentrations of aTc (section 2.11). Following induction an 
aliquot of each culture was removed at various time points and bacteria were pelleted by 
centrifugation. This method was also repeated following induction taking aliquots at the 
same time points, but bacterial cultures were diluted to an OD500 of 0.5 prior to 
centrifugation so that equivalent amounts of bacteria were present in each sample 
(section 2.11). SDS-PAGE was performed using 10% (w/v) resolving gels or 4-20% 
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(w/v) gradient gels (section 2.12). Following electrophoresis, each gel was either 
stained with Coomassie (section 2.12.1) or further analysed by Western blotting (section 
2.12.2, 2.12.2.1, 2.12.2.2).  
 
4.2.3.2 Shake-flask protein expression, purification and quantification 
 
Bacterial cultures were amplified until an OD500 of 0.5 was obtained and following 
induction protein samples were prepared and purified by column purification (section 
2.13.1, 2.13.2, 2.13.3). Eluted protein samples were concentrated in MWCO spin 
columns and buffer exchanged (section 2.13.4). Protein samples were quantified by 
Bradford assay (section 2.13.5) and further characterised by SDS-PAGE and Western 
blotting (section 2.13.6). 
 
4.3 Results 
 
4.3.1 Amplification of peptide sequences  
 
Plasmid DNA encoding peptide sequences containing no stop codons were amplified by 
PCR using primers specific to amplify the full thioredoxin gene (Table 2.2; ThioFor and 
ThioRev) whereby the individual peptide sequences are situated within the middle of 
the thioredoxin sequence. Subsequently the ThioFor primer was modified to incorporate 
a 15 lysine linker on the N-terminal primer to facilitate subsequent conjugation to the 
photosensitiser (Table 2.2; ThioLysineFor). PCR was performed to amplify the 435 bp 
insert (thioredoxin containing insert plus linker) from plasmid DNA derived following 
panning and DNA sequencing. A representative example of an agarose gel of the 
thioredoxin inserts with and without the lysine linker following amplification and 
purification is shown in Fig 4.1 (lanes 1-3 and 5-7 respectively). For all subsequent 
cloning and DNA sequencing analysis, different modified thioredoxins containing 
unique peptides (either as DNA sequences or recombinant proteins) will be referred to 
based on the peptide sequence number identified in Figure 3.4 (Chapter 3).  
 
Colony PCR was performed on competent cells alone and competent cells transformed 
with an empty expression vector using combinations of primers detailed in Table 2.2 
(section 2.9.1; Chapter 2). Colony PCR performed on competent cells alone (Fig 4.2;  
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top row lanes 1-3) and cells transformed with an empty expression vector (i.e. no cloned 
thioredoxin or GFP; Fig 4.2; bottom row lanes 1-3), using PCR primers specific for 
thioredoxin, produced a product of approximately 350 bp corresponding to natural E. 
coli thioredoxin (Stefankova et al., 2005). 
 
PCR using primers specific for the empty expression vector produced a PCR product of 
approximately 270 bp corresponding to the empty vector (Fig 4.2; bottom row lanes 14-
16) that was not present in competent cells only (Fig 4.2; top row lanes 9-11) 
demonstrating no DNA corresponding to the expression vector was present in 
competent cells alone. Amplification using primer combinations of both thioredoxin and 
expression vector of competent cells only (Fig 4.2; top row lanes 5-7) and competent 
cells transformed with an empty expression vector (Fig 4.2; bottom row lanes 5-7, 9-11) 
were blank signifying no template DNA. 
 
Furthermore, competent cells only (Fig 4.3 - Panel A) and competent cells transformed 
with an empty expression vector (Fig 4.3 - Panel B) were analysed by Western blot to 
ascertain the molecular weight of natural E. coli thioredoxin which was observed to be 
approximately 12 kDa (predicted Mw = 11.9 kDa). Following 2 h amplification, a small 
increase in the concentration of thioredoxin was observed (Fig 4.3- Panels A and B; 
lane 2) compared to initial concentrations (Fig 4.3 - Panels A and B; lane 1). However, 
when the optical density of the bacteria were diluted to starting values, no increase in 
thioredoxin was observed (Fig 4.3 - Panels A and B; lane 5). Additionally, no 
thioredoxin was observed in the supernatant of bacterial cultures (Fig 4.3 - Panels A and 
B; lanes 3 and 7). Furthermore, induction of bacterial cultures with 0.1 ng/ml aTc for 2 
h (conditions determined to be optimal for protein expression) demonstrated no increase 
in thioredoxin concentration (Fig 4.3- Panels A and B; lane 8) when normalised to pre 
induction absorbance starting values (Fig 4.3 - Panels A and B; lane 5). However, as 
expected, a small increase was observed following 2 h amplification without 
normalisation (Fig 4.3 - Panels A and B; lane 6). Although the membrane was reprobed 
with an antibody specific for the 6xHN tag, visualisation was not possible due to the 
small size (4.6 kDa) of the product without an inserted cloned sequence for protein 
expression. 
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4.3.2 Cloning of peptides into pPROTet 
 
Thioredoxin inserts of interest (n=9) and the expression vector pPROTet were digested 
and the ligation reactions optimised to determine the optimal insert to vector ratio for 
ligation. The optimal ligation ratio was determined to be 25:1 insert to vector 
respectively, as preliminary investigation using 5:1 and 10:1 demonstrated inconsistent 
ligation reactions (i.e. no ligated vector). Additionally, the optimal host E. coli strain for 
transformation was found to be JM109; as this resulted in successful transformations of 
all ligated vectors. Transformation of vectors into other competent strains (GC10 and 
BL21) to attempt to improve subsequent protein production were largely unsuccessful, 
mainly due to bad batches of commercial cells whereby approximately 15 independent 
transformations were attempted and no transformants were selected. A typical 
representative gel showing successful ligation prior to transformation is shown in Figure 
4.4 (lanes 4-8) for thioredoxin 5, 11 12, 14 and 19/pPROTet ligated vectors; note the 
multiple bands indicative of ligated product.  
 
Successful transformants were analysed by colony PCR to ensure the presence of the 
insert, in the correct orientation, using a forward primer specific for the expression 
vector and a reverse primer corresponding to thioredoxin to produce a band 
corresponding to 549 bp. On average, 6 clones for each recombinant protein of interest 
were analysed in duplicate. Following colony PCR screening to determine the presence 
of the insert each transformant was subsequently amplified in liquid culture and stored 
in glycerol for future use. A typical representative agarose gel of samples following 
colony PCR is shown in Fig 4.5. Additionally, DNA sequencing was performed in both 
directions on a selection of clones following transformation in order to confirm that 
thioredoxin inserts had been successfully cloned downstream of the PLtet0‐1 and in-frame 
of the start codon in the right orientation. DNA sequences were translated using the 
ExPASy proteomics server of the Swiss Institute of Bioinformatics 
(http://www.expasy.ch/) (Bioinformatics, 2009). 
 
4.3.3 Amplification of GFP and cloning of GFP and thioredoxin into pPROTet 
 
GFP containing its natural stop codon and also a substitution to code for an alternative 
amino acid (to allow read through and possibly adopt more favourable protein folding  
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for comparison) were amplified by PCR. Following digestion, PCR products were 
cleaned-up and cloned in-frame into the pPROTet expression vector. Successful 
transformants were confirmed positive for GFP by confocal microscopy (Fig 4.6) and 
those of the highest relative fluorescence selected for future cloning. Plasmid DNA of 
positive clones were digested and ligated with thioredoxin inserts containing different 
peptide sequences (without the additional lysine linker; Fig 2.1). Following 
transformation of thioredoxin/GFP/pPROTet ligated vectors and overnight incubation, 
all thioredoxin/GFP (with stop)/pPROTet colonies appeared visibly green on the plate 
whereas thioredoxin/GFP (without stop)/pPROTet had a mixture of green and white 
colonies (approximately 50:50). Plasmid DNA was extracted from transformants and 
analysed for the presence of GFP and thioredoxin by PCR (Fig 4.7). Analysis by gel 
electrophoresis indicated that thioredoxin was only present in the colonies containing 
the expression vector with GFP with no natural stop codon and only in white colonies 
selected (Fig 4.7; lanes 5-8) whereas no thioredoxin was amplified from green colonies 
selected with the substituted stop codon (Fig 4.7; lanes 1-4). Additionally, no 
thioredoxin was present in vectors that retained GFP’s natural stop codon (Fig 4.7; lanes 
9-12).  
 
Colony PCR of selected positive transformants (white colonies containing thioredoxin 
5/GFP (no stop)/pPROTet) using different primer combinations specific for thioredoxin, 
GFP and the expression vector produced PCR products of the expected size (Fig 4.8). 
Furthermore, DNA sequencing of two randomly selected white colonies containing 
thioredoxin 5/GFP (no stop)/pPROTet was performed. Full sequencing was performed 
in both directions to verify the DNA coding sequence. Thioredoxin and GFP had been 
successfully cloned in-frame into the expression vector. No mutations were found in 
one transformant whereas sequencing of the other transformant demonstrated the 
presence of numerous premature stop codons resulting in protein termination and 
therefore no GFP coded for with the construct. This was due to a deletion in the 
sequence that resulted in the wrong amino acid being coded for (threonine (ACG) rather 
than aspartic acid (GAC)) resulting in a frameshift mutation so that the following DNA 
sequence coded for the wrong amino acids until a premature stop codon was reached. 
Furthermore DNA sequencing of two thioredoxin 5/GFP (with stop)/pPROTet clones 
indicated the vector had no thioredoxin. 
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4.3.4 Protein expression of thioredoxin inserts in pPROTet 
 
Protein expression, induced by varying concentrations of aTc, was analysed by SDS-
PAGE and Western blotting. Gels stained with Coomassie reagent demonstrated various 
bands indicating the presence of numerous proteins isolated from the bacterial pellets 
(Fig 4.9 lanes 1-7). Stained gels also indicated that 2 h induction had the greatest 
amount of protein present as indicated by the presence of darker bands (Fig 4.9 lane 2) 
compared with other incubation times (Fig 4.9 lane 1, 3-7), although it was not possible 
to visualise the exact protein band of interest from the gel. No thioredoxin protein was 
determined to be secreted into the supernatant as indicated by the presence of no bands 
following a Western blot probing for thioredoxin as determined from two repeat 
experiments. 
 
Optimal protein expression was determined by Western blotting over a range of inducer 
concentrations and different durations of induction. Western blot analysis showed that 
induction with 0.1 ng/ml of aTc for 2 h was optimal for thioredoxin 19 protein (P19) 
production (predicted MW = 19.6 kDa), giving a band corresponding to approximately 
26 kDa when probing for thioredoxin with an anti-thioredoxin antibody (Fig 4.10; lane 
2). A two hour induction was also demonstrated to be optimal for protein production 
using different concentrations of inducer (e.g. 0.1, 1, 10 & 100 ng/ml).  Furthermore, in 
addition to optimal P19 protein expression, these conditions were shown optimal for 
recombinant thioredoxin protein production that contained a different peptide 
(peptide12) and therefore were subsequently used for all protein expression. Following 
determination of optimal conditions, the membranes were stripped and reprobed for the 
6xHN tag (Fig 4.11) and demonstrated a band corresponding to the same molecular 
weight indicating production of 6xHN tagged thioredoxin proteins (lane 2; ~26 kDa).  
 
4.3.4.1 Extraction and purification of thioredoxin proteins 
 
Preliminary attempts at protein extraction and purification were probably unsuccessful 
due to the limited amount of bacterial lysis following sonication for 3 x 10 sec and 3 x 
30 sec to disrupt the bacteria and release the protein. However, the protocol was 
optimised to improve bacterial lysis by using a One Shot cell disruptor to achieve 
maximal lysis. Samples from using the sonication method always appeared very  
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translucent in colour whereas, One Shot derived lysates were noticeably more yellow in 
colour and of greater viscosity. Proteins were initially analysed using native SDS-PAGE 
to confirm the presence of thioredoxin. This method was initially optimised so that 
proteins were analysed using a precast 10% (w/v) resolving gel to ascertain the size of 
the product and further optimised to use 4-20% (w/v) gradient gels due to the relatively 
small size of the expected product, to allow better visualisation as the product was 
situated at the bottom of the gel.  
 
The protein purification process was analysed by SDS-PAGE and Western blotting. 
Staining with Coomassie reagent produced very faint single bands observed following 
elution and concentration/buffer exchange but was not able to be clearly photographed. 
A typical representative Western blot to analyse thioredoxin 12 (P12) purification 
probing for thioredoxin (predicted MW = 19.4 kDa) with an anti-thioredoxin antibody is 
shown in Figure 4.12. Bacteria were analysed before and after induction (Fig 4.12; lanes 
1+2 respectively), and following lysis to extract the protein (clarified sample - Fig 4.12; 
lane 3) whereby a protein band corresponding to approximately 26 kDa was observed. 
A small amount of thioredoxin protein did not bind to the resin during the purification 
process as indicated by the very faint band present in lane 4 in Figure 4.12. Eluted 
protein fractions (Fig 4.12; lane 5) were concentrated (Fig 4.12; lane 6) and were still 
present following buffer exchange (Fig 4.12; lanes 7+8) prior to conjugation to the 
photosensitiser. Additionally, the same membrane was reprobed for the 6xHN tag and 
produced faint bands of the same size and position as the thioredoxin probe (Fig 4.13: 
lanes 5-8 although most prominent in lane 6).  
 
Following purification, concentration and buffer exchange the final concentration of the 
purified proteins were determined spectrophotometrically. The final concentration of 
P12 was determined to be 219 µg/ml, P19 was 175 µg/ml and thioredoxin 5 protein (P5) 
was calculated to be 299 µg/ml. However, the initial concentration of aliquots of P12 
and P19 were also determined prior to volume concentration and buffer exchange of 
eluted proteins in the MWCO spin columns, and indicated that there was only a 26.8% 
and 25.9% recovery of each protein respectively resulting in a lower than expected 
yield. Further analysis indicated that there was no protein present in the buffer exchange 
flow-through from the column, thus the remaining protein had probably adhered to the 
membrane of the spin column.  
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4.3.4.2 Extraction and purification of thioredoxin/GFP proteins 
 
Samples were analysed by SDS-PAGE and Coomassie staining (Fig 4.14). Coomassie 
staining of samples show that more thioredoxin 5/GFP protein (P5/GFP) had been 
produced following induction (Fig 4.14; lane 2) compared with starting values (Fig 
4.14; lane 1) and a similar effect was demonstrated following induction of P5 only (Fig 
4.14; lanes 5+6). However, it was not possible to visualise bands following protein 
concentration and buffer exchange for thioredoxin 5/GFP (Fig 4.14; lanes 3+4). 
However, multiple bands were detected in P5 following buffer exchange (Fig 4.14; lane 
8) that were not observed in the concentrated sample (Fig 4.14; lane 7) indicating that a 
pure product was not obtained on this occasion. 
 
Protein expression and purification of P5/GFP was analysed by Western blotting by 
probing for thioredoxin (Fig 4.15). Bacterial lysates following One Shot extraction were 
analysed before and after induction with 0.1 ng/ml aTc for 2 h (Fig 4.15; lanes 1+2 
respectively) and indicated protein had been produced. Following protein purification 
and concentration, aliquots were analysed and a band corresponding to approximately 
40 kDa was observed (Fig 4.15; lane 3) which remained following buffer exchange (Fig 
4.15; lane 4) (predicted weight = 44.1 kDa). Additionally, P5/GFP production was 
compared to thioredoxin P5 production before and after induction (Fig 4.15; lanes 5+6 
respectively and following concentration and buffer exchange (Fig 4.15; 7+8 
respectively) in order to compare the relative size of extracted proteins with and without 
GFP. The concentration of the P5/GFP fusion protein was determined 
spectrophotometrically to be 414 µg/ml. These purified recombinant proteins are further 
characterised and discussed in Chapter 5.  
 
4.4 Discussion 
 
Selected clones P5, P12 and P19, identified through panning of the library (Chapter 3) 
for binding specificity to MRSA, were chosen for further analysis and cloned in-frame 
into an expression vector for protein production. In addition, one construct (P5) was 
cloned in-frame as a GFP fusion protein. This resulting fusion construct thus permits 
binding to MRSA through the thioredoxin containing peptide region and also GFP as a 
potential diagnostic tool for the rapid identification of MRSA.  
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It was considered that because the peptides of interest were small, 12-mer, and that the 
downstream application involved conjugation to a photosensitiser or GFP, that each 
peptide should be produced within the entire thioredoxin protein for stability, especially 
as they were initially selected in this format. The CGPC active site loop of E. coli 
thioredoxin is surface exposed that is situated at the end of a beta-strand and beginning 
of an alpha-helix (Kern et al., 2003). Therefore, because each peptide is situated within 
the active site loop of thioredoxin, it is predicted that the peptides will remain surface 
exposed in a similar construct to the original library (described by Lu et al., 1995). 
 
The methodology for cloning of thioredoxin into the expression vector followed a now 
commonly used PCR cloning procedure whereby restriction enzyme sites were 
incorporated into the forward and reverse primers for successive cloning into the vector 
cut with the same enzymes, described by Scharf et al (1986). Additionally primers were 
designed to add extra base pairs before the restriction site because not all restriction 
enzymes are efficient at cutting at the ends of DNA (Kaufman and Evans, 1990). 
Furthermore, the cloning strategy was designed to perform double digestions of vector 
and insert DNA with different restriction enzymes to prevent self-ligation of the cut 
vector (without requiring dephosphorylation) and that restriction enzymes used for 
double digests of DNA (either thioredoxin or GFP) had compatible buffers and 
temperatures. Amplification of DNA by PCR was successful in identifying DNA bands 
of the correct size corresponding to thioredoxin and additionally following 
reamplification with the 15 lysine residue linker.  Although the original amplified 
thioredoxin sequence did include lysine residues (accounting for 10/122 codons of the 
thioredoxin sequence, not including any lysine residues present in the peptide 
sequence), the addition of a 15 lysine linker was considered an important step in 
facilitating the subsequent conjugation of thioredoxin proteins to the photosensitiser.  
 
An important step was the ability to differentiate natural E. coli thioredoxin from cloned 
thioredoxin because each different recombinant thioredoxin would subsequently be 
cloned into an expression vector for protein production in E. coli. The DNA from E. 
coli not containing recombinant protein (i.e. no individual peptides/additional lysine 
linker) was amplified by PCR from the bacterial strain used for protein production and 
visualisation of the amplified DNA demonstrated that the competent cells (alone or with 
an empty expression vector) were able to code for natural thioredoxin (Fig 4.2). This is 
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not surprising due to the ubiquitous nature of thioredoxin (Arner and Holmgren, 2000). 
Furthermore, DNA bands observed were of the predicted size for natural E. coli 
thioredoxin (i.e. no peptide and no lysine linker) that were smaller than DNA bands 
observed containing the inserted peptide and/or lysine linker. Visualisation of natural E. 
coli thioredoxin was further characterised by Western blotting and determined to be 
approximately 12 kDa (Fig 4.3). This is in agreement with the published literature 
whereby thioredoxin have a molecular weight of approximately 12 kDa (Stefankova et 
al., 2005). 
 
All attempts at cloning thioredoxin only into the pPROTet expression vector were 
successful indicating that this system could be used to screen many different 
thioredoxin containing peptides with different MRSA binding specificities. However, it 
is unclear why restriction enzymes SalI and BamHI did not digest GFP (with 
stop)/pPROTet plasmids to obtain a linearised vector to allow insertion of thioredoxin 
inserts. This is in contrast to GFP (no stop)/pPROTet plasmids whereby partial cutting 
was achieved, in order to permit thioredoxin ligation, and resulted in a mixture of 
colonies that did and did not contain the thioredoxin insert. An extended digestion of the 
plasmids by addition of supplemental restriction enzymes during the incubation period 
may facilitate more efficient cutting in future investigations. However, because 
successful cloning of thioredoxin into GFP (no stop)/pPROTet was only observed in 
white colonies following transformation and not green colonies from the same vector or 
any colony from thioredoxin/GFP (with stop)/pPROTet vectors, it enabled a fast 
screening method to be developed for the selection of the required positive 
transformants. DNA sequencing of thioredoxin 5/GFP (no stop)/pPROTet constructs 
resulted in the correct sequence of one construct, but a premature stop codons in the 
other indicating that correct translation would not occur. 
 
An advantage of this expression system for protein expression is that it involved 
expression of E. coli thioredoxin (a prokaryotic protein). Therefore no detrimental effect 
based on differences in codon usage between eukaryotes and prokaryotes was likely to 
occur; an effect that can often impact on eukaryotic protein production in prokaryotic 
hosts (Baneyx, 1999). Additionally, E. coli hosts can sometimes have difficulty in 
expressing eukaryotic proteins which may require modifications of proteins such as 
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glycosylation or other post translational modifications thus leading to non functional 
products (Terpe, 2006). 
 
Protein production using the pPROTet bacterial expression system was optimised to 
increase the yield of recombinant protein by determining the optimal concentration of 
the inducer and the time of induction. In this system it was determined that optimal 
protein production was achieved following 2 h incubation after induction with 0.1 ng/ml 
aTc (Fig 4.9, Fig 4.10 & Fig 4.11). In theory, the longer the incubation following 
induction, the more protein should be produced but conversely longer periods of 
induction may allow for greater accumulation of inclusion body formation. Nonetheless, 
in this instance, 2 h incubation following induction with a range of inducer 
concentrations (0.1-100 ng/ml) was observed to be optimal for protein expression and 
therefore suggests that time of induction rather than concentration of inducer was a 
more important factor. However, 2 h induction was also shown to be optimal for protein 
expression even with no induction. This observation is difficult to explain, due to the 
proposed tight regulation of the expression vector, which should not allow any 
induction without the addition of aTc to the culture medium. A similar induction time 
was also employed by Tao et al (2000) who demonstrated that induction for 2.5 h was 
sufficient for small scale protein production.  However, contrary to results indicated 
here, this group did not see any increased expression in the absence of induction (Tao et 
al., 2000). Membranes containing positive samples that were reprobed for the 6xHN 
tag, demonstrated a band that was only observed following 2 h incubation further 
supporting that 2 h incubation was the optimum time (Fig 4.11). The presence of a 
protein band of the same size following probing for thioredoxin and the 6xHN tag 
determined that the correct protein had been successfully induced.  
 
Interestingly, Western blot analysis probing for thioredoxin produced at band at 
approximately 26 kDa whereas the predicted molecular weight was 19.6 kDa. However, 
analysis of thioredoxin/GFP fusion protein by Western blotting resulted in a slightly 
smaller size than predicted. Size determination using SDS-PAGE is not only determined 
by the protein size but also by charge and may also be slightly altered by other factors 
such as running conditions, gel concentration and pH. Western blotting of thioredoxin 
indicated the presence of multiple bands in addition to the band of interest. Oxidised 
and reduced thioredoxin have been demonstrated to interact with unfolded proteins and 
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have been suggested (along with thioredoxin reductase) to have chaperone-like 
properties (Kern et al., 2003). Therefore multiple bands may be due to the chaperoning 
function/protein interactions of natural thioredoxin protein with other proteins that were 
not separated by lysis in SDS loading buffer and therefore appear as protein dimers on 
the blot. However, this is considered unlikely as the interaction of thioredoxin and 
proteins was hypothesised by Kern et al (2003) to be due to weak hydrophobic 
interactions and unlike thioredoxin reductase, thioredoxin was not demonstrated to be 
able to form stable complexes with unfolded proteins in HPLC gel filtration 
experiments. However, thioredoxin binding to proteins was suggested to involve the 
active site (Lennon et al., 2000) and in this system novel peptides within the active site 
may have contributed to protein binding properties. A more likely explanation of the 
presence of multiple bands is the non-specific reactivity of the primary or secondary 
antibody. Therefore the use of a monoclonal thioredoxin antibody (instead of a 
polyclonal thioredoxin antibody) may reduce this.  
 
Although sonication is a routine method employed to release proteins from cells, in this 
system protein release was greatly improved by using a One Shot cell disruptor. It is 
possible that the extraction process is not fully optimised and a variety of other 
approaches could be utilised to improve yield. Nonetheless, although protein extraction 
was improved, full extraction and recovery is unlikely in any system where proteins 
accumulate in the cytoplasm whereby some protein will nearly always remain in the 
bacterial debris as insoluble inclusion bodies. It is possible to solubilise proteins with a 
denaturing agent and refold the protein, although there is no certainty that the protein 
will refold in vitro in a biologically active form (Baneyx, 1999). Therefore native 
protein extraction of thioredoxin/thioredoxin GFP was preferable even if only a 
relatively small percentage is obtained compared with extraction under denaturing 
conditions.  
 
In this expression system, although the formation of inclusion bodies cannot be 
completely excluded, because this system was largely expressing bacterial thioredoxin it 
was unlikely to be affected by substantial problems with insolubility. Thioredoxin has 
been used often as a fusion partner to enhance the solubility of passenger proteins and 
therefore is unlikely to form inclusion bodies. Both the N- and C- termini of thioredoxin 
are available for fusion (Katti et al., 1990) although thioredoxin is more frequently 
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placed at the N-termini when used as a fusion partner (Terpe, 2003). Therefore if 
thioredoxin fusions are typically used to improve the solubility of passenger proteins 
then the production of thioredoxin only in a soluble form seems achievable. 
Thioredoxin fusion proteins have been successful in improving solubility of numerous 
proteins. For example, thioredoxin fusion was employed to produce functional 
mammalian cytokines/growth factors at high levels that had previously only been 
formed as inclusion bodies (Lavallie et al., 1993). It has been suggested that 
improvement of passenger protein folding is due to rapid and correct folding of the 
fusion protein (e.g. thioredoxin, but also maltose-binding protein and glutathione-S-
transferase) thus promoting downstream correct structure configuration in downstream 
folding units (Baneyx, 1999). Each purified protein (P5, P12 and P19) resulted in fairly 
similar yield obtained indicating that the induction time and inducer concentration used 
here were desirable for the generic expression of such protein constructs. Furthermore, 
purified thioredoxin/GFP fusion proteins gave approximately double the concentration 
of thioredoxin only recombinant proteins. The GFP fusion protein was approximately 
double the molecular weight of thioredoxin only proteins and therefore the number of 
moles of recombinant protein appears consistent suggesting favourable protein 
production even with the additional GFP protein sequence in the construct.  
 
Purification of thioredoxin proteins was successful by affinity chromatography utilising 
the polyhistidine tag present at the N-terminus of the protein. Histidine tags present a 
low metabolic burden to bacteria and tags present at the N-terminus may improve the 
yield of recombinant protein due to efficient initialisation of translation (Waugh, 2005). 
Protein activity is unlikely to be affected by the presence of the tag and cleavage of the 
tag is not always necessary depending on the downstream application (Terpe, 2003) 
although this possibility cannot be excluded (Waugh, 2005, Terpe, 2003). Cleavage of 
the affinity tag from the recombinant thioredoxin proteins is possible utilising 
enterokinase although in this system cleavage of the tag was not performed as it was 
considered unlikely that this would inhibit peptide binding.  
 
All of the recombinant proteins (P5, P12, P19 and P5/GFP) could be expressed 
suggesting that no recombinant thioredoxin proteins were toxic to the host. Although 
determination of the optimal inducer concentration and time of induction were 
performed in order to increase the yield of recombinant protein produced and also the 
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method of extracting the protein changed to improve yield, ultimately only a small 
amount of each protein was produced for further characterisation of protein binding to 
MRSA. Production using JM109 competent cells may have limited the protein 
produced. Although this strain is used in many applications such as routine subcloning, 
it is not an ideal for protein production. However, attempts were made to produce 
protein in strains that are more optimal for protein production (i.e. BL21 and GC10) but 
was not possible due to multiple unsuccessful transformations. One solution to achieve 
the desired amount of recombinant protein would be to scale up from shake flask 
expression to fermentation under more controlled conditions, or ultimately a different 
expression system, such as a yeast model, could be employed to attempt to improve 
protein yield. However, the limited amount of recombinant protein produced was 
mainly due to only a small recovery of purified protein following concentration in the 
MWCO spin column. Although some protein can be expected to be lost in this 
procedure, this recovery was a lot lower than anticipated. The protein was not lost in the 
column flow through and therefore it can only be assumed that the protein remained 
firmly bound to the membrane, although the reason behind this is unclear. In summary, 
despite considerable technological difficulties this system was successfully used to 
produce a selection of functional recombinant thioredoxin proteins containing different 
individual peptides cloned into a vector for expression in E. coli. Furthermore, the 
expression of these proteins was optimised in terms of yield, to develop a system for the 
production of recombinant proteins for subsequent analysis. 
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CHAPTER FIVE 
Characterisation of recombinant protein binding potential and conjugation to a 
porphyrin photosensitiser for photodynamic therapy 
 
5.1 Introduction 
 
The continued evolution of bacterial resistance both generally and more specifically 
within chronic wounds has led to the requirement for novel modes of bacterial targeting 
and elimination, particularly methodologies whereby bacterial resistance cannot be 
easily gained. Photodynamic therapy (PDT) has been demonstrated to have an 
antimicrobial effect and subsequently shown not to be affected by microorganisms 
acquiring resistance (Wainwright and Crossley, 2004); however, its effects were not 
fully utilised mostly due to the discovery of highly efficient broad spectrum antibiotics 
(mainly during the 1950’s). PDT involves the accumulation of a photosensitiser, either 
intracellularly or at the cell surface, and subsequent activation with an appropriate 
wavelength of light, in the presence of oxygen to produce reactive oxygen species (e.g. 
singlet oxygen) that causes bacterial killing (Wainwright, 1998). Since its discovery, 
PDT has been demonstrated to be an effective treatment against a wide range of Gram-
positive and Gram-negative bacteria and also against viruses, fungi, parasites and yeast 
(Jori and Brown, 2004). However clinically, PDT has recently been utilised as a 
treatment for age-related macular degeneration and a few forms of cancer (Brown et al., 
2004, Bressler and Bressler, 2000). 
 
One approach for effective antimicrobial PDT could involve targeting specific 
pathogens within a wound. This would require existing or novel biomolecules that are 
effective against specific pathogenic bacteria, whilst avoiding other commensal bacteria 
or eukaryotic cell types. These biomolecules could then be covalently conjugated to a 
photosensitiser that has bactericidal activity against the target without its activity being 
affected by conjugation. One group of porphyrin photosensitisers containing a single 
reactive isothiocyanate group (NCS) were developed previously (Sutton et al., 2002, 
Clarke and Boyle, 1999). Conjugation of the porphyrin photosensitiser to the 
biomolecule of interest is achieved through reaction of the NCS group and the amine 
group contained in lysine residues forming a covalent bond between the two molecules 
under mild conditions without unwanted byproducts (Staneloudi et al., 2007). Recently, 
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isothiocyanate porphyrins have been conjugated to monoclonal antibodies (Hudson et 
al., 2005) and single chain Fv fragments (Staneloudi et al., 2007) highlighting their 
potential for use in targeted therapy.  
  
Ideally, like other antibacterial agents now in general use, all new molecules developed 
that are involved in selective bacterial targeting/elimination should have pathogenic 
bacterial specificity with little or no specificity for host cell types. Furthermore, in 
addition to targeted PDT, new molecules with a high degree of bacterial specificity may 
also have potential utility as a novel approach of bacterial identification (Carnazza et al., 
2008), offering a rapid diagnostic approach that could be used in conjunction with the 
current culture methods currently employed.  
 
In this study, the purified P12 protein from the previous chapter with potential binding 
ability to MRSA was conjugated to a photosensitiser and the cytotoxic effects of the 
bioconjugate (P12 conjugate) against MRSA was characterised in comparison to any 
effects on E. coli and keratinocytes. Cell toxicity was also compared with the 
unconjugated porphyrin. In addition, two further recombinant proteins (P5 and P19) 
were characterised for the specificity of binding to MRSA in comparison with Gram-
negative species and a keratinocyte cell line. One of these proteins was subsequently 
expressed as a GFP fusion protein and assessed for use as a rapid MRSA diagnosis tool. 
 
5.2 Methods 
 
5.2.1 Bioconjugation and visualisation of recombinant protein P12 and porphyrin 
 
The capped and uncapped porphyrins used in this study were dissolved in anhydrous 
DMSO to a 5 mM stock concentration. Purified P12 was conjugated to the porphyrin at 
a molar ratio of 5:1,  purified through a PD10 column to remove unbound porphyrin, 
and characterised spectrophotometrically (section 2.14.2). The P12 conjugate and 
capped porphyrin were separated by gel electrophoresis and illuminated by UV light 
and Coomassie stained for visualisation of porphyrin and conjugated protein 
respectively (section 2.14.2).  
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5.2.2 Cytotoxicity assays 
 
Cytotoxicity assays were performed against MRSA, E. coli (section 2.15) and a human 
keratinocyte cell line (section 2.15.1). Bacteria or keratinocytes were incubated with 
either the P12 conjugate or capped porphyrin alone, either at the same porphyrin 
concentration as the P12 conjugate or a 10-fold excess of capped porphyrin for 
comparison. Cells only and media only were used as controls to determine any effect of 
light alone. Unbound P12 conjugate or porphyrin was removed by washing, and then 
cells plated in triplicate onto two separate plates. One plate was irradiated at 633 nm 
whilst the other acted as a dark control to determine any dark toxicity. Following 
overnight incubation, bacterial proliferation was determined by measuring absorbance at 
630 nm. MRSA cultures from the irradiated plate were serially diluted and plated out 
onto agar. Following overnight incubation, the number of cfu/ml was determined 
(section 2.15). Keratinocyte cell proliferation was determined by MTT assay (section 
2.15.1).  
 
5.2.3 Assessment of binding of unconjugated proteins by flow cytometry 
 
The binding ability of purified recombinant proteins P5 and P19 to MRSA, E. coli and a 
keratinocyte cell line was determined by flow cytometry (section 2.16). Having 
incubated either keratinocytes or bacterial cultures with P5 or P19 proteins, binding was 
assessed by incubation with an anti-thioredoxin antibody followed by washing and 
detection with a secondary antibody prior to flow cytometry (section 2.16). 
 
5.2.4 Binding assessment of P5/GFP by flow cytometry 
 
The binding of P5/GFP to MRSA, E. coli and keratinocytes was determined directly by 
flow cytometry. A range of concentrations of P5/GFP were incubated with bacteria or 
keratinocytes to demonstrate protein binding. Cells were washed in PBS to remove any 
unbound protein prior to flow cytometric analysis (section 2.16.1).  
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5.3 Results 
 
5.3.1 Conjugation and cytotoxicity assays of the conjugated P12 protein  
 
A pilot study undertaken with P12 was performed to test conjugation and the cytotoxic 
potential of the P12 conjugate to assess the validity of the approach. Following 
conjugation of the porphyrin to P12, the degree of loading was calculated to be 0.22 
moles of porphyrin per mole P12. It was not possible to visualise the porphyrin under 
UV light, and subsequent SDS-PAGE followed by Coomassie staining to detect the 
protein, observed only a very weak band at approximately 20 kDa that could not be 
observed photographically and was not repeated due to the limited sample size.   
 
Incubation of MRSA with the P12 conjugate demonstrated a 66% reduction in cell 
growth following irradiation (Fig 5.1; purple bar - irradiation) compared with non 
irradiated control cells (Fig 5.1; blue bar - no irradiation). In comparison, incubation 
with the same concentration of unconjugated capped porphyrin resulted in only a 20% 
reduction in cell growth (Fig 5.1: yellow bar - irradiation) whereas a 10-fold excess of 
the porphyrin alone demonstrated a 91% reduction (Fig 5.1; green bar - irradiation). It 
should be noted that a 24% reduction was observed following irradiation with red light 
alone (Fig 5.1; blue bar - irradiation), a similar effect to that observed with the lower 
concentration of capped porphyrin alone. In contrast, non-irradiated MRSA incubated 
with the P12 conjugate, capped porphyrin or 10-fold excess of porphyrin demonstrated 
an increase in cell growth (6, 36% and 20% respectively) (Fig 5.1; purple, yellow and 
green bars - no irradiation) in comparison to the non-irradiated control. Bacterial 
colonies plated out onto agar following overnight incubation showed a similar trend of 
cell growth as determined by calculating cfu/ml. Bacteria incubated with the P12 
conjugate resulted in a count of 2.01 x 108 cfu/ml, a 78% reduction compared with 
bacteria irradiated with red light only (9.33 x 108 cfu/ml). A similar trend was observed 
with the unconjugated porphyrin alone resulting in a 17% reduction (7.79 x 108 cfu/ml) 
compared with bacteria following no treatment except irradiation with red light. MRSA 
incubated with a 10-fold excess of porphyrin and showed no growth following 
overnight incubation indicating that no viable bacteria were present following treatment.  
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Irradiation of E. coli following incubation with the P12 conjugate, capped porphyrins or 
bacteria only showed approximately a 10% decrease in bacterial growth in comparison 
with untreated E. coli alone (Fig 5.2). Similarly, non-irradiated E. coli showed 2-3% 
reduction in growth compared to the control samples. Keratinocytes incubated with the 
conjugated P12 protein and irradiated demonstrated a 13% reduction in cell viability 
compared with untreated, non irradiated keratinocytes (Fig 5.3). However, this effect is 
also observed (14% reduction) following incubation with the P12 conjugate without 
irradiation. The capped porphyrin without irradiation resulted in a 16% decrease, a 
similar effect to the conjugated protein, when neither was irradiated whereas, a 10-fold 
excess of porphyrin demonstrated a small increase in cell growth (6%) compared to the 
control cells (Fig 5.3). Incubation of keratinocytes with the capped porphyrin 
demonstrated a 29% decrease in cell growth following irradiation whereas, a 10-fold 
excess of porphyrin resulted in a 98% decrease in cell growth, a similar response to that 
seen against MRSA.  
 
5.3.2 Investigation of thioredoxin proteins binding by flow cytometry  
 
The binding of P5 and P19 to MRSA, E. coli and keratinocytes was characterised by 
flow cytometry to determine any MRSA specific binding of purified proteins. The 
FACS profiles used to determine non-specific binding of detection antibodies to MRSA 
to enable subsequent analysis of P5 and P19 are shown in Figure 5.4. The FSC/SSC 
(Fig 5.4; Panel A) was used to identify the MRSA population gate for subsequent 
analysis of control reagent (primary and secondary antibodies) and test reagent (P5 and 
P19) binding. Control experiments were performed to assess the non-specific binding of 
the primary and secondary antibodies used for detection. Negligible binding of the anti-
thioredoxin primary antibody was observed (Fig 5.4; Panel B; mean = 2.6) in 
comparison to bacteria alone (mean = 1.1). However an increase in mean fluorescence 
was observed following incubation with the secondary antibody alone (Fig 5.4; Panel C; 
mean = 129.1). In addition incubation of both primary and secondary antibodies without 
recombinant protein resulted in a further increase in mean fluorescence (Fig 5.4; Panel 
D; mean = 568.6) thus indicating the binding potential of the detection antibodies alone.  
 
FACS analysis to determine binding of P5 and P19 indicated two distinct fluorescent 
peaks upon analysis (Fig 5.4b; Panels A and B respectively) that were not observed with  
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detection antibodies alone. Although the second larger peak observed is attributable to 
non-specific antibody binding (as determined from analysis of Fig 5.4; Panels C and D), 
the smaller peak of lower fluorescence (determined by the marker M1) was not 
observed due to non-specific binding of detection reagents. This was presumed to be 
attributable to recombinant protein binding to bacteria and binding assessed as the 
percentage of events in M1 in comparison to the events in M1 of both detection 
antibodies. A small amount of P5 binding was observed (Fig 5.4b; Panel A; gated 
marker = 20.5%) in comparison to detection antibodies (Fig 5.4; Panel D; gated marker 
= 7.0%). A further increase in binding of P19 was also observed (Fig 5.4b; Panel B; 
gated marker = 30.5%) in comparison to detection antibodies only controls.  
 
The non-specific binding of detection antibodies against E. coli was also assessed (Fig 
5.5) to allow characterisation of P5 and P19 binding. The main bacterial population was 
determined by FSC/SCC (Panel A). Similar to MRSA, the primary antibody showed 
little specificity against E. coli (Panel B; mean = 1.6) in comparison to unlabelled 
bacteria (mean = 1.2). A small degree of non-specific binding of the secondary antibody 
was observed (Panel C; mean = 5.0). A similar effect was seen following incubation 
with both primary and secondary antibodies alone (Panel D; mean = 6.8). Binding of P5 
and P19 to E. coli was also assessed following comparison as a percentage of the gated 
marker (M1) in comparison to the percentage of E. coli that was dual labelled with both 
antibodies. The gated marker for E. coli was set at the same percentage of ‘bacteria 
only’ used as a negative control for analysis of MRSA (0.06%).  Binding of P5 was 
slightly increased (Fig 5.5b; Panel A; gated marker = 68.9%) in comparison to E. coli 
labelled with both detection antibodies alone (Fig 5.5; Panel D; gated marker = 66.1%). 
A similar binding effect of P19 against E. coli was also observed (Fig 5.5b; Panel B; 
gated marker = 69.0) indicating minor binding of P5 and P19 to E. coli. 
 
Binding of P5 and P19 to keratinocytes was assessed by flow cytometry and is shown in 
Fig 5.6. Panel A (Fig 5.6) demonstrates a typical FSC/SSC profile used to identify the 
keratinocyte cell population. The primary antibody alone showed no particular 
specificity for keratinocytes (Fig 5.6; Panel B; mean = 5.7). An increase in binding was 
observed following incubation with the secondary antibody alone (Fig 5.6; Panel C; 
mean = 17.2) and further increased following dual labelling with both primary and 
secondary antibodies (Fig 5.6; Panel D; mean = 21.9). The gated marker (M1) for  
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keratinocytes was set at 0.03% of the unlabelled negative control cells (a similar 
percentage to conditions used for bacterial binding analysis (0.06%)). Binding of 
keratinocytes was determined based on differences in the percentage of the gated 
marker of recombinant protein binding in comparison to cells dual labelled with 
detection antibodies only. A small amount of P5 binding to keratinocytes was observed 
(Fig 5.6b; Panel A; gated marker = 20.4%) in comparison to both detection antibodies 
alone (Fig 5.6; Panel D; gated marker = 13.0%). Similar to P5, a small level of P19 
binding was also observed (Fig 5.6b; Panel B; gated marker = 18.6%), albeit to a 
slightly lesser extent.   
 
5.3.3 Assessment of a thioredoxin/GFP fusion protein binding by flow cytometry 
 
The binding of P5/GFP fusion protein was assessed by flow cytometry. A range of 
concentrations of P5/GFP (40-398 µg/ml) was assessed for binding against MRSA, E. 
coli and keratinocytes (Fig 5.7). The main cell populations of MRSA, E. coli and 
keratinocytes were determined by FSC/SSC analysis shown in Panels A, C and E 
respectively (Fig 5.7). Binding of P5/GFP protein to MRSA (Fig 5.7; Panel B), E. coli 
(Fig 5.7; Panel D) and keratinocytes (Fig 5.7; Panel F) was assessed as any increase in 
mean fluorescence in comparison to unlabelled cells. The data showed a very small 
increase in binding with increasing concentration of protein. Mean fluorescence values 
demonstrating this increase are shown in Table 5.1.   
 
Table 5.1: Mean fluorescence (MF) values after incubation of P5/GFP with MRSA, 
E. coli and keratinocytes for determination of binding 
 
Concentration of 
P5/GFP 
MF of MRSA MF of E. coli 
MF of 
keratinocytes 
Cells alone 1.5 1.7 4.4 
40 µg/ml P5/GFP 1.6 1.7 4.6 
200 µg/ml P5/GFP 1.7 1.9 4.8 
398 µg/ml P5/GFP 1.9 2.0 4.9 
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5.4 Discussion 
 
The use of PDT for the topical treatment of infected/chronic wounds has previously 
been suggested (Zolfaghari et al., 2009, Embleton et al., 2005, Lambrechts et al., 2005, 
Embleton et al., 2002, Karrer et al., 1999, Griffiths et al., 1997). A range of 
photosensitisers have been shown to have bactericidal photodynamic action to eliminate 
bacteria that could potentially play a successful role in treatment of wounds. The 
development of photosensitisers with antimicrobial action, that can be conjugated in a 
defined manner to novel or existing biomolecules to enhance specificity for the target 
organism/s that increase the cytotoxic effectiveness of the photosensitiser whilst 
minimising damage to surrounding eukaryotic cells would enhance the overall 
effectiveness of PDT for wound management.  
 
5.4.1 Conjugation of recombinant protein P12 to a porphyrin photosensitiser and 
cytotoxicity assays  
 
In this chapter one of the peptides (peptide12) that had previously been shown to bind 
preferentially to MRSA by flow cytometry in Chapter 1 was cloned within the full 
thioredoxin protein sequence into a bacterial expression vector and following 
subsequent expression and purification (Chapter 2) conjugated to an isothiocyanate 
porphyrin. Previous work investigating porphyrins as photosensitisers has also showed 
the feasibility of conjugation of isothiocyanate porphyrins to biomolecules such as BSA 
(Sutton et al., 2002) and monoclonal antibodies (Hudson et al., 2005). This group of 
porphyrins has also been conjugated to scFvs displaying colorectal tumour cell 
reactivity and demonstrated a selective photocytotoxic effect against colorectal cell lines 
as an alternative to whole IgG molecules thereby offering enhanced tumour penetration 
and faster clearance from the bloodstream (Staneloudi et al., 2007). The purified 
proteins investigated here are approximately the same size as a scFv protein investigated 
by Staneloudi et al (2007) therefore demonstrating the feasibility of this approach. The 
current study has shown that it was possible to conjugate the recombinant protein of 
interest with proposed binding specificity to MRSA to the desired porphyrin, via 
coupling of the NCS group of the porphyrin that covalently binds to lysine residues on 
the protein. Following bioconjugation, attempts were made to visualise the P12 
conjugate and capped porphyrin by SDS-PAGE and visualised by irradiation with UV 
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light. However, the P12 conjugate and the capped porphyrin were not readily detectable 
under UV light presumably due to the relatively low concentration of the P12 conjugate 
separated on the gel. 
 
In this pilot study it was demonstrated that the conjugated P12 protein caused a decrease 
in growth of MRSA following irradiation with red light in comparison to non treated 
control cells (Fig 5.1). A reduction in cell growth following incubation and irradiation 
with an equal concentration of unconjugated capped porphyrin was also observed 
however, this reduction was to a lesser extent than PDT using the P12 conjugate. This 
may suggest that the conjugated P12 protein enhanced the efficacy of PDT over use of 
photosensitiser alone and therefore indicates some degree of cellular specificity of the 
conjugate. Conjugation of photosensitisers to biomolecules, such as antibodies, for 
enhanced killing of S. aureus strains including MRSA in comparison to the 
photosensitiser alone has previously been demonstrated to improve specificity towards 
the potential pathogenic bacteria (Embleton et al., 2002, Embleton et al., 2004, Gross et 
al., 1997). Further to this, antibodies directed towards other potential pathogens such as 
P. ginivalis (Bhatti et al., 2000) and P. aeruginosa (Berthiaume et al., 1994), have also 
been utilised as targeting moieties suggesting that this approach can improve 
photodynamic inactivation. Interestingly, Berthiaume et al (1994) found that the non 
conjugated photosensitiser had no effect using an in vivo model targeting P. aeruginosa, 
whereas the specific targeting moiety resulted in a 75% reduction in the number of 
viable bacteria. Furthermore, groups have demonstrated that antibody conjugated 
photosensitisers were able to selectively kill bacteria in a mixed bacterial suspension 
(Bhatti et al., 2000, Embleton et al., 2002). Therefore, it may be possible to use similar 
approach to identify and develop novel biomolecules against MRSA that are an 
alternative to antibody based biomolecules, with varying specificities for different 
bacteria as targeting vehicles to deliver the photodynamic agents.  
 
However, although targeted therapy appears promising, investigations have looked at 
photosensitisers used without targeted biomolecules with very effective results (Maisch 
et al., 2005). In addition, Bertoloni et al (2000) demonstrated that a very low binding 
capacity of haematoporphyrin (less than 1% tightly bound to bacteria) was still 
sufficient to cause a cytotoxic effect. Therefore, although targeted photosensitisers are 
an attractive target worthy of investigation, some photosensitisers are effective even 
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without the requirement of cell-specific reagents. In this study, incubation of the 
bacteria with a 10-fold excess of the photosensitiser resulted in highly efficient killing 
of MRSA (Fig 5.1), suggesting that the use of this photosensitiser alone may be 
effective against a wider range of Gram-positive pathogens. However, because a similar 
killing effect was also observed against keratinocytes, it may suggest that this particular 
photosensitiser is not suitable for use on its own for PDT as surrounding tissue may also 
be damaged, whereas conjugation resulted in killing of MRSA with limited damage to 
keratinocytes.   
 
Interestingly, in this study a reduction in bacterial growth was also observed following 
treatment with the red light alone, similar to the effect seen following PDT with the 
lower concentration of capped porphyrin thus indicating that light alone can apparently 
cause a certain reduction in cell growth. Therefore, the reduction in bacterial growth 
observed following treatment with the lower concentration of capped porphyrin and 
irradiation may suggest that this is due to the irradiation effect and that a greater 
concentration of porphyrin is required to affect cell growth. This also indicates that 
targeted treatment with the same concentration of P12 conjugated porphyrin rather than 
free porphyrin was effective at eliminating bacteria and suggests that lower doses of 
targeted therapy may be required than using the porphyrin alone. Additionally, a greater 
reduction in bacterial growth observed following incubation of MRSA with the P12 
conjugate or high concentration of capped porphyrin may also indicate that in this case 
red light alone may just accentuate the killing effect following these treatments. In 
contrast to the current investigation, Grinholc et al (2008) demonstrated that no 
cytotoxic effect of light alone was observed following photodynamic inactivation of 40 
different clinical strains of MRSA and 40 separate strains of MSSA. However, Griffiths 
et al (1997) found that there was an effect of light alone on 3 of the 16 different 
EMRSA investigated that resulted in a reduction of bacterial viability and therefore 
susceptibility to light alone appears to be strain dependent. Additionally, the effect of 
light alone has been demonstrated to have a damaging effect on wound healing in S. 
aureus infected burn wounds in mice, whereby wounds took 6.2 days more to heal in 
the irradiation group than the dark, although this was probably due to the high light dose 
(either 211 Jcm-2 or 423 Jcm-2) used in comparison to other studies (Lambrechts et al., 
2005).  
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Determination of cell viability as a measure of absorbance or by determining the 
number of cfu/ml gave similar results and further supported the binding potential of the 
conjugated P12 protein suggesting that the conjugate or high concentration of porphyrin 
were more successful in treatment than the lower concentration of capped porphyrin that 
was equivalent to the conjugate. The slight difference in bacterial viability between 
methods is presumably because that although bacteria may be present in the sample that 
can be measured by absorbance, the bacteria are not necessarily truly viable, i.e. capable 
of dividing, and therefore do not form visible colonies on plates.  
 
Growth of MRSA was enhanced following incubation with the low and high 
concentrations of capped porphyrin alone (36% and 20% respectively) following no 
irradiation and slightly increased following incubation with the P12 conjugate (6%) 
suggesting that neither the conjugate nor porphyrin has cellular toxicity in the absence 
of activation on its own. Similar effects on bacterial proliferation without irradiation 
were observed by Karrer et al (1999) whereby an increase in growth of S. aureus was 
observed following incubation with varying concentrations 5-aminolevulinic acid and 
no irradiation in a dose-dependent manner however, growth of S. epidermidis was noted 
to decrease. Additionally in 80 different S. aureus strains, Grinholc et al (2008) 
demonstrated very limited toxicity of the photosensitiser (less than 0.2 log10 reduction in 
viable count) when not activated by light. Although limited toxicity of the 
photosensitiser used in this and previous studies may be advantageous in that it suggests 
that bacterial elimination can be controlled with targeted irradiation with the light 
source, bacterial cytotoxicity of the unirradiated photosensitiser may not necessarily be 
a disadvantage as long as the damage is pathogen and not host cell specific. However, in 
this study incubation with the P12 conjugate or porphyrin without irradiation enhanced 
bacterial proliferation whereas a certain degree of dark toxicity against keratinocytes 
was observed and therefore only short incubation times prior to irradiation should be 
applied to maximise bacterial killing whilst minimising damage to the host.  
 
There was no cytotoxic effect on E. coli following incubation and irradiation with either 
the P12 conjugate or either concentration of photosensitiser as demonstrated by a very 
small decrease in viability compared to the non-treated control cells (Fig 5.2). Similarly, 
cells treated and not exposed to light showed a smaller reduction in growth, thus 
indicating that the compounds have little cytotoxic effects. Furthermore, it may suggest 
 158 
that the P12 conjugate may have some level of MRSA specificity due to the small 
reduction in bacterial growth following treatment and also that the capped porphyrin 
alone has little effect in E. coli. However this effect is more likely due to differences in 
the bacterial cell walls whereby Gram-positive bacteria are more susceptible to 
photodynamic therapy than Gram-negative bacteria, particularly with anionic or neutral 
photosensitisers (O’Riordan et al., 2005). However, although the photosensitiser used in 
this case was cationic and therefore should be more effective than an anionic or neutral 
photosensitiser, in this instance no killing was observed, even using a 10-fold excess of 
porphyrin that was sufficient to kill 91% of MRSA and therefore higher concentrations 
could be investigated to attempt to eliminate E. coli.  
 
The decrease in MRSA bacterial growth observed following PDT with the P12 
conjugate was greater than the cell knockdown observed in keratinocytes (66% vs. 13% 
respectively) and therefore may suggest a preferential targeting of the conjugate. The 
small decrease in cell growth following incubation with the P12 conjugate was also 
observed following incubation of the conjugate without irradiation suggesting the same 
amount of light and dark toxicity of the conjugate and therefore may be independent of 
light treatment and the generation of reactive oxygen species. Eukaryotic species are 
known to be more resistant to PDT than prokaryotic cells, e.g. Zeina et al (2002) 
demonstrated that sufficient conditions required to kill skin flora (such as S. aureus) did 
not induce a great cytotoxic effect in keratinocytes in vitro whereby the kill rate was up 
to 200 times slower than prokaryotic cells.  Additionally treatment of keratinocytes 
under the same conditions that induce prokaryotic death was not sufficient to induce a 
genotoxic effect as determined by comet assay to detect DNA damage (Zeina et al., 
2003).  Similarly, Embleton et al (2005) demonstrated that a phage conjugate did not 
affect the viability of human epithelial cells in vitro following treatment whilst retaining 
specificity for EMRSA-16, suggesting that targeting with biomolecules can offer an 
advantage in PDT. However, in this investigation, treatment with the low concentration 
of porphyrin alone (1.25 µM) had a slightly greater cytotoxic effect, albeit a small 
difference (~9%), against keratinocytes compared to MRSA. This further suggests the 
requirement of targeted PDT with biomolecules to reduce damage to host cells. 
 
The low concentration of the capped porphyrin demonstrated a greater decrease in 
keratinocyte proliferation than the P12 conjugate, even though both contained the same 
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concentration of porphyrin, therefore suggesting that the conjugated P12 protein caused 
less cellular damage than the porphyrin only and therefore possibly indicates some 
degree of specificity for MRSA in comparison with E. coli or keratinocytes. However, a 
10-fold excess of the photosensitiser demonstrated a large reduction in cell 
proliferation. This effect was similar to that observed in MRSA treatment, indicating the 
high cytotoxic potential of the porphyrin alone against these cell types, although not 
observed when used against E. coli. In contrast to MRSA and E. coli, the effect of light 
alone was demonstrated to have a slight increase on cell proliferation in keratinocytes. 
Maisch et al (2007) demonstrated using a porcine skin model that irradiation of the 
epidermis with light alone did not demonstrate a significant increase in apoptotic cells. 
Therefore if treatment with light can decrease bacterial growth whilst boosting 
eukaryotic growth then this may also be advantageous for antimicrobial PDT that may 
be further enhanced by the use of specific targeting agents.  
 
One obvious drawback in this pilot investigation was the limited concentration of 
purified protein produced in order to test the photodynamic potential of the conjugated 
protein. Future experiments that investigate the effect of increasing the P12 conjugate 
concentration and light dose and also determine these effects on different growth phases 
of bacteria could improve the effectiveness of PDT using this biomolecule. In order to 
achieve greater specificity and potentially more effective killing, the resulting 
bioconjugate should demonstrate that, following conjugation, the biomolecule retains or 
improves its target binding affinity and additionally the photosensitiser remains fully 
active. However, due to the limited concentration of the extracted purified protein, it 
was not possible to determine the binding ability of P12 before and after conjugation to 
determine any gross loss (or gain) of binding specificity. Although it is desirable to 
determine that no loss of binding specificity of the protein occurred, the results here 
indicate that the P12 conjugate was bound to the MRSA as indicated by the 
photocytotoxic effect of the conjugate against MRSA compared with controls. 
However, previous investigations had demonstrated that the individual peptide sequence 
when conjugated to FITC was able to bind MRSA and therefore it is reasonable to 
assume that the peptide of interest situated within the entire protein sequence that is 
surface accessible should retain the same binding affinity, especially because it had 
been selected for this display format. If the increased yield of protein could be achieved 
then not only could the characterisation of the conjugate in a dose-dependent manner be 
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investigated but also the initial toxicity of the protein prior to conjugation. However, 
toxicity of thioredoxin itself seems unlikely because this protein is ubiquitously 
expressed (Arner and Holmgren, 2000). However, it is theoretically possible that the 
individual peptide sequence expressed within the active site of thioredoxin could 
potentially have toxic properties, although in this case it would be expected that 
significant dark toxicity would be observed. Furthermore, toxicity of the bacteria 
expressing the peptide during the panning would perhaps also be expected; hence no 
such peptides would be generated.  
 
In addition to investigating the photodynamic potential of the P12 conjugate and capped 
photosensitiser against MRSA, it would be interesting to investigate the effect of the 
compounds against other Staphylococcal species, including a non-resistant strain of S. 
aureus and S. epidermidis. Grinholc et al (2008) and Szpakowska et al (2001) both 
demonstrated that MRSA resistance to photodynamic therapy was higher than MSSA 
strains, which may suggest that factors conferring drug resistance to bacteria may be 
associated with increased resistance to photodynamic therapy. Four strains of MRSA 
out of 40 investigated were resistant, whereas no MSSA strains showed resistance; with 
a broad range of intermediately resistant, sensitive and highly sensitive strains across 
both MRSA and MSSA strains. These data suggests a strain-dependent nature of the 
photodynamic effect, that was hypothesised to be associated with the ability to produce 
biofilms (Grinholc et al., 2008). However, although drug-resistant strains have been 
observed to be potentially less susceptible to photodynamic therapy, a range of different 
photosensitisers should be investigated in these cases to explore the effects of different 
classes of photodynamic compounds.  
 
5.4.2 Characterisation of recombinant protein binding specificity 
 
In addition to new methods of targeting bacteria for treatment regimens, novel 
biomolecules that recognise and bind specific pathogens might have an important 
alternative function in the rapid diagnosis of different bacterial species, possibly from 
wounds or to determine carriage, as an alternative to the usual culture techniques. Two 
novel proteins (P5 and P19) similar in structure were assessed for binding ability to 
MRSA and also to E. coli and keratinocytes for comparison. Assessment of binding of 
the unconjugated proteins by flow cytometry was characterised using antibodies that 
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specifically recognise the protein of interest (thioredoxin) and appropriate secondary 
reagents for detection. Characterisation of P5 and P19 binding to MRSA suggested that 
both proteins were bound to MRSA, with P19 appearing to bind MRSA slightly better 
than P5. A very small amount of P5 and P19 binding against E. coli was observed 
whereby both proteins demonstrated the same, small level, of binding which therefore 
may possibly be due to non specific interaction. However, flow cytometry data should 
be interpreted with caution due to non-specific binding of the antibodies used for 
detection. MRSA express protein A on their surface that enables binding of many 
isotypes of IgG antibodies via the Fc region of the molecule (Roberts and Gaston, 1987) 
making analysis of true binding ability difficult to interpret. However, expression of 
protein A has previously been exploited for targeted PDT towards the surface of 
bacteria (Embleton et al., 2002, Embleton et al., 2004, Gross et al., 1997). The 
photodynamic effect was negated by incubation of bacteria with natural IgG, by 
blocking the binding site in a strain of S. aureus Cowen I, a strain with naturally high 
expression of protein A on the surface (Gross et al., 1997). Therefore, in order to assess 
binding potential accurately one possible approach could be to coat the bacteria with 
non-specific antibodies to block the non-specific binding sites of the primary and 
secondary antibodies. In this investigation blocking by incubation of bacteria with milk 
proteins and BSA was not sufficient enough to exclude non-specific binding of the 
antibodies used for detection. Therefore future binding experiment must involve more 
effective blocking of the bacterial Fc receptors. Ideally, this would involve blocking 
with purified IgG from the host species of the secondary antibody, so in this case 
bacteria could be blocked with purified sheep IgG. Alternatively, incubation with non 
specific antibodies, for example, those derived from human serum, provided that the 
serum donor has not been exposed to MRSA and raised antibodies against it, should be 
effective in blocking non-specific binding. Another simple strategy to assess binding 
more effectively would be to use the primary antibody directly conjugated to the 
fluorphore for detection and measure the mean fluorescence following incubation with 
the purified protein and subtract the mean fluorescence observed from the antibody and 
cells only.  
 
Although P5 and P19 have very similar homology, differences in binding of the two 
have been observed against the different cell types. This suggests that it is the 
differences in the peptides displayed in the active site that affect the binding ability of 
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each protein. Overall, it appeared that P19 had greater binding ability against the 
prokaryotic cell types than P5. However, P5 showed a greater specificity for 
keratinocytes. The ideal biomolecule should show good binding of prokaryotes with 
little specificity for eukaryotic cells and therefore future investigation should focus on 
screening a range of recombinant proteins identified from panning and sequencing for 
binding potential to MRSA. Although P19 appears to bind greater to MRSA than P5 
and therefore may have some utility in bacterial targeting, the conjugation of the 
photosensitiser to P19 may affect the ability of the recombinant protein to bind to the 
bacterial target due to the presence of a lysine residue within the peptide sequence that 
may interrupt binding. Conversely, if the binding potential was retained (whereby the 
binding properties were due to a different part of the displayed peptide), then the killing 
ability may be enhanced in this instance, by bringing the photosensitiser in closer 
proximity to the bacterial cell wall. However, this is very speculative and requires 
further investigation to identify the advantages/disadvantages of lysine residues within 
the peptide sequence.  
 
One protein (P5) was expressed as a GFP fusion protein to investigate the feasibility of 
developing novel cell specific reagents for rapid diagnosis that circumvents the 
utilisation for antibodies for detection. Binding experiments were performed starting at 
approximately 4-fold the typical concentration of antibodies routinely utilised for 
detection (0.5 µg) within our laboratory as a starting concentration, and subsequently 
increasing the concentration of P5/GFP (40-398 µg/ml). However, results indicated a 
very small level of initial binding with very slight increases in binding observed as 
concentration of the fusion protein increased in a dose-dependent manner similar to that 
of an antibody titre. Therefore, it could be concluded that this compound does not have 
the same specificity as an antibody and therefore may not be useful for rapid diagnosis 
of pathogens. Alternatively, considering that P5 was shown to bind previously, loss of 
binding ability may suggest that the GFP is blocking the protein binding site and 
therefore modification to the structure of the fusion protein is required for this 
biomolecule to be effective as a diagnostic tool.  
 
The continued development of bacterial resistance and the limited discovery of new 
antimicrobials have led to novel methodologies for eradication of bacteria to be 
required, of which PDT represents a promising approach. Numerous photosensitisers 
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and a range of light sources can provide inexpensive tools for the treatment of bacterial 
infection (Wainwright, 1998). The pilot data presented here suggest that it may be 
possible to utilise recombinant proteins with bacterial binding properties for targeted 
PDT that may have enhanced bacterial killing properties than the photosensitiser alone. 
Furthermore, more screening of other recombinant proteins identified from panning 
against MRSA may identify new proteins with greater MRSA specificity. Therefore it 
seems feasible to identify other proteins with different binding properties to a range of 
bacteria that, following demonstration of clear binding, may then be conjugated to 
either a photosensitiser for targeted PDT or a fluorescent tag for rapid diagnosis of 
pathogenic bacteria.  
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CHAPTER SIX 
General discussion 
 
6.1 Summary 
 
This thesis has identified a selection of 12-mer peptides with binding specificity for 
MRSA that have potential as new detection and targeting moieties. Similar to phage 
technology, microbial display has developed a large number of potential applications 
including high throughput screening of peptide, antibody and enzyme libraries, live 
vaccine development/antibody production, epitope mapping, development of 
bioadsorbents and diagnostic tools/biosensors (Benhar, 2001, Chen and Georgiou, 2002, 
Lee et al., 2003). Peptides can have similar binding affinities to those of antibodies and 
furthermore, the small size of peptides and rapid clearance from the blood may be 
advantageous in comparison with antibodies for in vivo studies (Zitzmann et al., 2005). 
Additionally, the removal of the peptides from the display vehicle would result in 
straightforward production as peptides are easy to produce, and may also result in 
longer shelf life than within the display format (De et al., 2005). Furthermore, not only 
can peptides be produced in large quantities, peptides are amenable to modifications, 
and may be able to access some binding sites easier than monoclonal antibodies due to 
their smaller size (Zhou et al., 2004). 
 
In this study the FliTrx TM bacterial display random peptide library, containing an 
estimated 1.77 x 108 individual peptides, developed by Lu et al (1995), was screened to 
identify MRSA-specific peptides. Following selection, through panning, and DNA 
sequencing, peptides of interest were synthesised. Peptide binding to various bacterial 
strains and a keratinocyte cell line were performed in order to characterise peptide 
binding ability and specificity to both pathogen and mammalian cell types. Direct 
binding of FITC-labelled peptides was observed against all strains of MRSA tested, 
with greater binding observed using the cyclic construct, presumably because this 
conformation more closely replicated the original selection format than the linear 
construct. Furthermore, no binding to keratinocytes was observed indicating selective 
targeting of MRSA over mammalian cell types. Display technologies provide a very 
useful technology in the isolation of cell specific ligands because no knowledge of the 
target is required prior to selection (Bishop-Hurley et al., 2005, Zhou et al., 2004). The 
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panning and characterisation of peptide binding described here has shown that the 
process of screening bacteria to identify peptides with pathogen-specific properties is 
feasible and therefore represents an adaptable system that could be used to further 
identify many different pathogen-specific peptides.  
 
The continuous increase in bacterial resistance has necessitated the development of 
alternative treatments that target resistant pathogens. These novel agents need bacterial 
specificity for pathogen elimination that is independent of pathogen resistance status 
and little or no cross reactivity for host cells or commensal bacteria. Antimicrobial PDT 
represents an alternative treatment that has been reported to be effective against both 
sensitive and drug resistant strains of S. aureus (Griffiths et al., 1997, Grinholc et al., 
2008, Maisch et al., 2005, Szpakowska et al., 2001). Furthermore, conjugation of 
different photosensitisers to various biomolecules has previously demonstrated the 
feasibility of targeted antimicrobial PDT strategies directed against both MRSA and 
other pathogenic organisms (Hope et al., 2009, Embleton et al., 2004, Hamblin et al., 
2002a, Bhatti et al., 2000, Gross et al., 1997, Berthiaume et al., 1994). Therefore, PDT 
shows promise as an effective topical treatment of chronic wounds, that may be useful 
either alone or in conjunction with antibiotics to reduce bacterial bioburden and aid 
wound healing. 
 
The synthesis of high purity (>95%) peptides with modifications such as cyclisation and 
addition of detection molecules (e.g. biotin or FITC) can be relatively expensive on a 
small scale. Therefore, a further aim of this thesis was to develop a system to produce 
native recombinant thioredoxin proteins each containing different peptide sequences of 
interest previously derived from panning. An E. coli based expression and purification 
system (Clontech) was optimised for successful production of recombinant proteins 
containing the peptides of interest. In this thesis recombinant proteins were 
characterised for binding specificity and one protein was conjugated to a porphyrin 
photosensitiser to determine the cytotoxic effect of the bioconjugate. This pilot study 
successfully demonstrated the rapid and simple conjugation of the porphyrin to 
recombinant proteins. The use of the targeted photosensitiser (P12 conjugate) resulted 
in a greater decrease in MRSA growth than treatment with an equal concentration of the 
unconjugated capped porphyrin suggesting that direct targeting of pathogens may 
enhance treatment. This preliminary work strongly supports the concept of an increase 
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in effectiveness of PDT and therefore it is possible that optimising experimental 
conditions could further enhance the killing potential of the conjugate. Previously, 
Embleton et al (2002) demonstrated not only a dose dependent increase in bacterial cell 
death following an increase in either light dose or photosensitiser concentration 
separately, however in both cases the IgG conjugated photosensitiser was more 
effective in treatment than the photosensitiser alone (Embleton et al., 2002). 
Additionally this group showed a similar effect using a different targeting moiety 
(phage 75) to deliver the same photosensitiser to varying strains of MRSA (Embleton et 
al., 2005); demonstrating that targeting of photosensitisers is efficacious.  
 
For successful use a number of factors need to be considered. Photodynamic therapy of 
wounds may require multiple doses of treatment to eliminate all of the bacteria from the 
site. Treatment also requires sufficient light and generation of sufficient reactive oxygen 
species to eradicate bacteria, even those penetrating deeper layers as bacterial regrowth 
may occur if not all of the microbes are eradicated. Using an animal model for treatment 
of burn wounds in mice, Lambrechts et al (2005) suggested that future experiments 
targeting the photosensitiser specifically to the bacteria in the wound may improve 
efficacy of this treatment and prevent bacterial re-growth that was observed following 
the experimental PDT, whilst minimising host damage. Furthermore, other groups have 
demonstrated that repeated PDT exposure on bacterial survivors following previous 
treatments could still decrease bacterial numbers and that resistant populations 
unaffected by treatment did not arise (Embleton et al., 2004, Griffiths et al., 1997), 
further suggesting PDT as a new method of treating pathogens where resistance is not 
able to develop. Therefore, investigations into the optimal treatment 
frequencies/dosages to eliminate bacteria completely from wounds are clearly 
warranted. 
 
6.2 Future work 
 
In this thesis, removal of the peptide of interest from the display vehicle was shown to 
retain binding against MRSA. However, it may be considered that synthesis following 
removal from the original structure may not necessarily assume the exact conformation 
for binding as the original fusion (Lu et al., 1995). Future work should include 
increasing the valency of peptides by developing multiple peptide display constructs to 
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attempt to further improve binding by displaying peptides in a more similar 
conformation to the original selection format.   
 
Sequencing against MRSA, S. aureus and S. epidermidis identified no obvious 
consensus sequence which may suggest the identification of peptides that bind to more 
than one target and therefore may have a range of binding abilities. Future work should 
involve further large scale DNA sequencing (200+ sequences) of panned clones to 
identify any consensus or repeated sequences/subunits and then synthesis of the 
consensus sequence peptide if found. Additionally, further synthesis of the other 
identified peptides and assessment of binding specificity may identify a range of 
peptides from MRSA specific, to Staphylococcal specific to prokaryotic specific or 
broad binding to all cells types. 
 
Previous studies have already demonstrated the utility of incorporating negative 
panning steps to identify peptides with affinity for cancer cell types over normal tissue 
(Brown et al., 2000, Dane et al., 2006, Li et al., 2008). In order to search for truly 
prokaryotic markers, future panning studies should incorporate more subtractive 
panning steps performed throughout selected rounds by panning against eukaryotic cells 
prior to selection against prokaryotes. Additionally to identify MRSA specific clones, 
negative panning could first be performed against S. aureus in each round prior to 
MRSA selection. Additionally to negative panning steps, more stringent wash 
conditions and continuous panning cycles until very few clones are selected may 
improve specificity of isolated sequences.  
 
Future studies could also involve screening of many other bacterial targets in order to 
identify peptides against a range of pathogens involved in chronic wounds. Panning 
could be performed either against intact pathogenic bacteria or against a single target 
known to be present on the cell surface. However, it may be more advantageous to pan 
against intact bacteria thus panning against a range of cellular targets, albeit unknown, 
to identify a series of biomolecules rather than a single target in order to hinder target 
modification or bacterial adaptation to lose or decrease expression of the target over 
time.  
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Furthermore, it would be interesting to compare peptides isolated from this display 
system with a different display system, e.g. a phage system. Although numerous 
successes in identifying ligands derived from both display systems have been described, 
few direct comparisons between the systems have been reported. Lunder et al (2005) 
compared a commercially available phage and bacterial library and reported that the 
phage system outperformed the bacterial system following panning against a single 
purified target (streptavidin). However, it would be interesting to compare the 
differences between display systems following panning against a more diverse target, 
such as eukaryotic or prokaryotic cells.  
 
Even though the expression and purification system for recombinant protein production 
was optimised to improve yield, one limitation of this study was the amount of 
recombinant protein recovered and therefore alternative systems to produce 
recombinant proteins need to be identified. However, the associated added cost of using 
a different expression system should be taken into account. The cytotoxicity assays 
performed here represent pilot data demonstrating the feasibility of using biomolecules 
conjugated to photosensitiser for targeted antimicrobial PDT. Future work should be 
based on investigating the potential of all of the other recombinant thioredoxins 
successfully cloned into the expression vector (7 against MRSA, 3 against S. aureus and 
2 against S. epidermidis).  Additionally varying the concentrations of the conjugate, 
varying the light dose/frequency, and characterisation of killing potential for other 
photosensitisers will allow determination of the optimal killing conditions of the 
conjugate for maximal bacterial death. Finally, investigation into conjugation of the 
peptides or recombinant proteins to other antimicrobial compounds to improve the 
efficacy of these compounds may be useful, and also specific targeting could provide a 
platform to use more potent drugs that currently cannot be used because of damage to 
the host.  
 
It would be interesting to investigate the differences in the photodynamic action of both 
the conjugate and photosensitiser alone against a non-resistant strain of S. aureus. 
Previous work on a similar topic by Embleton et al (2004) using an antibody directed 
against MRSA was shown to also be effective against MSSA and showed some 
potential against S. epidermidis. It was hypothesised that this was due to some antigens 
being shared and therefore some cross-reactivity with the antibody conjugate was also 
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observed. In this thesis, although originally the conjugate was derived from panning 
against MRSA, it may be expected to be effective against non-resistant S. aureus and 
possibly have some activity against S. epidermidis. This thesis demonstrated that FITC-
labelled peptide derived from panning against MRSA also showed various levels of 
binding to S. aureus and S. epidermidis. It may therefore be reasonable to assume that 
the recombinant protein conjugated to the porphyrin studied here would have some 
level of cross-reactivity with Staphylococci but may also be shown to cross-react with 
all Gram-positive species to some degree, therefore further testing against these bacteria 
and other Gram-positive pathogens such as Streptococci is warranted. Additionally, as 
the FITC-labelled peptide was shown to bind P. aeruginosa, cytotoxicity assays should 
be performed against this pathogen in order to assess the utility of the conjugate against 
this Gram-negative species. However, although very unlikely, it is also possible that the 
conjugate is MRSA strain specific and therefore will only be effective against MRSA; 
thus investigation into different bacterial strain targeting would clearly be advantageous 
to at least begin to elucidate the protein binding target on the bacterial surface. It would 
also be of interest to determine whether the original peptide sequence conjugated 
directly to the photosensitiser performs as well or better/worse then the peptide 
embedded within the full thioredoxin protein.  
 
Cytotoxicity assays targeting bacteria, as part of a biofilm or in animal models rather 
than in suspension would also be worthy of future investigation. Lambrechts et al 
(2005) demonstrated that a substantially higher concentration of photosensitiser was 
required to kill S. aureus in vivo than in vitro (500 µM and 1.6 µM respectively). 
Similarly the light dose required was also higher (211 J cm-2 in vivo and 0.6 J –2 in 
vitro). Additionally, Maisch et al (2007) used a 100-fold higher concentration of 
photosensitiser to treat bacteria in an ex vivo porcine skin model than this group had 
previously used in in vitro studies (Maisch et al., 2005). Furthermore, testing the 
conjugate at different phases of bacterial growth (i.e. lag, exponential and stationary 
phase) at different concentrations needs investigating. For example, Embleton et al 
(2002) demonstrated that bacteria exposed to their IgG-conjugated photosensitiser in 
both the exponential and stationary growth phase were substantially reduced following 
photodynamic therapy, whereas the susceptibility of bacteria in the lag phase was 
unaffected. Other studies have shown that S. aureus was more resistant in the stationary 
phase (Nitzan et al., 1989). In contrast others have failed to show an effect of growth 
 170 
phase on bacterial photosensitisation potential (Embleton et al., 2004, Embleton et al., 
2005, Griffiths et al., 1997, Wilson and Pratten, 1995), which suggests that the effect on 
growth phase appears to be due to the photosensitiser and/or the targeting moiety. 
Nonetheless, it may be of interest to investigate if there is a growth phase dependent 
binding effect of the protein which may help to establish if the target on the bacteria is 
up or down regulated in each growth phase, which may help to characterise the target on 
the bacterial surface. 
 
To summarise, although PDT shows increasing promise in treatment for eradicating 
pathogenic bacteria in vitro, further investigations in vivo are required that investigates 
the contribution of host factors, bacterial synergy/mixed populations and biofilm 
formations. The use of different photosensitisers/concentrations, bacterial 
strains/concentration, light sources, duration/intensity of light, type of dosage, recovery 
times, viability measurement, host factors, incubation times, in vitro vs. in vivo studies 
and general study design (i.e. investigating different strain susceptibility or measuring 
total bacterial eradication) often make antimicrobial studies difficult to compare. 
Nonetheless, although it appears to be a multifaceted process, antimicrobial PDT has 
emerged as a potential powerful tool to treat a range of bacterial pathogens, including 
those with developing resistant traits that are now difficult to treat with conventional 
treatments. 
 
6.3 Conclusions 
 
The increasing prevalence of drug resistant bacterial isolates and the bacterial ability to 
acquire further resistance has led to new and alternative methods of bacterial targeting 
and detection being urgently required. These new methods employed should be 
pathogen specific, that are not susceptible to bacterial resistance mechanisms thus 
rendering the new drugs ineffective, that are able to be used and modified over time to 
improve efficacy. Although PDT on its own has shown some success, by adopting a 
targeted antimicrobial PDT approach to select for pathogenic bacteria, indiscriminate 
killing of host cells and commensal bacteria can be avoided (Bhatti et al., 2000). 
 
This thesis has described a system to identify and produce different proteins that could 
be utilised for targeted PDT against a range of pathogenic bacteria identified within 
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chronic wounds for localised treatment with limited damage to the host. Not only does 
PDT represents a very attractive candidate independently but also identification of novel 
proteins with pathogenic selectively can only help to enhance this potential. PDT may 
also provide a very cost effective treatment modality compared to some conventional 
expensive antimicrobial therapies and requires relatively little infrastructure.  
Furthermore, novel biomolecules with specific pathogen selectively may have even 
further applications in addition to targeted PDT as potential rapid diagnostic agents. I 
believe that targeted antimicrobial PDT represents a truly exciting approach as an 
alternative treatment of pathogenic organisms that are resistant to conventional therapy, 
offering great potential to improve treatment times, reduce costs and increase patient 
quality of life. A collaborative effort should be made between biologists, chemists, 
microbiologists and clinicians to ensure the development of new biomolecules with 
enhanced selectively that make their way into general practice.   
 
 
 
 
 
 
 
 
 
 
 
 172 
REFERENCES 
 
AGTERBERG, M., ADRIAANSE, H., VANBRUGGEN, A., KARPERIEN, M. & 
TOMMASSEN, J. (1990) Outer-Membrane PhoE Protein of Escherichia-Coli 
K-12 as an Exposure Vector - Possibilities and Limitations. Gene, 88, 37-45. 
ALOUINI, Z. & JEMLI, M. (2001) Destruction of helminth eggs by photosensitized 
porphyrin. Journal of Environmental Monitoring, 3, 548-551. 
AMEMIYA, K., NAKATANI, T., SAITO, A., SUZUKI, A. & MUNAKATA, H. 
(2005) Hyaluronan-binding motif identified by panning a random peptide 
display library. Biochimica Et Biophysica Acta-General Subjects, 1724, 94-99. 
ANWAR, H., DASGUPTA, M. K. & COSTERTON, J. W. (1990) Testing the 
susceptibility of bacteria in biofilms to antibacterial agents. Antimicrobial 
Agents and Chemotherapy, 34, 2043-2046. 
ARNER, E. S. J. & HOLMGREN, A. (2000) Physiological functions of thioredoxin and 
thioredoxin reductase. European Journal of Biochemistry, 267, 6102-6109. 
AZZAZY, H. M. E. & HIGHSMITH, W. E. (2002) Phage display technology: clinical 
applications and recent innovations. Clinical Biochemistry, 35, 425-445. 
BANEYX, F. (1999) Recombinant protein expression in Escherichia coli. Current 
Opinion in Biotechnology, 10, 411-421. 
BANEYX, F. & MUJACIC, M. (2004) Recombinant protein folding and misfolding in 
Escherichia coli. Nature Biotechnology, 22, 1399-1408. 
BARRETT, J. F. (2004) MRSA: status and prospects for therapy? An evaluation of key 
papers on the topic of MRSA and antibiotic resistance. Expert Opinion on 
Therapeutic Targets, 8, 515-519. 
BENHAR, I. (2001) Biotechnological applications of phage and cell display. 
Biotechnology Advances, 19, 1-33. 
BERTHIAUME, F., REIKEN, S. R., TONER, M., TOMPKINS, R. G. & YARMUSH, 
M. L. (1994) Antibody-targeted photolysis of bacteria in-vivo. Bio-Technology, 
12, 703-706. 
BERTOLONI, G., LAURO, F. M., CORTELLA, G. & MERCHAT, M. (2000) 
Photosensitizing activity of hematoporphyrin on Staphylococcus aureus cells. 
Biochimica Et Biophysica Acta-General Subjects, 1475, 169-174. 
BERTOLONI, G., ROSSI, F., VALDUGA, G., JORI, G., ALI, H. & VANLIER, J. E. 
(1992) Photosensitizing activity of water-soluble and lipid-soluble 
phthalocyanines on prokaryotic and eukaryotic microbial-cells. Microbios, 71, 
33-46. 
 173 
BERTOLONI, G., ROSSI, F., VALDUGA, G., JORI, G. & VANLIER, J. (1990) 
Photosensitizing activity of water-soluble and lipid-soluble phthalocyanines on 
Escherichia-coli. Fems Microbiology Letters, 71, 149-155. 
BHATTI, M., MACROBERT, A., HENDERSON, B., SHEPHERD, P., CRIDLAND, J. 
& WILSON, M. (2000) Antibody-targeted lethal photosensitization of 
Porphyromonas gingivalis. Antimicrobial Agents and Chemotherapy, 44, 2615-
2618. 
BIOINFORMATICS, S. I. O. (2009) ExPASy Proteomics Server. Swiss Institute of 
Bioinformatics. 
BISHOP-HURLEY, S. L., SCHMIDT, F. J., ERWIN, A. L. & SMITH, A. L. (2005) 
Peptides selected for binding to a virulent strain of Haemophilus influenzae by 
phage display are bactericidal. Antimicrobial Agents and Chemotherapy, 49, 
2972-2978. 
BISLAND, S. K., CHIEN, C., WILSON, B. C. & BURCH, S. (2005) Pre-clinical in 
vitro and in vivo studies to examine the potential use of photodynamic therapy 
in the treatment of osteomyelitis. Optical Methods for Tumor Treatment and 
Detection: Mechanisms and Techniques in Photodynamic Therapy XIV, 5689, 
26-38. 
BJARNSHOLT, T., KIRKETERP-MOLLER, K., JENSEN, P. O., MADSEN, K. G., 
PHIPPS, R., KROGFELT, K., HOIBY, N. & GIVSKOV, M. (2008) Why 
chronic wounds will not heal: a novel hypothesis. Wound Repair and 
Regeneration, 16, 2-10. 
BLISS, J. M., BIGELOW, C. E., FOSTER, T. H. & HAIDARIS, C. G. (2004) 
Susceptibility of Candida species to photodynamic effects of photofrin. 
Antimicrobial Agents and Chemotherapy, 48, 2000-2006. 
BOEHNCKE, W. H., ELSHORST-SCHMIDT, T. & KAUFMANN, R. (2000) Systemic 
photodynamic therapy is a safe and effective treatment for psoriasis. Archives of 
Dermatology, 136, 271-272. 
BOWLER, P. G., DUERDEN, B. I. & ARMSTRONG, D. G. (2001) Wound 
microbiology and associated approaches to wound management. Clinical 
Microbiology Reviews, 14, 244-+. 
BOWLER, P. G. & DAVIES, B. J. (1999) The microbiology of infected and 
noninfected leg ulcers. International Journal of Dermatology, 38, 573-578. 
BRADFORD, M. M. (1976) Rapid and sensitive method for quantitation of microgram 
quantities of protein utilizing principle of protein-dye binding. Analytical 
Biochemistry, 72, 248-254. 
BREKKE, O. H. & LOSET, G. A. (2003) New technologies in therapeutic antibody 
development. Current Opinion in Pharmacology, 3, 544-550. 
 174 
BRESSLER, N. M. & BRESSLER, S. B. (2000) Photodynamic therapy with verteporfin 
(visudyne): Impact on ophthalmology and visual sciences. Investigative 
Ophthalmology & Visual Science, 41, 624-628. 
BROOK, I. & FRAZIER, E. H. (1998) Aerobic and anaerobic microbiology of chronic 
venous ulcers. International Journal of Dermatology, 37, 426-428. 
BROWN, S. B., BROWN, E. A. & WALKER, I. (2004) The present and future role of 
photodynamic therapy in cancer treatment. Lancet Oncology, 5, 497-508. 
BROWN, C. K., MODZELEWSKI, R. A., JOHNSON, C. S. & WONG, M. K. K. 
(2000) A novel approach for the identification of unique tumor vasculature 
binding peptides using an E-coli peptide display library. Annals of Surgical 
Oncology, 7, 743-749. 
BUCHLI, P. J., WU, Z. N. & CIARDELLI, T. L. (1997) The functional display of 
interleukin-2 on filamentous phage. Archives of Biochemistry and Biophysics, 
339, 79-84. 
BUSSOW, K., NORDHOFF, E., LUBBERT, C., LEHRACH, H. & WALTER, G. 
(2000) A human cDNA library for high-throughput protein expression 
screening. Genomics, 65, 1-8. 
CALZAVARA-PINTON, P. G., VENTURINI, M. & SALA, R. (2005) A 
comprehensive overview of photodynamic therapy in the treatment of superficial 
fungal infections of the skin. Journal of Photochemistry and Photobiology 
B:Biology, 78, 1-6. 
CARBON, C. (1999) Costs of treating infections caused by methicillin-resistant 
Staphylococci and vancomycin-resistant Enterococci. Journal of Antimicrobial 
Chemotherapy, 44, 31-36. 
CARNAZZA, S., FOTI, C., GIOFFRE, G., FELICI, F. & GUGLIELMINO, S. (2008) 
Specific and selective probes for Pseudomonas aeruginosa from phage-displayed 
random peptide libraries. Biosensors & Bioelectronics, 23, 1137-1144. 
CHAN, Y. & LAI, C. H. (2003) Bactericidal effects of different laser wavelengths on 
periodontopathic germs in photodynamic therapy. Lasers in Medical Science, 
18, 51-55. 
CHANG, S., SIEVERT, D. M., HAGEMAN, J. C., BOULTON, M. L., TENOVER, F. 
C., DOWNES, F. P., SHAH, S., RUDRIK, J. T., PUPP, G. R., BROWN, W. J., 
CARDO, D., FRIDKIN, S. K. & VANCOMYCIN-RESISTANT, S. (2003) 
Infection with vancomycin-resistant Staphylococcus aureus containing the vanA 
resistance gene. New England Journal of Medicine, 348, 1342-1347. 
CHARBIT, A., MOLLA, A., SAURIN, W. & HOFNUNG, M. (1988) Versatility of a 
Vector for Expressing Foreign Polypeptides at the Surface of Gram-Negative 
Bacteria. Gene, 70, 181-189. 
 175 
CHEN, W. & GEORGIOU, G. (2002) Cell-surface display of heterologous proteins: 
From high-throughput screening to environmental applications. Biotechnology 
and Bioengineering, 79, 496-503. 
CHOW, J. W. (2000) Aminoglycoside resistance in enterococci. Clinical Infectious 
Diseases, 31, 586-589. 
 
CLARKE, O. J. & BOYLE, R. W. (1999) Isothiocyanatoporphyrins, useful 
intermediates for the conjugation of porphyrins with biomolecules and solid 
supports. Chemical Communications, 2231-2232. 
CONNER-KERR, T. A., SULLIVAN, P. K., GAILLARD, J., FRANKLIN, M. E. & 
JONES, R. M. (1998) The effects of ultraviolet radiation on antibiotic-resistant 
bacteria in vitro. Ostomy Wound Management, 44, 50-6. 
DANE, K. Y., CHAN, L. A., RICE, J. J. & DAUGHERTY, P. S. (2006) Isolation of 
cell specific peptide ligands using fluorescent bacterial display libraries. Journal 
of Immunological Methods, 309, 120-129. 
DANIELSEN, L., BALSLEV, E., DORING, G., HOIBY, N., MADSEN, S. M., 
AGREN, M., THOMSEN, H. K., FOS, H. H. S. & WESTH, H. (1998) Ulcer 
bed infection - Report of a case of enlarging venous leg ulcer colonized by 
Pseudomonas aeruginosa. Acta Pathologica, Microbiologica et Immunologica 
Scandinavica, 106, 721-726. 
DAVIS, E. (1996) Don’t deny the chance to heal!. 2nd joint Meeting of the Wound 
healing Society and the European Tissue Repair Society. Boston. 
DE HAARD, H. J., VAN NEER, N., REURS, A., HUFTON, S. E., ROOVERS, R. C., 
HENDERIKX, P., DE BRUINE, A. P., ARENDS, J. W. & HOOGENBOOM, 
H. R. (1999) A large non-immunized human Fab fragment phage library that 
permits rapid isolation and kinetic analysis of high affinity antibodies. Journal 
of Biological Chemistry, 274, 18218-18230. 
DE, J., CHANG, Y. C., SAMLI, K. N., SCHISLER, J. C., NEWGARD, C. B., 
JOHNSTON, S. A. & BROWN, K. C. (2005) Isolation of a Mycoplasma-
specific binding peptide from an unbiased phage-displayed peptide library. 
Molecular Biosystems, 1, 149-157. 
DI POTO, A., SBARRA, M. S., PROVENZA, G., VISAI, L. & SPEZIALE, P. (2009) 
The effect of photodynamic treatment combined with antibiotic action or host 
defence mechanisms on Staphylococcus aureus biofilms. Biomaterials, 30, 
3158-3166. 
DINGLASAN, R. R., PORTER-KELLEY, J. M., ALAM, U. & AZAD, A. F. (2005) 
Peptide mimics as surrogate immunogens of mosquito midgut carbohydrate 
malaria transmission blocking targets. Vaccine, 23, 2717-2724. 
DISSEMOND, J. (2009) Methicillin resistant Staphylococcus aureus (MRSA): 
Diagnostic, clinical relevance and therapy. Journal Der Deutschen 
Dermatologischen Gesellschaft, 7, 544-551. 
 176 
DONG, J., LIU, C., ZHANG, J., XIN, Z. T., YANG, G., GAO, B., MAO, C. Q., LIU, 
N. L., WANG, F., SHAO, N. S., FAN, M. & XUE, Y. N. (2006) Selection of 
novel nickel-binding peptides from flagella displayed secondary peptide library. 
Chemical Biology & Drug Design, 68, 107-112. 
DZIDIC, S., SUSKOVIC, J. & KOS, B. (2008) Antibiotic resistance mechanisms in 
bacteria: Biochemical and genetic aspects. Food Technology and Biotechnology, 
46, 11-21. 
EL ZOEIBY, A., SANSCHAGRIN, F., DARVEAU, A., BRISSON, J. R. & 
LEVESQUE, R. C. (2003) Identification of novel inhibitors of Pseudomonas 
aeruginosa MurC enzyme derived from phage-displayed peptide libraries. 
Journal of Antimicrobial Chemotherapy, 51, 531-543. 
ELSTON, D. M. (2007) Community-acquired methicillin-resistant Staphylococcus 
aureus. Journal of the American Academy of Dermatology, 56, 1-16. 
EMBLETON, M. L., NAIR, S. P., HEYWOOD, W., MENON, D. C., COOKSON, B. 
D. & WILSON, M. (2005) Development of a novel targeting system for lethal 
photo sensitization of antibiotic-resistant strains of Staphylococcus aureus. 
Antimicrobial Agents and Chemotherapy, 49, 3690-3696. 
EMBLETON, M. L., NAIR, S. P., COOKSON, B. D. & WILSON, M. (2004) 
Antibody-directed photodynamic therapy of methicillin resistant Staphylococcus 
aureus. Microbial Drug Resistance, 10, 92-97. 
EMBLETON, M. L., NAIR, S. P., COOKSON, B. D. & WILSON, M. (2002) Selective 
lethal photosensitization of methicillin-resistant Staphylococcus aureus using an 
IgG-tin(IV) chlorin e6 conjugate. Journal of Antimicrobial Chemotherapy, 50, 
857-864. 
ESTEY, E. P., BROWN, K., DIWU, Z. J., LIN, J. X., LOWN, J. W., MILLER, G. G., 
MOORE, R. B., TULIP, J. & MCPHEE, M. S. (1996) Hypocrellins as 
photosensitizers for photodynamic therapy: A screening evaluation and 
pharmacokinetic study. Cancer Chemotherapy and Pharmacology, 37, 343-350. 
FERRO, S., RICCHELLI, F., MANCINI, G., TOGNON, G. & JORI, G. (2006) 
Inactivation of methicillin-resistant Staphylococcus aureus (MRSA) by 
liposome-delivered photo sensitising agents. Journal of Photochemistry and 
Photobiology B:Biology, 83, 98-104. 
FILIUS, P. M. G. & GYSSENS, I. C. (2002) Impact of increasing antimicrobial 
resistance on wound management. American Journal of Clinical Dermatology, 
3, 1-7. 
FOSTER, T. J. & HOOK, M. (1998) Surface protein adhesins of Staphylococcus 
aureus. Trends in Microbiology, 6, 484-488. 
FRANCISCO, J. A., CAMPBELL, R., IVERSON, B. L. & GEORGIOU, G. (1993) 
Production and fluorescence-activated cell sorting of Escherichia-coli expressing 
a functional antibody fragment on the external surface. Proceedings of the 
 177 
National Academy of Sciences of the United States of America, 90, 10444-
10448. 
FRANCISCO, J. A., EARHART, C. F. & GEORGIOU, G. (1992) Transport and 
anchoring of beta-lactamase to the external surface of Escherichia-coli. 
Proceedings of the National Academy of Sciences of the United States of 
America, 89, 2713-2717. 
FREUDL, R., MACINTYRE, S., DEGEN, M. & HENNING, U. (1986) Cell-Surface 
Exposure of the Outer-Membrane Protein OmpA of Escherichia-Coli K-12. 
Journal of Molecular Biology, 188, 491-494. 
FRIEDBERG, J. S., TOMPKINS, R. G., RAKESTRAW, S. L., WARREN, S. W., 
FISCHMAN, A. J. & YARMUSH, M. L. (1991) Antibody-targeted photolysis - 
bacteriocidal effects of sn (iv) chlorin e6- dextran-monoclonal antibody 
conjugates. Temporal Control of Drug Delivery, 618, 383-393. 
FUCHS, P., WEICHEL, W., DUBEL, S., BREITLING, F. & LITTLE, M. (1996) 
Separation of E-coli expressing functional cell-wall bound antibody fragments 
by FACS. Immunotechnology, 2, 97-102. 
GAD, F., ZAHRA, T., FRANCIS, K. P., HASAN, T. & HAMBLIN, M. R. (2004a) 
Targeted photodynamic therapy of established soft-tissue infections in mice. 
Photochemical & Photobiological Sciences, 3, 451-458. 
GAD, F., ZAHRA, T., HASAN, T. & HAMBLIN, M. R. (2004b) Effects of growth 
phase and extracellular slime on photodynamic inactivation of gram-positive 
pathogenic bacteria. Antimicrobial Agents and Chemotherapy, 48, 2173-2178. 
GEORGIOU, G., STATHOPOULOS, C., DAUGHERTY, P. S., NAYAK, A. R., 
IVERSON, B. L. & CURTISS, R. (1997) Display of heterologous proteins on 
the surface of microorganisms: From the screening of combinatorial libraries to 
live recombinant vaccines. Nature Biotechnology, 15, 29-34. 
GIEBEL, L. B., CASS, R. T., MILLIGAN, D. L., YOUNG, D. C., ARZE, R. & 
JOHNSON, C. R. (1995) Screening of cyclic peptide phage libraries identifies 
ligands that bind streptavidin with high affinities. Biochemistry, 34, 15430-
15435. 
GJODSBOL, K., CHRISTENSEN, J. J., KARLSMARK, T., JORGENSEN, B., KLEIN, 
B. M. & KROGFELT, K. A. (2006) Multiple bacterial species reside in chronic 
wounds: a longitudinal study. International Wound Journal, 3, 225-31. 
GOLD, H. S. & MOELLERING, R. C. (1996) Drug therapy - Antimicrobial-drug 
resistance. New England Journal of Medicine, 335, 1445-1453. 
GRELLIER, P., SANTUS, R., MOURAY, E., AGMON, V., MAZIERE, J. C., 
RIGOMIER, D., DAGAN, A., GATT, S. & SCHREVEL, J. (1997) 
Photosensitized inactivation of Plasmodium falciparum- and Babesia divergens-
infected erythrocytes in whole blood by lipophilic pheophorbide derivatives. 
Vox Sanguinis, 72, 211-220. 
 178 
GREY, J. E., ENOCH, S. & HARDING, K. G. (2006) ABC of wound healing - Venous 
and arterial leg ulcers. British Medical Journal, 332, 347-350. 
GRIFFITHS, M. A., WREN, B. W. & WILSON, M. (1997) Killing of methicillin-
resistant Staphylococcus aureus in vitro using aluminium disulphonated 
phthalocyanine, a light-activated antimicrobial agent. Journal of Antimicrobial 
Chemotherapy, 40, 873-876. 
GRINHOLC, M., SZRAMKA, B., KURLENDA, J., GRACZYK, A. & BIELAWSKI, 
K. P. (2008) Bactericidal effect of photodynamic inactivation against 
methicillin-resistant and methicillin-susceptible Staphylococcus aureus is strain-
dependent. Journal of Photochemistry and Photobiology B:Biology, 90, 57-63. 
GROSS, S., BRANDIS, A., CHEN, L., ROSENBACH-BELKIN, V., ROEHRS, S., 
SCHERZ, A. & SALOMON, Y. (1997) Protein-A-mediated targeting of 
Bacteriochlorophyll-IgG to Staphylococcus aureus: A model for enhanced site-
specific photocytotoxicity. Photochemistry and Photobiology, 66, 872-878. 
GUIOTTO, A., CHILIN, A., MANZINI, P., DALLACQUA, F., BORDIN, F. & 
RODIGHIERO, P. (1995) Synthesis and antiproliferative activity of 
furocoumarin isosters. Farmaco, 50, 479-488. 
GUNNERIUSSON, E., SAMUELSON, P., UHLEN, M., NYGREN, P. A. & STAHL, 
S. (1996) Surface display of a functional single-chain Fv antibody on 
Staphylococci. Journal of Bacteriology, 178, 1341-1346. 
GURRAN, C., HOLLIDAY, M. G., PERRY, J. D., FORD, M., MORGAN, S. & ORR, 
K. E. (2002) A novel selective medium for the detection of methicillin-resistant 
Staphylococcus aureus enabling result reporting in under 24 h. Journal of 
Hospital Infection, 52, 148-151. 
HALBERT, A. R., STACEY, M. C., ROHR, J. B. & JOPP-MCKAY, A. (1992) The 
effect of bacterial colonization on venous ulcer healing. Australasian Journal of 
Dermatology, 33, 75-80. 
HALL, C. E. (2008) The synthesis of cationic porphyrins for use in photodynamic 
antimicrobial chemotherapy (PACT). Chemistry. Hull, Hull. 
HAMBLIN, M. R. & HASAN, T. (2004) Photodynamic therapy: a new antimicrobial 
approach to infectious disease? Photochemical & Photobiological Sciences, 3, 
436-450. 
HAMBLIN, M. R., ZAHRA, T., CONTAG, C. H., MCMANUS, A. T. & HASAN, T. 
(2003) Optical monitoring and treatment of potentially lethal wound infections 
in vivo. Journal of Infectious Diseases, 187, 1717-1725. 
HAMBLIN, M. R., O'DONNELL, D. A., MURTHY, N., RAJAGOPALAN, K., 
MICHAUD, N., SHERWOOD, M. E. & HASAN, T. (2002a) Polycationic 
photosensitizer conjugates: effects of chain length and Gram classification on 
the photodynamic inactivation of bacteria. Journal of Antimicrobial 
Chemotherapy, 49, 941-951. 
 179 
HAMBLIN, M. R., O'DONNELL, D. A., MURTHY, N., CONTAG, C. H. & HASAN, 
T. (2002b) Rapid control of wound infections by targeted photodynamic therapy 
monitored by in vivo bioluminescence imaging. Photochemistry and 
Photobiology, 75, 51-57. 
HERRICK, S. E., SLOAN, P., MCGURK, M., FREAK, L., MCCOLLUM, C. N. & 
FERGUSON, M. W. J. (1992) Sequential-changes in histologic pattern and 
extracellular-matrix deposition during the healing of chronic venous ulcers. 
American Journal of Pathology, 141, 1085-1095. 
HIRAMATSU, K., CUI, L., KURODA, M. & ITO, T. (2001) The emergence and 
evolution of methicillin-resistant Staphylococcus aureus. Trends in 
Microbiology, 9, 486-493. 
HIRAMATSU, K., ITO, T. & HANAKI, H. (1999) Mechanisms of methicillin and 
vancomycin resistance in Staphylococcus aureus. Baillieres Clinical Infectious 
Diseases, 5, 221-242. 
HIRAMATSU, K., HANAKI, H., INO, T., YABUTA, K., OGURI, T. & TENOVER, F. 
C. (1997) Methicillin-resistant Staphylococcus aureus clinical strain with 
reduced vancomycin susceptibility. Journal of Antimicrobial Chemotherapy, 40, 
135-136. 
HONGCHARU, W., TAYLOR, C. R., CHANG, Y. C., AGHASSI, D., 
SUTHAMJARIYA, K. & ANDERSON, R. R. (2000) Topical ALA-
photodynamic therapy for the treatment of acne vulgaris. Journal of 
Investigative Dermatology, 115, 183-192. 
HOPE, C. K., PACKER, S., WILSON, M. & NAIR, S. P. (2009) The inability of a 
bacteriophage to infect Staphylococcus aureus does not prevent it from 
specifically delivering a photosensitizer to the bacterium enabling its lethal 
photosensitization. Journal of Antimicrobial Chemotherapy, 64, 59-61. 
HOWELL-JONES, R. S., WILSON, M. J., HILL, K. E., HOWARD, A. J., PRICE, P. E. 
& THOMAS, D. W. (2005) A review of the microbiology, antibiotic usage and 
resistance in chronic skin wounds. Journal of Antimicrobial Chemotherapy, 55, 
143-149. 
HUANG, W. Z., PETROSINO, J. & PALZKILL, T. (1998) Display of functional beta-
lactamase inhibitory protein on the surface of M13 bacteriophage. Antimicrobial 
Agents and Chemotherapy, 42, 2893-2897. 
HUDSON, R., CARCENAC, M., SMITH, K., MADDEN, L., CLARKE, O. J., 
PELEGRIN, A., GREENMAN, J. & BOYLE, R. W. (2005) The development 
and characterisation of porphyrin isothiocyanate-monoclonal antibody 
conjugates for photoimmunotherapy. British Journal of Cancer, 92, 1442-1449. 
INFORMATION, N. C. F. B. (2009) Genbank. National Institutes of Health. 
INVITROGEN (2009) FliTrx™ Random Peptide Display Library (Version G). 
 180 
ITO, I., MITSUOKA, N., SOBAJIMA, J., UESUGI, H., OZAKI, S., OHYA, K. & 
YOSHIDA, M. (2004) Conformational difference in HMGB1 proteins of human 
neutrophils and lymphocytes revealed by epitope mapping of a monoclonal 
antibody. Journal of Biochemistry, 136, 155-162. 
JAYARAMAN, R. (2009) Antibiotic resistance: an overview of mechanisms and a 
paradigm shift. Current Science, 96, 1475-1484. 
 
JEVONS, M. P. (1961) ‘Celbenin’-resistant Staphylococci. British Medical Journal 1, 
124-5. 
JORI, G. & BROWN, S. B. (2004) Photosensitized inactivation of microorganisms. 
Photochemical & Photobiological Sciences, 3, 403-405. 
KAC, G., BUU-HOI, A., HERISSON, E., BIANCARDINI, P. & DEBURE, C. (2000) 
Methicillin-resistant Staphylococcus aureus nosocomial acquisition and carrier 
state in a wound care center. Archives of Dermatology, 136, 735-739. 
KARRER, S., SZEIMIES, R. M., ERNST, S., ABELS, C., BAUMLER, W. & 
LANDTHALER, M. (1999) Photodynamic inactivation of staphylococci with 5-
aminolaevulinic acid or photofrin. Lasers in Medical Science, 14, 54-61. 
KATTI, S. K., LEMASTER, D. M. & EKLUND, H. (1990) Crystal-structure of 
thioredoxin from Escherichia-coli at 1.68A resolution. Journal of Molecular 
Biology, 212, 167-184. 
KAUFMAN, D. L. & EVANS, G. A. (1990) Restriction endonuclease cleavage at the 
termini of PCR products. Biotechniques, 9, 304-306. 
KERN, R., MALKI, A., HOLMGREN, A. & RICHARME, G. (2003) Chaperone 
properties of Escherichia coli thioredoxin and thioredoxin reductase. 
Biochemical Journal, 371, 965-972. 
KHAN, A. S., THOMPSON, R., CAO, C. & VALDES, J. J. (2003) Selection and 
characterization of peptide memitopes binding to ricin. Biotechnology Letters, 
25, 1671-1675. 
KISHIMOTO, J., FUKUMA, Y., MIZUNO, A. & NEMOTO, T. K. (2005) 
Identification of the pentapeptide constituting a dominant epitope common to all 
eukaryotic heat shock protein 90 molecular chaperones. Cell Stress & 
Chaperones, 10, 296-311. 
KOMERIK, N., WILSON, M. & POOLE, S. (2000) The effect of photodynamic action 
on two virulence factors of gram-negative bacteria. Photochemistry and 
Photobiology, 72, 676-680. 
KREITNER, M., WAGNER, K.-H., ALTH, G., EBERMANN, R., FOISSY, H. & 
ELMADFA, I. (2003) Finding optimal photosensitisers for the decontamination 
of foods by the photodynamic effect. Forum of Nutrition, 56, 367-9. 
 181 
KUZNETSOVA, N. A., MAKAROV, D. A., KALIYA, O. L. & VOROZHTSOV, G. 
N. (2007) Photosensitized oxidation by dioxygen as the base for drinking water 
disinfection. Journal of Hazardous Materials, 146, 487-491. 
LAMBRECHTS, S. A. G., DEMIDOVA, T. N., AALDERS, M. C. G., HASAN, T. & 
HAMBLIN, M. R. (2005) Photodynamic therapy for Staphylococcus aureus 
infected burn wounds in mice. Photochemical & Photobiological Sciences, 4, 
503-509. 
LAVALLIE, E. R., LU, Z. J., DIBLASIO-SMITH, E. A., COLLINS-RACIE, L. A. & 
MCCOY, J. M. (2000) Thioredoxin as a fusion partner for production of soluble 
recombinant proteins in Escherichia coli. Applications of Chimeric Genes and 
Hybrid Proteins, Pt A, 326, 322-340. 
LAVALLIE, E. R., DIBLASIO, E. A., KOVACIC, S., GRANT, K. L., SCHENDEL, P. 
F. & MCCOY, J. M. (1993) A thioredoxin gene fusion expression system that 
circumvents inclusion body formation in the Escherichia-coli cytoplasm. Bio-
Technology, 11, 187-193. 
LEE, S. Y., CHOI, J. H. & XU, Z. H. (2003) Microbial cell-surface display. Trends in 
Biotechnology, 21, 45-52. 
LEE, J. S., SHIN, K. S., PAN, J. G. & KIM, C. J. (2000) Surface-displayed viral 
antigens on Salmonella carrier vaccine. Nature Biotechnology, 18, 645-648. 
LENNON, B. W., WILLIAMS, C. H. & LUDWIG, M. L. (2000) Twists in catalysis: 
Alternating conformations of Escherichia coli thioredoxin reductase. Science, 
289, 1190-1194. 
LI, W. H., LEI, P., YU, B., WU, S., PENG, J. L., ZHAO, X. P., ZHU, H. F., 
KIRSCHFINK, M. & SHEN, G. X. (2008) Screening and identification of a 
novel target specific for hepatoma cell line HepG2 from the FliTrx bacterial 
peptide library. Acta Biochimica et Biophysica Sinica, 40, 443-451. 
LIM, T. S., MWIPATAYI, B. P., MURRAY, R., SIEUNARINE, K., ABBAS, M. & 
ANGEL, D. (2006) Microbiological profile of chronic ulcers of the lower limb: 
A prospective observational cohort study. Anz Journal of Surgery, 76, 688-692. 
LIN, H. Y., CHEN, C. T. & HUANG, C. T. (2004) Use of merocyanine 540 for 
photodynamic inactivation of staphylococcus aureus planktonic and biofilm 
cells. Applied and Environmental Microbiology, 70, 6453-6458. 
LIVERMORE, D. M. (2000) Antibiotic resistance in staphylococci. International 
Journal of Antimicrobial Agents, 16, S3-S10. 
LU, Z. J., MURRAY, K. S., VANCLEAVE, V., LAVALLIE, E. R., STAHL, M. L. & 
MCCOY, J. M. (1995) Expression of thioredoxin random peptide libraries on 
the Escherichia-coli cell-surface as functional fusions to flagellin - a system 
designed for exploring protein-protein interactions. Bio-Technology, 13, 366-
372. 
 182 
LUNDER, M., BRATKOVIC, T., DOLJAK, B., KREFT, S., URLEB, U., STRUKELJ, 
B. & PLAZAR, N. (2005) Comparison of bacterial and phage display peptide 
libraries in search of target-binding motif. Applied Biochemistry and 
Biotechnology, 127, 125-131. 
LUTZ, R. & BUJARD, H. (1997) Independent and tight regulation of transcriptional 
units in Escherichia coli via the LacR/O, the TetR/O and AraC/I-1-I-2 regulatory 
elements. Nucleic Acids Research, 25, 1203-1210. 
MA, X. X., ITO, T., TIENSASITORN, C., JAMKLANG, M., CHONGTRAKOOL, P., 
BOYLE-VAVRA, S., DAUM, R. S. & HIRAMATSU, K. (2002) Novel type of 
staphylococcal cassette chromosome mec identified in community-acquired 
methicillin-resistant Staphylococcus aureus strains. Antimicrobial Agents and 
Chemotherapy, 46, 1147-1152. 
MACRAE, F. (2006) A bright new future for MRSA testing. Clinical Laboratory 
International. 
MADSEN, S. M., WESTH, H., DANIELSEN, L. & ROSDAHL, V. T. (1996) Bacterial 
colonization and healing of venous leg ulcers. Acta Pathologica, Microbiologica 
et Immunologica Scandinavica, 104, 895-899. 
MAISCH, T. (2007a) Anti-microbial photodynamic therapy: useful in the future? 
Lasers in Medical Science, 22, 83-91. 
MAISCH, T., BOSL, C., SZEIMIES, R. M., LOVE, B. & ABELS, C. (2007b) 
Determination of the antibacterial efficacy of a new porphyrin-based 
photosensitizer against MRSA ex vivo. Photochemical & Photobiological 
Sciences, 6, 545-551. 
MAISCH, T., BOSL, C., SZEIMIES, R. M., LEHN, N. & ABELS, C. (2005) 
Photodynamic effects of novel XF porphyrin derivatives on prokaryotic and 
eukaryotic cells. Antimicrobial Agents and Chemotherapy, 49, 1542-1552. 
MAJANDER, K., KORHONEN, T. K. & WESTERLUND-WIKSTROM, B. (2005) 
Simultaneous display of multiple foreign peptides in the FliD capping and FliC 
filament proteins of the Escherichia coli flagellum. Applied and Environmental 
Microbiology, 71, 4263-4268. 
MANIATIS, T., FRITSCH, E. F. & SAMBROOK, J. (1982) Molecular Cloning, A 
Laboratory Manual. , New York, Cold Spring Harbor Laboratory. 
MCCAFFERTY, J., JACKSON, R. H. & CHISWELL, D. J. (1991) Phage-Enzymes - 
Expression and Affinity-Chromatography of Functional Alkaline-Phosphatase 
on the Surface of Bacteriophage. Protein Engineering, 4, 955-961. 
MENEZES, S., CAPELLA, M. A. M. & CALDAS, L. R. (1990) Photodynamic-action 
of methylene-blue - repair and mutation in Escherichia-coli. Journal of 
Photochemistry and Photobiology B:Biology, 5, 505-517. 
MERCHAT, M., BERTOLINI, G., GIACOMINI, P., VILLANUEVA, A. & JORI, G. 
(1996) Meso-substituted cationic porphyrins as efficient photosensitizers of 
 183 
gram-positive and gram-negative bacteria. Journal of Photochemistry and 
Photobiology B:Biology, 32, 153-157. 
MERSICH, C. & JUNGBAUER, A. (2008) Generation of bioactive peptides by 
biological libraries. Journal of Chromatography B-Analytical Technologies in 
the Biomedical and Life Sciences, 861, 160-170. 
MINNOCK, A., VERNON, D. I., SCHOFIELD, J., GRIFFITHS, J., PARISH, J. H. & 
BROWN, S. B. (1996) Photoinactivation of bacteria. Use of a cationic water-
soluble zinc phthalocyanine to photoinactivate both gram-negative and gram-
positive bacteria. Journal of Photochemistry and Photobiology B-Biology, 32, 
159-164. 
MULLEN, L. M., NAIR, S. P., WARD, J. M., RYCROFT, A. N. & HENDERSON, B. 
(2006) Phage display in the study of infectious diseases. Trends in 
Microbiology, 14, 141-147. 
NAGAI, K., DAVIES, T. A., JACOBS, M. R. & APPELBAUM, P. C. (2002) Effects of 
amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on 
PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, 
cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -
intermediate, and -resistant pneumococci. Antimicrobial Agents and 
Chemotherapy, 46, 1273-1280. 
 
NAKAJIMA, H., SHIMBARA, N., SHIMONISHI, Y., MIMORI, T., NIWA, S. & 
SAYA, H. (2000) Expression of random peptide fused to invasin on bacterial 
cell surface for selection of cell-targeting peptides. Gene, 260, 121-131. 
NAZ, R. K., ZHU, X. L. & KADAM, A. L. (2000) Identification of human sperm 
peptide sequence involved in egg binding for immunocontraception. Biology of 
Reproduction, 62, 318-324. 
NGAMPASUTADOL, J., RICE, P. A., WALSH, M. T. & GULATI, S. (2006) 
Characterization of a peptide vaccine candidate mimicking an oligosaccharide 
epitope of Neisseria gonorrhoeae and resultant immune responses and function. 
Vaccine, 24, 157-170. 
NIGAM, Y., BEXFIELD, A., THOMAS, S. & RATCLIFFE, N. A. (2006) Maggot 
therapy: The science and implication for CAM - Part I - History and bacterial 
resistance. Evidence-Based Complementary and Alternative Medicine, 3, 223-
227. 
NISSIM, A., HOOGENBOOM, H. R., TOMLINSON, I. M., FLYNN, G., MIDGLEY, 
C., LANE, D. & WINTER, G. (1994) Antibody Fragments from a Single Pot 
Phage Display Library as Immunochemical Reagents. Embo Journal, 13, 692-
698. 
NITZAN, Y., SALMON-DIVON, M., SHPOREN, E. & MALIK, Z. (2004) ALA 
induced photodynamic effects on Gram positive and negative bacteria. 
Photochemical & Photobiological Sciences, 3, 430-435. 
 184 
NITZAN, Y., GUTTERMAN, M., MALIK, Z. & EHRENBERG, B. (1992) Inactivation 
of gram-negative bacteria by photosensitized porphyrins. Photochemistry and 
Photobiology, 55, 89-96. 
NITZAN, Y., SHAINBERG, B. & MALIK, Z. (1989) THE MECHANISM OF 
Photodynamic inactivation of staphylococcus-aureus by deuteroporphyrin. 
Current Microbiology, 19, 265-269. 
NOBLE, W. C., VIRANI, Z. & CREE, R. G. A. (1992) Co-transfer of vancomycin and 
other resistance genes from Enterococcus-faecalis nctc-12201 to 
Staphylococcus-aureus. Fems Microbiology Letters, 93, 195-198. 
O'BRIEN, F. G., PEARMAN, J. W., GRACEY, M., RILEY, T. V. & GRUBB, W. B. 
(1999) Community strain of methicillin-resistant Staphylococcus aureus 
involved in a hospital outbreak. Journal of Clinical Microbiology, 37, 2858-
2862. 
O'MEARA, S., AL-KURDI, D. & OVINGTON, L. G. (2008) Antibiotics and 
antiseptics for venous leg ulcers. Cochrane Database of Systematic Reviews. 
O'NEIL, K. T., HOESS, R. H., JACKSON, S. A., RAMACHANDRAN, N. S., 
MOUSA, S. A. & DEGRADO, W. F. (1992) Identification of novel peptide 
antagonists for GPIIb/IIIa from a conformationally constrained phage peptide 
library. Proteins-Structure Function and Genetics, 14, 509-515. 
O’RIORDAN, K., AKILOV, O. E. & HASAN, T. (2005) The potential for 
photodynamic therapy in the treatment of localized infections. Photodiagnosis 
and Photodynamic Therapy 2, 247-262. 
OLSEN, M. J., STEPHENS, D., GRIFFITHS, D., DAUGHERTY, P., GEORGIOU, G. 
& IVERSON, B. L. (2000) Function-based isolation of novel enzymes from a 
large library. Nature Biotechnology, 18, 1071-1074. 
ORENSTEIN, A., KLEIN, D., KOPOLOVIC, J., WINKLER, E., MALIK, Z., 
KELLER, N. & NITZAN, Y. (1997) The use of porphyrins for eradication of 
Staphylococcus aureus in burn wound infections. Fems Immunology and 
Medical Microbiology, 19, 307-314. 
RAAB, O. (1900) Ueber die Wirkung fluorizierender Stoffe auf Infusorien. Zeitschrift 
Biologie, 39, 524-546. 
REICHENBERG, J. & DAVIS, M. (2005) Venous ulcers. Seminars in Cutaneous 
Medicine and Surgery, 24, 216-226. 
ROBERTS, J. I. S. & GASTON, M. A. (1987) Protein-A and coagulase expression in 
epidemic and non-epidemic staphylococcus-aureus. Journal of Clinical 
Pathology, 40, 837-840. 
RUCKLEY, C. V. (1997) Socioeconomic impact of chronic venous insufficiency and 
leg ulcers. Angiology, 48, 67-69. 
 185 
SANGER, F., NICKLEN, S. & COULSON, A. R. (1977) DNA sequencing with chain-
terminating inhibitors. Proceedings of the National Academy of Sciences of the 
United States of America, 74, 5463-5467. 
SANTUS, R., GRELLIER, P., SCHREVEL, J., MAZIERE, J. C. & STOLTZ, J. F. 
(1998) Photodecontamination of blood components: advantages and drawbacks. 
Clinical Hemorheology and Microcirculation, 18, 299-308. 
SCHARF, S. J., HORN, G. T. & ERLICH, H. A. (1986) Direct cloning and sequence-
analysis of enzymatically amplified genomic sequences. Science, 233, 1076-
1078. 
SCHRAIBMAN, I. G. (1990) The significance of beta-hemolytic Streptococci in 
chronic leg ulcers. Annals of the Royal College of Surgeons of England, 72, 123-
124. 
SEGALLA, A., BORSARELLI, C. D., BRASLAVSKY, S. E., SPIKES, J. D., 
RONCUCCI, G., DEI, D., CHITI, G., JORI, G. & REDDI, E. (2002) 
Photophysical, photochemical and antibacterial photosensitizing properties of a 
novel octacationic Zn(II)-phthalocyanine. Photochemical & Photobiological 
Sciences, 1, 641-8. 
SHARMA, M., VISAI, L., BRAGHERI, F., CRISTIANI, I., GUPTA, P. K. & 
SPEZIALE, P. (2008) Toluidine blue-mediated photodynamic effects on 
staphylococcal biofilms. Antimicrobial Agents and Chemotherapy, 52, 299-305. 
SIDHU, S. S., WEISS, G. A. & WELLS, J. A. (2000) High copy display of large 
proteins on phage for functional selections. Journal of Molecular Biology, 296, 
487-495. 
SINGLETON, D. R., MASUOKA, J. & HAZEN, K. C. (2001) Cloning and analysis of 
a Candida albicans gene that affects cell surface hydrophobicity. Journal of 
Bacteriology, 183, 3582-3588. 
SMITH, G. P. (1985) Filamentous Fusion Phage - Novel Expression Vectors That 
Display Cloned Antigens on the Virion Surface. Science, 228, 1315-1317. 
SOMERS, V. A., BRANDWIJK, R. J., JOOSTEN, B., MOERKERK, P. T., ARENDS, 
J. W., MENHEERE, P., PIETERSE, W. O., CLAESSEN, A., SCHEPER, R. J., 
HOOGENBOOM, H. R. & HUFTON, S. E. (2002) A panel of candidate tumor 
antigens in colorectal cancer revealed by the serological selection of a phage 
displayed cDNA expression library. Journal of Immunology, 169, 2772-2780. 
SOUKOS, N. S., XIMENEZ-FYVIE, L. A., HAMBLIN, M. R., SOCRANSKY, S. S. & 
HASAN, T. (1998) Targeted antimicrobial photochemotherapy. Antimicrobial 
Agents and Chemotherapy, 42, 2595-2601. 
SOUSA, C., KOTRBA, P., RUML, T., CEBOLLA, A. & DE LORENZO, V. (1998) 
Metalloadsorption by Escherichia coli cells displaying yeast and mammalian 
metallothioneins anchored to the outer membrane protein LamB. Journal of 
Bacteriology, 180, 2280-2284. 
 186 
STANELOUDI, C., SMITH, K. A., HUDSON, R., MALATESTI, N., SAVOIE, H., 
BOYLE, R. W. & GREENMAN, J. (2007) Development and characterization of 
novel photosensitizer : scFv conjugates for use in photodynamic therapy of 
cancer. Immunology, 120, 512-517. 
STEFANKOVA, P., KOLLAROVA, M. & BARAK, I. (2005) Thioredoxin - Structural 
and functional complexity. General Physiology and Biophysics, 24, 3-11. 
STEPHENS, P., WALL, I. B., WILSON, M. J., HILL, K. E., DAVIES, C. E., HILL, C. 
M., HARDING, K. G. & THOMAS, D. W. (2003) Anaerobic cocci populating 
the deep tissues of chronic wounds impair cellular wound healing responses in 
vitro. British Journal of Dermatology, 148, 456-466. 
STRAUSS, A. & GOTZ, F. (1996) In vivo immobilization of enzymatically active 
polypeptides on the cell surface of Staphylococcus carnosus. Molecular 
Microbiology, 21, 491-500. 
SUTTON, J. M., CLARKE, O. J., FERNANDEZ, N. & BOYLE, R. W. (2002) 
Porphyrin, chlorin, and bacteriochlorin isothiocyanates: Useful reagents for the 
synthesis of photoactive bioconjugatest. Bioconjugate Chemistry, 13, 249-263. 
SZPAKOWSKA, M., LASOCKI, K., GRZYBOWSKI, J. & GRACZYK, A. (2001) 
Photodynamic activity of the haematoporphyrin derivative with rutin and 
arginine substituents (HpD-Rut(2)-Arg(2)) against Staphylococcus aureus and 
Pseudomonas aeruginosa. Pharmacological Research, 44, 243-246. 
TAO, J. S., WENDLER, P., CONNELLY, G., LIM, A., ZHANG, J. S., KING, M., LI, 
T. C., SILVERMAN, J. A., SCHIMMEL, P. R. & TALLY, F. P. (2000) Drug 
target validation: Lethal infection blocked by inducible peptide. Proceedings of 
the National Academy of Sciences of the United States of America, 97, 783-786. 
TASCHNER, S., MEINKE, A., VON GABAIN, A. & BOYD, A. P. (2002) Selection of 
peptide entry motifs by bacterial surface display. Biochemical Journal, 367, 
393-402. 
TELENTI, A., IMBODEN, P., MARCHESI, F., LOWRIE, D., COLE, S., COLSTON, 
M. J., MATTER, L., SCHOPFER, K. & BODMER, T. (1993) Detection of 
rifampicin-resistance mutations in Mycobacterium-tuberculosis. Lancet, 341, 
647-650. 
 
TERPE, K. (2006) Overview of bacterial expression systems for heterologous protein 
production: from molecular and biochemical fundamentals to commercial 
systems. Applied Microbiology and Biotechnology, 72, 211-222. 
TERPE, K. (2003) Overview of tag protein fusions: from molecular and biochemical 
fundamentals to commercial systems. Applied Microbiology and Biotechnology, 
60, 523-533. 
THAI, T. R., KEAST, D. H., CAMPBELL, K. E., WOODBURY, M. G. & 
HOUGHTON, P. E. (2005) Effect of ultraviolet light C on bacterial colonization 
in chronic wounds. Ostomy Wound Management, 51, 32-+. 
 187 
TOMMASSEN, J., AGTERBERG, M., JANSSEN, R. & SPIERINGS, G. (1993) Use of 
the Enterobacterial Outer-Membrane Protein PhoE in the Development of New 
Vaccines and DNA Probes. Zentralblatt Fur Bakteriologie-International 
Journal of Medical Microbiology Virology Parasitology and Infectious 
Diseases, 278, 396-406. 
TRENGOVE, N. J., STACEY, M. C., MCGECHIE, D. F. & MATA, S. (1996) 
Qualitative bacteriology and leg ulcer healing. Journal of Wound Care, 5, 277-
80. 
TRIAS, J. & GORDON, E. M. (1997) Innovative approaches to novel antibacterial drug 
discovery. Current Opinion in Biotechnology, 8, 757-762. 
TRIPP, B. C., LU, Z. J., BOURQUE, K., SOOKDEO, H. & MCCOY, J. M. (2001) 
Investigation of the 'switch-epitope' concept with random peptide libraries 
displayed as thioredoxin loop fusions. Protein Engineering, 14, 367-377. 
TSAI, T., YANG, Y. T., WANG, T. H., CHIEN, H. F. & CHEN, C. T. (2009) Improved 
Photodynamic Inactivation of Gram-Positive Bacteria Using Hematoporphyrin 
Encapsulated in Liposomes and Micelles. Lasers in Surgery and Medicine, 41, 
316-322. 
UENO, T., MISAWA, S., OHBA, Y., MATSUMOTO, M., MIZUNUMA, M., KASAI, 
N., TSUMOTO, K., KUMAGAI, I. & HAYASHI, H. (2000) Isolation and 
characterization of monoclonal antibodies that inhibit hepatitis C virus NS3 
protease. Journal of Virology, 74, 6300-6308. 
VALENCIA, I. C., KIRSNER, R. S. & KERDEL, F. A. (2004) Microbiologic 
evaluation of skin wounds: Alarming trend toward antibiotic resistance in an 
inpatient dermatology service during a 10-year period. Journal of the American 
Academy of Dermatology, 50, 845-849. 
VON TAPPEINER, H. (1904) Zur Kenntnis der lichtwirkenden (fluoreszierenden) 
Stoffe. Deutsche Medizinische Wochenschrift, 1, 579-580. 
WAINWRIGHT, M. & CROSSLEY, K. B. (2004) Photosensitising agents - 
circumventing resistance and breaking down biofilms: a review. International 
Biodeterioration & Biodegradation, 53, 119-126. 
WAINWRIGHT, M., PHOENIX, D. A., NICKSON, P. B. & MORTON, G. (2002) The 
use of new methylene blue in Pseudomonas aeruginosa biofilm destruction. 
Biofouling, 18, 247-249. 
WAINWRIGHT, M. (1998a) Photodynamic antimicrobial chemotherapy (PACT). 
Journal of Antimicrobial Chemotherapy, 42, 13-28. 
WAINWRIGHT, M., PHOENIX, D. A., LAYCOCK, S. L., WAREING, D. R. A. & 
WRIGHT, P. A. (1998b) Photobactericidal activity of phenothiazinium dyes 
against methicillin-resistant strains of Staphylococcus aureus. Fems 
Microbiology Letters, 160, 177-181. 
 188 
WAKAYAMA, Y., TAKAGI, M. & YANO, K. (1980) Photosensitized inactivation of 
Escherichia-coli-cells in toluidine blue-light system. Photochemistry and 
Photobiology, 32, 601-605. 
WALL, I. B., DAVIES, C. E., HILL, K. E., WILSON, M. J., STEPHENS, P., 
HARDING, K. G. & THOMAS, D. W. (2002) Potential role of anaerobic cocci 
in impaired human wound healing. Wound Repair and Regeneration, 10, 346-
353. 
WALSH, C. (2003) Antibiotics: actions, origins, resistance, Washington DC, ASM 
Press. 
WAUGH, D. S. (2005) Making the most of affinity tags. Trends in Biotechnology, 23, 
316-320. 
WERNERUS, H. & STAHL, S. (2004) Biotechnological applications for surface-
engineered bacteria. Biotechnology and Applied Biochemistry, 40, 209-228. 
WESTERLUND-WIKSTROM, B. (2000) Peptide display on bacterial flagella: 
Principles and applications. International Journal of Medical Microbiology, 290, 
223-230. 
WESTERLUND-WIKSTROM, B., TANSKANEN, J., VIRKOLA, R., HACKER, J., 
LINDBERG, M., SKURNIK, M. & KORHONEN, T. K. (1997) Functional 
expression of adhesive peptides as fusions to Escherichia coli flagellin. Protein 
Engineering, 10, 1319-1326. 
WHITE, R. J. & CUTTING, K. F. (2006) Critical colonization - The concept under 
scrutiny. Ostomy Wound Management, 52, 50-56. 
WILLATS, W. G. T. (2002) Phage display: practicalities and prospects. Plant 
Molecular Biology, 50, 837-854. 
WILSON, M., BURNS, T. & PRATTEN, J. (1996) Killing of Streptococcus sanguis in 
biofilms using a light-activated antimicrobial agent. Journal of Antimicrobial 
Chemotherapy, 37, 377-381. 
WILSON, M. & PRATTEN, J. (1995) Lethal photosensitization of staphylococcus-
aureus in-vitro - effect of growth-phase, serum, and preirradation time. Lasers in 
Surgery and Medicine, 16, 272-276. 
WILSON, M. & YIANNI, C. (1995) Killing of methicillin-resistant staphylococcus-
aureus by low-power laser-light. Journal of Medical Microbiology, 42, 62-66. 
XIN, Z. T., LIU, C., DONG, B., GAO, Y. P., SHAO, N. S., LIU, W., ZHANG, J., 
DONG, J., LING, S. G. & XUE, Y. N. (2004) A subtractive fluorescence-
activated cell-sorting strategy to identify mimotopes of HBV-preS protein from 
bacterially displayed peptide library. Journal of Immunological Methods, 293, 
13-21. 
XIN, Z. T., LIU, C., GAO, Y. P., MAO, C. Q., ZHAO, A., ZHANG, H., SHAO, N. S., 
LING, S. G. & XUE, Y. N. (2003) Identification of mimotopes by screening of a 
 189 
bacterially displayed random peptide library and its use in eliciting an immune 
response to native HBV-preS. Vaccine, 21, 4373-4379. 
YACOBY, I., SHAMIS, M., BAR, H., SHABAT, D. & BENHAR, I. (2006) Targeting 
antibacterial agents by using drug-carrying filamentous bacteriophages. 
Antimicrobial Agents and Chemotherapy, 50, 2087-2097. 
YANG, W. H., LUO, D. F., WANG, S. X., WANG, R., CHEN, R., LIU, Y., ZHU, T., 
MA, X. Y., LIU, R. H., XU, G., MENG, L., LU, Y. P., ZHOU, J. F. & MA, D. 
(2008) TMTP1, a novel tumor-homing peptide specifically targeting metastasis. 
Clinical Cancer Research, 14, 5494-5502. 
YOSHIDA, H., BAIK, S. H. & HARAYAMA, S. (2002) An effective peptide screening 
system using recombinant fluorescent bacterial surface display. Biotechnology 
Letters, 24, 1715-1722. 
ZANIN, I. C. J., LOBO, M. M., RODRIGUES, L. K. A., PIMENTA, L. A. F., 
HOFLING, J. F. & GONCALVES, R. B. (2006) Photosensitization of in vitro 
biofilms by toluidine blue O combined with a light-emitting diode. European 
Journal of Oral Sciences, 114, 64-69. 
ZEINA, B., GREENMAN, J., CORRY, D. & PURCELL, W. M. (2003) Antimicrobial 
photodynamic therapy: assessment of genotoxic effects on keratinocytes in vitro. 
British Journal of Dermatology, 148, 229-232. 
ZEINA, B., GREENMAN, J., CORRY, D. & PURCELL, W. M. (2002) Cytotoxic 
effects of antimicrobial photodynamic therapy on keratinocytes in vitro. British 
Journal of Dermatology, 146, 568-573. 
ZEINA, B., GREENMAN, J., PURCELL, W. M. & DAS, B. (2001) Killing of 
cutaneous microbial species by photodynamic therapy. British Journal of 
Dermatology, 144, 274-278. 
ZHAO, S. M. & LEE, E. Y. C. (1997) A protein phosphatase-1-binding motif identified 
by the panning of a random peptide display library. Journal of Biological 
Chemistry, 272, 28368-28372. 
ZHENG, X., SALLUM, U. W., VERMA, S., ATHAR, H., EVANS, C. L. & HASAN, 
T. (2009) Exploiting a Bacterial Drug-Resistance Mechanism: A Light-
Activated Construct for the Destruction of MRSA. Angewandte Chemie-
International Edition, 48, 2148-2151. 
ZHOU, X., CHANG, Y. C., OYAMA, T., MCGUIRE, M. J. & BROWN, K. C. (2004) 
Cell-specific delivery of a chemotherapeutic to lung cancer cells. Journal of the 
American Chemical Society, 126, 15656-15657. 
ZITZMANN, S., KRAMER, S., MIER, W., MAHMUT, M., FLEIG, J., ALTMANN, 
A., EISENHUT, M. & HABERKORN, U. (2005) Identification of a new 
prostate-specific cyclic peptide with the bacterial FliTrx system. Journal of 
Nuclear Medicine, 46, 782-785. 
 190 
ZOLFAGHARI, P. S., PACKER, S., SINGER, M., NAIR, S. P., BENNETT, J., 
STREET, C. & WILSON, M. (2009) In vivo killing of Staphylococcus aureus 
using a light-activated antimicrobial agent. Bmc Microbiology, 9. 
DOI:10.1186/1471-2180-9-27 
 191 
 
 
Fig 1.1: Potential microbial factors contributing to wound non-healing/infection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.1: Microbial factors that can contribute to the wound non-healing/ infection 
phenotype
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Fig 1.2: Structure of S. aureus cell wall peptidoglycan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.2: Schematic representation of peptidoglycan structure. Peptidoglycan consists of 
two joined amino sugars NAM and NAG with L-ala-D-gln-L-lys-D-ala peptides 
attached to the NAM linking strands by a pentaglycine bridge
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 Fig 1.3: Structure of S. aureus cell wall 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.3: Schematic representation of S. aureus cell wall composed of peptidoglycan, teichoic acid, lipoteichoic acid and wall associated proteins 
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 Fig 1.4: Diagrammatic representation of virulence factors possessed by S. aureus that enable host colonisation and infection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.4: Summary of virulence factors possessed by S. aureus that enable host colonisation and infection 
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 Fig 1.5: Schematic representation of the flagella filament  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Westerlund-Wikstrom, (2000)
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 Fig 1.6: Structure of the FliTrx™ peptide library 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from the FliTrx™ Random Peptide Display Library protocol (Invitrogen 2009)
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 Fig 1.7: Expression of the FliTrx™ peptide library  
 
Adapted from the FliTrx™ Random Peptide Display Library protocol (Invitrogen, 2009)
  
Table 1.1: Applications of the FliTrxTM random peptide library 
 
Application 
a) Target against which peptides were selected 
b) Number of panning rounds and clones sequenced 
c) Key findings  
Reference 
Epitope mapping 
a) 30 anti-human heat shock protein 90 monoclonal antibodies 
b) 5 rounds of panning, unknown number of clones sequenced 
c) Identification of common epitopes between immunogenic sites 
Kishimoto et al., 
2005 
Epitope mapping 
a) Anti-human high-mobility-group-box  monoclonal antibodies 
b) 5 rounds of panning, 352 clones sequenced 
c) Identified linear and conformational epitopes 
Ito et al., 2004 
Epitope mapping 
a) 6C5-H4CA monoclonal antibody 
b) 5 rounds of panning, unknown number of clones sequenced 
c) Identified peptides that may be involved in hydrophobic cell attachment of Candida 
albicans to host tissue 
Singleton et al., 
2001 
Epitope mapping 
a) Anti-human interleukin 8 monoclonal antibody 
b) 4 rounds of panning, 100 clones sequenced 
c) Identified peptides with reversible antibody binding mediated by metals or pH 
Tripp et al., 2001 
Epitope mapping 
a) Monoclonal antibodies against non-structural protein 3 of Hepatitis C virus 
b) 3 rounds of panning, 23 clones sequenced 
c) Modified panning method to use magnetic cell sorting 
Ueno et al., 2000 
Receptor-ligand 
a) Human umbilical cord hyaluronan 
b) 5 rounds of panning, 40 clones sequenced 
c) Peptides synthesised and peptide affinity measured 
Amemiya et al., 
2005 
Receptor-ligand 
a) Ricin  
b) 5 rounds of panning, 4 clones sequenced 
c) Synthesised peptide specific for ricin offering an alternative to antibody based detection 
currently utilised  
Khan et al., 2003 
  
Enzyme-
substrate 
a) Recombinant protein phosphatase 1 
b) 6 rounds of panning, 104 clones sequenced 
c) Identified a consensus peptide binding motif for protein binding to protein phosphatase 1 
Zhao and Lee, 1997 
Bioremediation 
a) Identified nickel binding peptides 
b) 4 rounds of panning, 10 clones sequenced 
c) Generated secondary libraries to select for peptides with up to 8-fold stronger affinity than 
identified from the original panned library. Identification of common epitopes between 
immunogenic sites 
Dong et al., 2006 
Vaccine 
development 
a) Anti-gonococcal lipooligosaccharide (2C7 epitope) 
b) 5 rounds of panning, 14 clones sequenced 
c) Synthesised cyclic, linear and multiple peptide display constructs 
Ngampasutadol et 
al., 2006 
Vaccine 
development 
a) Anti-hepatitis B virus-preS protein polyclonal antibody 
b) 4 rounds of panning, 13 clones sequenced 
c) Modified panning method to use flow cytometry 
Xin et al., 2004 
Vaccine 
development 
a) Human zona pellucida protein 
b) 5 rounds of panning, 18 clones sequenced  
c) Identified testis-specific peptides that inhibited sperm binding 
Naz et al., 2000 
  
Fig 1.8: Schematic representation of antimicrobial PDT 
 
 
 
 
 
 
 
Fig 1.8: Diagrammatic representation of antimicrobial PDT (adapted from O’Riordan et 
al, 2005). Following irradiation of the photosensitiser (porphyrin) by light of an 
appropriate wavelength (600-650 nm) to an excited state, the photosensitiser produces 
toxic species that damage DNA and/or membrane sites.  
  
 
Table 1.2: Different classes of antimicrobial photosensitisers  
 
Class of 
compound 
Name Site of action Reference 
Natural 
compounds 
Furanocoumarins 
 
Perylenequinonoin 
hypericin 
Intercalation of DNA 
 
Inhibitor of protein 
kinase C 
Guiotto et al., 1995 
 
Estey et al., 1996 
Phenothiazines 
Methylene blue 
Acridine 
Toluidine blue 
DNA interaction 
DNA interaction 
Plasma membrane 
Menezes et al., 1990 
Wainwright, 1998a 
Wakayama et al., 
1980 
Cyclic 
tetrapyrroles 
Phthalocyanines/ 
Porphyrins 
Membrane/cytosolic 
sites 
Bertoloni et al., 1992 
(Adapted from Maisch 2007a)
  
Table 1.3: Photosensitisers shown to be effective against drug resistant and drug sensitive strains of S. aureus 
 
Photosensitiser Bacterial strain/s tested Findings Group 
Protoporphyrin 
diarginate 
40 clinical MRSA and 40 
clinical methicillin 
sensitive S.  aureus 
(MSSA) strains and 1 
reference strain 
PDT effect was strain dependent 
MRSA resistance to PDT was higher than MSSA strains 
Grinholc et 
al., 2008 
Haematoporphyrin 2 strains of MRSA 
Photosensitiser showed dose-dependent effect 
Plasma membrane is the major target of PDT whereas, DNA damage is 
secondary 
Bertoloni et 
al., 2000 
Haematoporphyrin  
derivatives (HpD-
Rut2-Arg2) 
17 MRSA and 11 MSSA 
Higher photosensitiser concentration required for MRSA than MSSA to 
achieve bactericidal effect 
Szpakowska 
et al., 2001 
XF73 
(porphyrin based) 
MRSA and MSSA 
Time and dose-dependent effects of the photosensitiser observed in an ex 
vivo porcine skin model and no damage of surrounding tissue 
Maisch et al., 
2007b 
5-phenyl-10,15,20-
tris(N -methyl-4-
pyridyl)-porphyrin 
chloride 
Bioluminescent S. aureus 
Treatment of third degree burn wounds in mice infected with S. aureus 
was effective but bacterial regrowth was also observed 
Lambrechts et 
al., 2005 
  
3 porphyrin based 
photosensitisers 
(XF70, XF73, CTP1) 
2 strains of MRSA, 1 strain 
of MSSA and 1 strain of 
methicillin resistant S. 
epidermidis 
Greater than 99.9% bactericidal activity of two photosensitisers against all 
Staphylococci tested, independent of resistance profile 
No toxicity against eukaryotic cells was observed at similar concentrations 
 
Maisch et al., 
2005 
Deuteroporphyrin-
hemin complex 
Multidrug resistant S. 
aureus 
Bactericidal effect in vitro without photosensitisation 
Greater than 99% reduction of S. aureus in infected burn wounds in an 
animal model 
Orenstein et 
al., 1997 
5-aminolevulinic acid 
or Photofrin® 
S. aureus and S. epidermidis 
Photofrin® effective but showed dark toxicity and a limited effect observed 
with 5-aminolevulinic acid 
Karrer et al., 
1999 
5-aminolevulinic acid MRSA and S. epidermidis 
5-aminolevulinic acid induced the endogenous porphyrin biosynthesis 
pathway resulting in a significant decrease in viability 
Nitzan et al., 
2004 
Methylene blue or 5-
aminolevulinic acid 
Bioluminescent biofilm-
producing S. aureus 
Both compounds effective in vitro against bacterial suspensions 
3 dosages of light investigated: single acute, fractionated or metronomic 
ALA partially inhibited biofilms in an in vivo animal model of osteomyelitis 
and may be a potential treatment of microbial bone infection 
Bisland et al., 
2005 
Methylene blue EMRSA-16 
A 25-fold and 14-fold reduction in viable bacteria in excision and superficial 
wounds respectively in an in vivo murine wound model without damage to 
host tissue 
Zolfaghari et 
al., 2009 
Methylene blue S. aureus and S. epidermidis Both strains were more susceptible to treatment than C. albicans 
Zeina et al., 
2001 
  
Free chlorine6, 
polylysine- chlorine6 
and methylene blue 
Wild-type and mutant S. 
aureus and S. epidermidis 
PDT was affected by growth phase and production/absence of extracellular 
slime layer 
Greater sensitivity of non-biofilm producing strains 
Gad et al., 
2004a 
Polylysine- chlorine6 
and chlorine6 
Bioluminescent S. aureus 
Light dose dependent effect using an in vivo murine model targeting 
established soft tissue infections, however bacterial regrowth occurred  
Gad et al., 
2004b  
Toluidine blue MRSA and S. epidermidis 
Light dose dependent inactivation of cells and disruption of biofilm structure 
Enhanced PDT against S. epidermidis but not S. aureus biofilms following 
the treatment of biofilms with EDTA 
Sharma et al., 
2008 
Toluidine blue MRSA 
Dose dependent effect for light and photosensitiser concentration whereas 
varying the incubation of the photosensitiser prior to irradiation had little 
effect 
Wilson and 
Yianni, 1995 
5 phenothiazinium 
dyes 
4 strains of MRSA 
1 strain of S. aureus 
2 of the compounds (DMMB and NMB) were bactericidal at lower 
concentrations than vancomycin against EMRSA-15 and -16 
Wainwright et 
al., 1998b 
Merocyanine 540 S. aureus 
Lower light doses required to kill planktonic cultures of S. aureus than  cells 
present as a biofilm due to limited penetration of light 
Lin et al., 2004 
Aluminium 
disulphonated 
phthalocyanine 
EMRSA 1-16 
All strains were susceptible with a photosensitiser concentration and light 
dose-dependent effect 
Not dependent on growth phase or preincubation time 
Griffiths et al., 
1997 
Aluminium 
disulphonated 
phthalocyanine 
MRSA 
Bactericidal effect was not dependent on growth phase 
Killing was decreased when serum was added to the medium 
Wilson and 
Pratten, 1995 
  
Table 1.4: Conjugated photosensitisers for targeting of MRSA and S. aureus 
 
Photosensitiser Bacterial strain/s tested Conjugate/Findings Reference 
5-(4’-
carboxybutylamino)-
9-diethylaminobenzo 
[a]phenothiazinium 
chloride 
Four strains of MRSA, 
S. aureus 
Conjugated to a cephalosporin derivative 
Cleavage of the cephalosporin !-lactam ring by MRSA expressing !-
lactamase releases the quenched photosensitiser to an activated state  
Strain dependent susceptibility that was inversely correlated to 
bacterial susceptibility to penicillin G (corresponding to greater !-
lactamase activity and hydrolysis of the photosensitiser) 
Zheng et al., 2009 
Tin (IV) chlorine6 
conjugate 
EMRSA-16,  
S. aureus,  
E. coli 
Conjugated to bacteriophage "11 
Both strains of S. aureus were susceptible even though the phage was 
not able to infect EMRSA-16 
No effect against E. coli 
Hope et al., 2009 
Tin (IV) chlorin e6 
conjugate 
EMRSA-1, -3, -15, -16, 
-17, VISA, community-
acquired hypervirulent 
strain, MSSA 
Conjugated to S. aureus bacteriophage 75 
All strains susceptible and not growth phase dependent 
No effect on epithelial cells 
Embleton et al., 
2005 
Tin (IV) chlorin e6 
conjugate 
EMRSA-1, -3, -15, -16, 
MSSA, S. epidermidis, 
E. coli 
Conjugated to a polyclonal anti-MRSA antibody 
Effective against all MRSA strains at all growth phases 
Specificity for EMRSA-16 in mixed suspension with E. coli and S. 
epidermidis, although some kill observed against S. epidermidis 
Embleton et al., 
2004 
Tin (IV) chlorin e6 
conjugate 
EMRSA-1, -3, -15, -16, 
S. aureus and S. 
sanguis 
Conjugated to IgG 
Strain variability effect and growth phase dependent 
Embleton et al., 
2002 
Bacteriochlorophyll  S. aureus Cowen I Conjugated to rabbit IgG Conjugate more effective than a non-targeted serine conjugate Gross et al., 1997 
 
  
Table 1.5: Photosensitisers conjugated to biomolecules for targeting of bacteria 
 
Photosensitiser Bacterial strain/s  tested Conjugate/Findings Reference 
Chlorin e6 P. aeruginosa 
Conjugated to poly-L-lysine 
Light dose dependent response using an in vivo murine wound model 
and wounds healed faster than treatment with a topical antimicrobial 
agent. 
Hamblin et al., 2003 
Chlorin e6 
Non pathogenic 
bioluminescent  E. coli 
Conjugated to poly-L-lysine 
Light dose dependent reduction following treatment with the 
conjugate in a wound infection murine model with little damage to 
host tissue. 
Hamblin et al., 
2002b 
Tin (IV) chlorin e6  
Actinomyces viscosus 
and Porphyromonas 
gingivalis 
Conjugated to poly-L-lysine 
Greater than 99% killing of bacterial species with little damage to an 
oral epithelial cell line 
Soukos et al., 1998  
Tin (IV) chlorin e6 P. aeruginosa 
Conjugated to an anti- P. aeruginosa antibody 
Greater than 75% decrease in viable bacteria using a specific 
conjugate whereas bacterial growth observed using a non-specific 
conjugate in an in vivo murine skin model infected with P. 
aeruginosa 
Berthiaume et al., 
1994 
Tin (IV) chlorin e6 P. aeruginosa Conjugated to a monoclonal antibody against P. aeruginosa Selective killing of P. aeruginosa in a mixed suspension of S. aureus Friedberg et al., 1991 
Toluidine blue Porphyromonas gingivalis 
Conjugated to a monoclonal antibody against Porphyromonas 
gingivalis lipopolysaccharide.  
Demonstrated Porphyromonas gingivalis specificity in mixed 
cultures with Streptococcus sanguis or human dermal fibroblasts 
Bhatti et al., 2000 
  
 
 
Table 2.2: Primer sequences 
 
Primer Sequence 
ThioFor 
 
GGT  GGA GTC GAC1 ATG AGC GAT 
AAA AAT ATT CAC CTG 
(1 = SalI) 
ThioRev 
TCC ACC GGA TCC2 CAG GTT AGC 
GTC GAG GAA CTC 
(2 = BamHI) 
ThioLysineFor 
 
GGT GGA GTC GAC1 AAA AAA AAG 
AAA AAA AAG AAA AAA AAG AAA 
AAA AAG AAA AAA AAG ATG AGC 
GAT AAA AAT ATT CAC CTG 
(1 = SalI) 
pPROTetFor 
5 - TGA GCA CAT CAG CAG GAC 
GCA – 3’ 
pPROTetRev 
5’ - GGA GAG CGT TCA CCG ACA 
AAC – 3’ 
GFPFor 
5’ - GGA GGC CTG CAG3 ATG GTG 
AGC AAG GGC GCC GAG CTG - 3’ 
(3 = PstI) 
GFPRev(WS) 
5’ - CTA CTA CGA TCG4 TCA CTT 
GTA CAG CTC ATC CAT GCC - 3’ 
(4 = PvuI) 
GFPRev(NS) 
5’ - TCC ACC GCG ATC G4GA CTT 
GTA CAG CTC ATC CAT GCC - 3’ 
(4 = PvuI) 
 
  
Fig 2.1: Diagrammatic representation of the overall cloning procedure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.1: Flow diagram demonstrating overall process to clone thioredoxin 
containing peptides (A) and also as a GFP fusion construct (B) into the E. coli 
A      B 
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expression vector. 
  
Fig 2.2: Diagrammatic representation of the thioredoxin/pPROTet and 
thioredoxin/GFP/pPROTet final vector constructs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.2: Overall final vector cloning construct for thioredoxin/pPROTet (A) and 
thioredoxin/GFP/pPROTet (B). 
 
 
6 x HN 
tag   
Thioredoxin  
containing peptide 
stop  
codon PLtetO- 
 
pPROTet 
vector 
 
 
 
6 x HN 
tag 
Thioredoxin  
containing peptide 
stop  
codon PLtetO- 
 
 
pPROTet 
vector 
GFP 
A 
B 
  
Fig 3.1: Typical confocal microscopy images of live/dead stained MRSA cultures 
with and without UV irradiation 
 
         
 
     Live MRSA culture                UV irradiated MRSA culture 
 
Fig 3.1: MRSA cultures were grown to late log phase. One aliquot was subjected to UV 
irradiation for 5 min using a 15 W 254 nm UV lamp for comparison against an 
identical, non-irradiated sample. The samples were stained with SYTO 9 and PI and 
analysed using a confocal microscope, equipped with a x60 magnification objective. 
Results shown are typical of three repeat experiments on independent cultures of MRSA 
and indicated that >90% cell death was achieved.  
 
 
 
 
 
 
 
 
  
Fig 3.2: Bacterial immobilisation and washing procedure on different substrates 
using live and dead bacterial cultures 
 
Fig 3.2: Bacterial adhesion investigations were performed using 6-well plates coated 
with either collagen I, poly-L-lysine or poly-D-lysine. Bacterial cultures (40 ml) were 
grown to late log phase and concentrated using centrifugation. Bacteria were killed by 
UV irradiation for 5 min using a 15 W 254 nm lamp. Live and dead/non-viable bacterial 
cultures (2 ml) were added to each plate and left to adhere overnight at 4°C. The plates 
were washed and vortexed as per the panning protocol and the bacteria that remained 
adhered to the plate were stained with methylene blue. The bacteria were destained with 
ethanol and the absorbance measured at 668 nm to ascertain the relative amount of 
bacteria that remained attached to the plate. The blue bars represent live bacteria that 
had remained adhered to the plate whereas the purple bars represent UV-inactivated 
bacteria. The yellow bars represent control wells that contained no bacteria. The error 
bars represent the standard deviation from 4 repeat plates. 
 
  
Fig 3.3: Photograph of immobilised bacteria 
 
         Live           Dead      Dead 
  
 
 
Fig 3.3: Photograph following bacterial immobilisation onto a collagen I plate. Live and 
dead/non-viable bacteria were applied to the wells and left to adhere overnight at 4ºC. 
Following washing, the plates were stained with methylene blue.  
Control 
 
  
 Fig 3.4: Peptide sequences derived from panning against MRSA 
 
 
- = stop codon 
 
Fig 3.4: PCR products were sequenced in both directions and the amino acid 
configuration of the 36 bp peptides sequences were determined. Amino acid sequences 
are depicted as amino acid three letter abbreviations.  
 
 
  
Fig 3.5: Peptide sequences selected from panning against S. aureus 
 
 
 
-   = stop codon 
 
Fig 3.5: The amino acid sequences of the randomly selected clones were determined 
following DNA sequencing in both directions of the amplified PCR products.  
 
  
Fig 3.6: Peptide sequences derived from panning against S. epidermidis 
 
 
- = stop codon 
 
Fig 3.6: PCR products were sequenced in both directions and the amino acid sequence 
determined.  
  
Fig 3.7: Flow cytometric analysis to investigate binding of biotinylated peptides to 
MRSA 
 
Fig 3.7: Flow cytometry profiles for binding assessment of two different biotinylated 
peptides as both cyclic and linear constructs to live and UV-inactivated MRSA. Panel A 
represents FSC/SSC used to determine the bacterial population of MRSA1 for analysis. 
Panels B and C represent profiles used to characterise binding of peptide19 cyclic (green 
line) and linear (pink line) and peptide12 cyclic (blue line) and linear (orange line) to live 
MRSA1. Panels D and E characterise peptide binding against the same strain except that 
MRSA1 had been UV-inactivated. The purple filled line denotes MRSA incubated with 
streptavidin PE:Cy5 only as a negative control. Flow cytometry analysis was based on 
counting 50,000 events. Similar results were obtained characterising binding of the peptides 
against two different strains of MRSA (MRSA2 & MRSA3), S. aureus and S. epidermidis. 
  
Fig 3.8: Assessment of biotinylated peptide binding to MRSA1 by flow cytometry 
 
Fig 3.8: Flow cytometry profiles characterising binding of biotinylated peptides to MRSA. 
The bacterial population of MRSA1 was gated to determine the main bacterial population 
for analysis (Panel A). Panels B and C represent profiles characterising cyclic (green) and 
linear (pink) constructs of peptide19 binding to MRSA1. Panels D and E demonstrate cyclic 
(blue) and linear (orange) peptide12 binding to MRSA1. The turquoise line represents 
bacteria preincubated with biotin complexed with unconjugated streptavidin (5:1) prior to 
incubation with peptides. The peach line represents preincubation of bacteria with biotin 
complexed with unconjugated streptavidin (50:1) prior to peptide incubation. The purple 
filled line represents MRSA1 incubated with streptavidin PE:Cy5 only as a negative 
control. For analysis, 50,000 events were counted. Similar results were obtained 
characterising binding of the peptides against a different strain of MRSA (MRSA2). 
  
Table 3.1: Mean fluorescence intensities for assessment of biotinylated peptide 
binding to MRSA1 
Peptide19 (cyclic) – Panel C Mean fluorescence Gated marker (%) 
Control 140.4 8.2 
Peptide:streptavidin PE:Cy5 147.0 9.2 
Unconjugated streptavidin:biotin + 
peptide:streptavidin PE:Cy5 
168.2 12.2 
Unconjugated streptavidin:10Xbiotin 
+ peptide:streptavidin PE:Cy5 
215.6 20.3 
Peptide19 (linear) – Panel D Mean fluorescence Gated marker (%) 
Control 140.4 8.2 
Peptide:streptavidin PE:Cy5 129.4 6.5 
Unconjugated streptavidin:biotin + 
peptide:streptavidin PE:Cy5 
161.5 11.2 
Unconjugated streptavidin:10Xbiotin 
+ peptide:streptavidin PE:Cy5 
218.2 21.0 
Peptide12 (cyclic) – Panel E Mean fluorescence Gated marker (%) 
Control 140.4 8.2 
Peptide:streptavidin PE:Cy5 131.0 6.7 
Unconjugated streptavidin:biotin + 
peptide:streptavidin PE:Cy5 
162.6 11.0 
Unconjugated streptavidin:10Xbiotin 
+ peptide:streptavidin PE:Cy5 
223.7 21.5 
Peptide12 (linear) – Panel F Mean fluorescence Gated marker (%) 
Control 140.4 8.2 
Peptide:streptavidin PE:Cy5 139.5 7.6 
Unconjugated streptavidin:biotin + 
peptide:streptavidin PE:Cy5 
158.4 10.7 
Unconjugated streptavidin:10Xbiotin 
+ peptide:streptavidin PE:Cy5 
220.1 21.3 
 
In all cases 50,000 cells were analysed. A marker (M1) was set based on the distribution 
of the control plot. 
  
Fig 3.9: Characterisation of biotinylated peptide binding to MRSA using an anti-
biotin detection antibody 
 
Fig 3.9: Flow cytometry profiles for assessment of biotinylated peptide binding to 
strains of MRSA characterised using an anti-biotin antibody. Panels A and B represents 
FSC/SSC used to determine bacterial populations of MRSA1 and MRSA2 respectively 
for analysis. Panel C represents a flow cytometry profile used to characterise peptide19 
cyclic (green) and linear (pink) constructs to MRSA1 in comparison to the negative 
control (purple filled line). Panel D represents binding of peptide12 cyclic (blue) and 
linear (orange) constructs to MRSA1 in relation to the negative. For flow cytometry 
analysis 50,000 events were counted. Panels E and F are the same as C and D except 
that peptide binding was characterised against MRSA2. 
  
Fig 3.10a: Characterisation of FITC-labelled peptide binding by flow cytometry 
 
 
Fig 3.10a: Flow cytometry profiles for assessment of FITC-labelled peptide binding to 
MRSA. The main bacterial population for analysis was determined by FSC/SSC (Panel 
A). Binding of cyclic peptide12 (green) and linear peptide12 (pink) was characterised 
against MRSA1, -2 and -3 (Panels B-D respectively) in comparison to bacteria only as a  
negative control (purple filled line). Each profile was based upon counting 100,000 
events. 
  
Fig 3.10b: Assessment of FITC-labelled peptide binding by flow cytometry 
 
 
Fig 3.10b: Flow cytometry profiles for assessment of FITC-labelled peptide binding to 
S. aureus, S. epidermidis, E. coli, P. aeruginosa and a keratinocyte cell line (Panels A-E 
respectively). Cell populations for analysis were determined based on FSC/SSC as 
previously described in Figure 3.10a. Binding of cyclic peptide12 (green) and linear 
peptide12 (pink) was characterised in comparison to an unlabelled cell population 
(purple filed line). Flow cytometry analysis was based on counting 100,000 events for 
bacterial populations and 10,000 events for keratinocytes. Note that the keratinocyte 
profile (Panel E) has been drawn so that the cell count has been adjusted to 200.  
  
Fig 4.1: Typical agarose gel depicting individual thioredoxin inserts following DNA 
amplification 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.1: Gel electrophoresis was performed to visualise amplified DNA following PCR 
using primers designed to amplify the thioredoxin moiety containing peptide sequences 
5, 12 and 19 (lanes 1-3 respectively) or with an additional 15 lysine residue linker (lanes 
5-7 respectively). PCR was performed using ThioFor or ThioLysineFor primers and 
ThioRev primers. PCR products (3 µl) were visualised on a 2% (w/v) gel. Thioredoxin 
containing the peptides of interest produce an expected DNA fragment of 390 bp (lanes 
1-3) whereas those with the additional lysine linker are expected to be 435 bp (lanes 5-
7). A 100 bp ladder was used to determine the size of the bands observed (lane L). Lane 
4 is the negative control containing no template DNA and therefore indicates there was 
no contamination of reagents. 
L        1          2           3         4           5           6          7         
400 bp 
  
Fig 4.2: Amplification of natural E. coli thioredoxin 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.2: Gel electrophoresis to visualise amplified DNA following colony PCR of 
competent cells alone (top row) and competent cells transformed with an empty 
pPROTet expression vector (bottom row). PCR products (5 µl) were visualised on a 2% 
(w/v) gel.  
Lane order (top):          Expected product 
L, 14, 15 = 100 bp ladder 
1-3 = PCR product (ThioFor and ThioRev primers)     354 bp 
5-7 = PCR product (pPROTetFor and ThioRev primers)    none 
9-11 = PCR product (pPROTetFor and pPROTetRev primers)   none 
4, 8, 12 = negative controls        none 
13, 16-18 = empty lanes       none 
 
Lane order (bottom):          Expected product 
L, 18 = 100 bp ladder 
1-3 = PCR product (ThioFor and ThioRev primers)     354 bp 
5-7 = PCR product (ThioLysineFor and pPROTetRev primers)   none 
9-11 = PCR product (pPROTetFor and ThioRev primers)    none 
14-16 = PCR product (pPROTetFor and pPROTetRev primers)   267 bp 
4, 8, 12, 17 = negative controls      none 
13 = empty lanes        none
   L   1    2     3    4    5   6    7    8   9   10   11  12 13 14  15 16  17  18  
400 bp 
400 bp 
Competent cells 
Competent cells + 
empty expression  
vector 
  
Fig 4.3: Induction of competent cells only and competent cells transformed with an 
empty expression vector 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.3: Competent cells only (Panel A) and competent cells transformed with an empty 
expression vector (Panel B) were analysed by Western blotting probing for thioredoxin (1:1000 
dilution) to ascertain the size of natural E. coli thioredoxin. Bacteria were grown to an optical 
density of OD500 = 0.5 (lane 1) and amplified for a further 2 hr (lane 2). Following 2 hrs, cells 
were normalised to the same optical density as starting values (lane 4). Bacterial aliquots (1 ml) 
were lysed and an aliquot (12 µl) loaded onto a 4-20% (w/v) gradient gel. Additionally, 
following centrifugation to pellet the bacteria, the supernatant (30 µl) was also analysed for the 
presence of thioredoxin (lanes 3, 7). Bacterial cultures were also induced by the addition of 0.1 
ng/ml aTc for 2 hr (lane 6) and compared to initial starting concentrations (lane 5) and also to 
normalised values (lane 8). Similar to non-induced samples, bacteria (1 ml) were lysed and 12 
µl loaded onto a gradient gel. Lane B is blank. Faint bands were observed corresponding to 
natural E. coli thioredoxin (predicted molecular weight = ~12 kDa) in lanes 2 and 6 (Panels A 
and B) following incubation for 2 hr both with and without the addition of aTc that were not 
observed preinduction or following 2 hr incubation following normalisation to starting 
concentrations. 
  
Fig 4.4: Typical representative agarose gel to visualise ligation reactions  
 
 
 
 
 
 
 
 
 
 
 
Fig 4.4: Ligated vector (1 µl) visualised by gel electrophoresis prior to transformation 
using a 0.7% (w/v) gel. Thioredoxin 5, 11 12, 14 and 19/pPROTet ligated vectors (lanes 
4-8 respectively) were visualised and compared against an aliquot (1 µl) of BamHI and 
SalI digested pPROTet vector (lane 1; 2.15 kb). PCR products (3 µl) of amplified 
thioredoxin DNA containing peptides 5 and 12 respectively (ThioLysineFor and 
ThioRev primers) were visualised in lanes 2 and 3 respectively (435 bp) for 
comparison. The uncut pPROTet vector (0.5 µl) is shown in lane 9. A 100 bp ladder 
(lane L) and 1 kb ladder (L2) were used to determine the size of the bands.  
 
L      1       2       3      4      5      6       7      8       9      L     L2   
1500 bp 
400 bp 
  
Fig 4.5: A typical agarose gel electrophoresis image following colony PCR 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.5: Amplification of DNA by colony PCR following successful transformation, 
using pPROTetFor and ThioRev primers. DNA from randomly selected colonies 
following transformation containing the thioredoxin 5, 12 and 19/pPROTet ligated 
vectors was amplified and PCR products (5 µl) were visualised by agarose gel 
electrophoresis (lanes 1-4 = thioredoxin 5/pPROTet, 5-8 = thioredoxin 12/pPROTet and 
9-13 = thioredoxin 19/pPROTet respectively) on a 2% (w/v) gel. The expected size of 
PCR products was 549 bp. A 100 bp ladder (lane L) was used to determine the size of 
the observed bands.  
 
L   1     2     3    4     5    6     7     8    9   10   11   12  13    L       
500 bp 
  
Fig 4.6: Typical confocal microscopy image to confirm successful cloning of 
GFP/pPROTet into E. coli 
 
 
 
Fig 4.6: Transformants were selected and analysed using a confocal microscope, 
equipped with a x60 magnification objective to confirm successful transformation of 
GFP/pPROTet.  
 
 
 
 
 
  
Fig 4.7: PCR analysis of thioredoxin and GFP inserts following transformation  
 
 
 
 
 
 
 
 
 
 
Fig 4.7: Amplification of DNA from plasmid preparations following transformation of 
thioredoxin 5/GFP/pPROTet ligated vector. Plasmid DNA was extracted from transformants 
from both green and white colonies. Plasmid DNA was amplified using the pPROTetFor and 
either GFPRev(WS or NS) primer or pPROTet reverse primers to determine the presence of 
GFP and thioredoxin. PCR products (5 µl) were analysed in duplicate by agarose gel 
electrophoresis to visualise the product on a 2% (w/v) gel. Note lane 13 appears blank whereby 
the digested and cleaned PCR products were not of sufficient concentration to be visualised.  
Lane order: 
L = 100 bp ladder 
1-4 = Green colonies containing thioredoxin 5/GFP (no stop) expression vector (pPROTetFor 
and GFPRev(NS) primers) (expected product = 876 bp) 
5, 6 = White colonies containing thioredoxin 5/GFP (no stop) expression vector (pPROTetFor 
and GFPRev(NS) primers) (expected product = 1236 bp)  
7, 8 = White colonies containing thioredoxin 5/GFP (no stop) expression vector (pPROTetFor 
and pPROTetRev primers) (expected product = 1335 bp) 
9-12 = Green colonies containing thioredoxin 5/GFP (with stop) expression vector 
(pPROTetFor and GFPRev(WS) primers) (expected product = 876 bp) 
13,14 = Thioredoxin containing peptide3 following digestion and clean up and peptide5 prior to 
digestion and purification respectively (ThioFor and ThioRev primers) (expected product = 390 
bp) 
15 = GFP (with stop) PCR product (GFPFor and GFPRev(WS) primers) (expected product = 
744 bp) 
16 = GFP (no stop) PCR product (GFPFor and GFPRev(NS) primers) (expected product = 744 
bp) 
17 = negative control
L   1   2   3   4    5   6   7   8    9   10  11 12 13  14 15 16  17  L 
1000 bp 
500 bp 
  
Fig 4.8: Colony PCR of thioredoxin 5/GFP (no stop) expression vector (white 
colony) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.8: Agarose gel electrophoresis to visualise PCR products (5 µl) amplified by 
colony PCR from positive transformants using different primer combinations. PCR 
products were visualised on a 2% (w/v) gel. Colony PCR was performed on three 
different colonies randomly selected following transformation.  
Lane order (top):          Expected product 
L = 100 bp ladder 
1-3 = PCR product (ThioFor and ThioRev primers)    390 bp 
5-7 = PCR product (pPROTetFor and GFPRev(NS) primers)  1236 bp 
9-11 = PCR product (ThioFor and pPROTetRev primers)   1209 bp 
4, 8, 12 = negative control  
 
Lane order (bottom):          Expected product 
L = 100 bp ladder 
1-3 = PCR product (pPROTetFor and pPROTetRev primers)  1335 bp 
5-7 = PCR product (GFPFor and GFPRev(NS) primers)   744 bp 
4, 8 = negative control 
L    1      2      3     4     5      6     7      8     9    10    11  12    L 
400 bp 
1500 bp 
700 bp 
1500 bp 
  
Fig 4.9: Typical representative gel stained with Coomassie reagent to determine 
optimal protein induction 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.9: Coomassie stained gel to determine optimal expression of recombinant protein. 
Bacteria were induced with 0.1 ng/ml aTc when an OD500 of 0.5 was reached and 
amplified for 0, 2, 4, 6, 7 and 24 hours respectively (lanes 1-6). Following induction, 
bacterial cultures were normalised so that the final absorbance was the same as pre-
induction absorbance values to give the same concentration of bacteria. An aliquot (1 
ml) of each bacterial culture was lysed in SDS-sample buffer and loaded onto a 4-20% 
(w/v) precast gradient gel. Lane 7 demonstrates bacteria after 24 hours following no 
induction, that was normalised to pre-induction absorbance values.  Protein size was 
determined against prestained protein ladders (15 µl; lane L).  
 
          L       1         2         3        4         5         6        7         L                 
      (kDa)                                                                            (kDa) 
64 kDa 
26 kDa 
  
Fig 4.10: Typical representative Western blot to determine optimal expression 
conditions  
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.10: The optimal expression of recombinant thioredoxin protein 19 was analysed 
by Western blotting probing for thioredoxin using the same samples that had previously 
been stained with Coomassie reagent. Bacteria were amplified and induced with aTc 
when an OD500 of 0.5 was reached, and then incubated for 0-24 h to determine the 
optimum incubation time. Following induction, the absorbance of bacterial cultures 
were normalised to preinduction values, i.e. the same concentration of bacteria/ml were 
lysed. Bacterial cultures (1 ml) were lysed in SDS-sample buffer and aliquots (12 µl) 
loaded onto 4-20% (w/v) precast gels. Following transfer the membrane was incubated 
with an anti-thioredoxin antibody (1:1000 dilution). Lanes 1-6 indicate bacterial 
samples that were incubated for 0, 2, 4, 6, 7 and 24 hr respectively following 
normalisation to preinduction concentrations. Recombinant thioredoxin produced an 
observed band at approximately 26 kDa. A prestained protein ladder (15 µl) was used to 
determine the size of the proteins (lane L). Representative of 2 repeats.  
       L                            1               2            3            4                5            6                     
   (kDa) 
64 
 
 
 
26 26 kDa 
15 
  
Fig 4.11: Reprobe of Western blot to confirm the presence of the protein of interest 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.11: Following the Western blot confirming the presence of thioredoxin the same 
nitrocellulose membrane was stripped and reprobed for the 6xHN tag to confirm that the 
protein of interest had been induced and that the protein was of the correct size. Protein 
size was determined against a prestained protein ladder (Lane L). Bacterial cultures 
were induced for 0, 2, 4, 6, 7 and 24 hours (lanes 1-6 respectively). The membrane was 
incubated with an anti-6xHN tag antibody (1:1000 dilution). A single band was 
observed at 26 kDa following 2 h induction (lane 2); this was not observed in any other 
lane. Representative of 2 repeats.  
              L                            1              2             3               4                5             6                     
          (kDa) 
26 kDa 
64 
15 
26 
  
Fig 4.12: Western blot analysis of extracted and purified proteins 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.12: The extraction and purification process was analysed by Western blotting. 
Samples were separated on a 4-20% (w/v) precast gradient gel and following transfer 
were probed for thioredoxin (1:1000 dilution). Bacteria were induced by addition of 0.1 
ng/ml aTc for 2 hr (lane 2) and compared to pre-induction (lane 1). Pre and post 
induction bacterial aliquots (1 ml) were lysed in SDS-sample buffer and 12 µl were 
applied to the gel. Lane 3 (12 µl loaded) is the clarified sample following extraction by 
lysis and centrifugation to pellet unwanted debris. Lane 4 represents protein that did not 
bind to the column (12 µl). Eluted protein is shown in lane 5, concentrated eluted 
protein in lane 6 and following buffer exchange in lanes 7 and 8 (all 30 µl loaded), 
observed as bands of approximately 26 kDa. The sizes of proteins were compared to a 
prestained protein ladder (L). Representative of 2 repeats. Lane B is blank.  
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Fig 4.13: Reprobe of Western blot to determine the presence of thioredoxin with 
6xHN tagged protein 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.13: Following probing for thioredoxin, the membrane was stripped and reprobed 
for the 6xHN tag (1:1000 dilution) to confirm purification of the protein of interest. 
Bacteria were induced by addition of 0.1 ng/ml aTc for 2 hr (lane 2) and compared to 
pre-induction (lane 1). Lane 3 is the clarified sample following extraction by lysis. Lane 
4 represents protein that did not bind to the column. Eluted protein is shown in lane 5, 
concentrated eluted proteins in lane 6 and following buffer exchange in lanes 7 and 8 
observed as very faint bands at approximately 26 kDa. The sizes of proteins were 
compared to a prestained protein ladder (L). Lane B is blank. Representative of 2 
repeats.  
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Fig 4.14: Coomassie staining of thioredoxin/GFP proteins 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.14: Protein expression of P5/GFP and P5 was analysed by staining with 
Coomassie reagent following separation using a 4-20% (w/v) precast gradient gel in 
order to visualise protein bands. Protein production was induced by addition of 0.1 
ng/ml aTc for 2 h and analysed by lysing a bacterial aliquot (1 ml) in SDS-sample 
buffer and loading 12 µl onto a precast gel. Protein expression was analysed before and 
after induction for P5/GFP (lanes 1+2 respectively) and additionally for P5 (lanes 5+6 
respectively). P5/GFP was concentrated (lane 3; 30 µl loaded) and buffer exchanged 
(lane 4; 30 µl loaded) and compared to P5 (lanes 7+8 respectively; 30 µl loaded). 
Protein size was determined against a prestained protein ladder (lane L; 15 µl).  
fig92 
 1      L         2        3       4       5        L        6       7         8                 
      (kDa)                                        (kDa) 
64 kDa 
26 kDa 
  
Fig 4.15: Western blot analysis of thioredoxin/GFP proteins 
 
 
  
 
 
 
 
 
 
 
 
 
Fig 4.15: Protein expression of P5/GFP and P5 were analysed by Western blot probing 
for thioredoxin (1:1000 dilution) following separation on a 4-20% (w/v) precast 
gradient gel. Bacteria were induced for 2 hr with 0.1 ng/ml aTc when an OD500 of 0.5 
was reached. Protein expression was analysed before and after induction for P5/GFP 
(lanes 1+2 respectively) and additionally for P5 (lanes 5+6 respectively). Pre and post 
induction samples were analysed by loading 12 µl isolated from an aliquot of each 
bacterial culture (1 ml). P5/GFP was concentrated (lane 3; 30 µl loaded) and buffer 
exchanged (lane 4; 30 µl loaded) and compared to P5 (lanes 7+8 respectively; 30 µl 
loaded). Lane B is blank.  
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Fig 5.1: Determination of the cytotoxic effect of the conjugated protein and capped 
porphyrin on MRSA with and without irradiation 
 
 
 
Fig 5.1: The cytotoxic effect of the conjugated protein and capped photosensitiser 
against MRSA was determined following irradiation with red light and non-irradiated 
bacteria as a dark control. Following overnight growth the absorbance was measured at 
630 nm and bacterial survival calculated as percentage viability in comparison to the 
untreated, non-irradiated culture. Untreated bacteria are represented by the blue bars 
following irradiation and no irradiation. The purple bars indicate bacteria incubated with 
the P12 conjugate and the yellow bars indicate MRSA incubated with the same 
concentration of capped porphyrin as the P12 conjugate (1.25 µM - low concentration). 
The green bars represent bacteria incubated with a 10-fold excess of capped 
photosensitiser (12.5 µM - high concentration). The error bars represent the standard 
deviation from 3 repeat wells. 
 
  
Fig 5.2: Determination of the cytotoxic effect of the P12 conjugate and capped 
porphyrin on E. coli following irradiation and no irradiation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.2: The P12 conjugate and capped photosensitisers were assessed for cytotoxic 
activity against E. coli following irradiation with red light and no irradiation as a 
control. Untreated control cells are represented by the blue bars and used to compare 
bacterial viability following incubation with the P12 conjugate (purple bars), low 
porphyrin concentration (1.25 µM - yellow bars) and high porphyrin concentration (12.5 
µM - green bars). Following overnight incubation, absorbance was measured at 630 nm 
and used to calculate the percentage viability of bacteria. The error bars represent the 
standard deviation from 3 repeat wells. 
 
  
Fig 5.3: Determination of the cytotoxic effect of the P12 conjugate and capped 
porphyrin on keratinocytes with and without irradiation 
 
 
 
Fig 5.3: Conjugated protein P12 and capped photosensitiser were assessed for cytotoxic 
potential against a keratinocyte cell line. Cell growth was measured by MTT assay and 
compared to untreated control cells. Untreated keratinocytes are represented as blue 
bars. The purple bars indicate keratinocytes incubated with the P12 conjugate whereas 
the yellow and green bars indicate keratinocyte incubation with a low (1.25 µM) and 
high (12.5 µM) concentration of capped photosensitiser respectively. The error bars 
represent the standard deviation from 3 repeat wells. 
 
 
 
 
 
Fig 5.4: Flow cytometric analysis to determine binding of detection antibodies to 
MRSA 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.4: Flow cytometry profiles of control experiments to determine non-specific 
binding of detection antibodies to MRSA. Panel A represents FSC/SSC used to define 
bacterial populations for analysis. Panel B represents incubation with the anti-
thioredoxin primary antibody alone. Panel C represents a bacterial population incubated 
with the secondary antibody only and Panel D represents binding of both the primary 
and secondary antibodies. The purple filled lines denote MRSA only used as a negative 
control. The green lines denote an increase in fluorescence following incubation with 
detection antibodies compared to the negative control. 
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Fig 5.4b: Flow cytometric analysis to determine P5 and P19 binding to MRSA 
 
 
 
 
 
 
 
 
 
Fig 5.4b: Flow cytometry profiles assessing P5 and P19 binding to MRSA. Panels A 
and B represent profiles used to characterise binding of P5 and P19 respectively. 
Bacterial populations for analysis were determined based on FSC/SSC properties shown 
in Figure 5.4 (Panel A). The purple filled lines denote MRSA only as a negative control. 
The green lines denote an increase in fluorescence following protein binding compared 
to the negative control. The gated marker (M1) was used to identify recombinant 
protein binding to MRSA in comparison to bacteria dual labelled with both detection 
antibodies. 
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Fig 5.5: Analysis of binding specificity of detection antibodies against E. coli 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.5: Flow cytometric analysis profiles of control experiments to assess detection 
antibody binding to E. coli. The bacterial population for analysis was determined by 
FSC/SSC as demonstrated in Panel A. Binding of the primary antibody alone (Panel B), 
secondary antibody only (Panel C) and primary and secondary antibodies (Panel D) is 
demonstrated by the green line denoting an increase in fluorescence in comparison to E. 
coli only as a negative control (filled purple line). 
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Fig 5.5b: Characterisation of binding specificity of P5 and P19 against E. coli by 
flow cytometry 
 
 
 
 
 
 
 
 
 
Fig 5.5b: Demonstration of P5 and P19 binding against E. coli. Panels A and B 
represent profiles used to characterise binding of P5 and P19 respectively. The bacterial 
population for analysis was determined based on FSC/SSC properties shown in Figure 
5.5 (Panel A). The purple filled line denotes E. coli only used as a negative control 
whereas the green line denotes an increase in fluorescence compared to the negative 
control. The gated marker (M1) was used to identify recombinant protein binding to E. 
coli. 
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Fig 5.6: Assessment of detection antibody binding to keratinocytes by flow 
cytometry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.6: Flow cytometry profiles of control experiments to determine binding of 
detection antibodies to keratinocytes. Panel A represents FSC/SSC used to define the 
keratinocyte cell population for analysis. Panel B depicts keratinocyte incubation with 
the primary antibody alone whilst Panel C represents a cell population incubated with 
the secondary antibody only. Panel D represents the primary and secondary antibody 
incubated with cells. The purple filled line denotes keratinocytes only used a negative 
control whereas the green line denotes an increase in fluorescence following detection 
antibody binding compared to that of the negative control. 
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Fig 5.6b: Binding characterisation of P5 and P19 to keratinocytes 
 
 
 
 
 
 
 
 
Fig 5.6b: FACS profiles assessing binding potential of P5 and P19 to keratinocytes. 
Keratinocyte populations for analysis were determined based on FSC/SSC properties 
shown in Figure 5.6 (Panel A). Panels A and B represent profiles used to characterise 
binding of P5 and P19 respectively. The purple filled line represents fluorescence of the 
untreated control cells. The green line demonstrates an increase in fluorescence 
compared to the negative control. The gated marker (M1) was used to identify 
recombinant protein binding to keratinocytes. 
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Fig 5.7: Characterisation of P5/GFP binding to MRSA, E. coli and keratinocytes 
by flow cytometry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.7: Binding of P5/GFP to MRSA, E. coli and keratinocytes was analysed by flow 
cytometry. Panels A, C and E represent FSC/SSC used to define the MRSA, E. coli and 
keratinocyte cell populations respectively for analysis.  A range of concentrations of 
P5/GFP was incubated with MRSA, E. coli and keratinocytes separately and an increase in 
fluorescence characterising protein binding is demonstrated as the green (40 µg/ml), pink 
(200 µg/ml) and blue (398 µg/ml) lines respectively compared to control cells only (purple 
filled line). 
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